» 21st International Congress

Date: Thursday, January 1, 1970

Time: 12:00am-12:00am

Meeting:

1:45pm-3:15pm: Demographic and Clinical Characters of Parkinson’s Disease in Tertiary Hospital in Kuwait

W. Kamel, J. Al Hashel, S. Ahmed (Kuwait, Kuwait)

1:45pm-3:15pm: Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation

C. Fitzer-Attas, D. Stephenson, K. Romero, J. Neville, C. Sampaio (Critical Path Institute, Tucson, AZ; CHDI Foundation, Princeton, NJ)

1:45pm-3:15pm: Integration of risk factors for PD in two large longitudinal cohorts

I. Kim, E. O'Reilly, K. Hughes, X. Gao, M. Schwarzschild, A. Ascherio (Boston, MA, USA)

1:45pm-3:15pm: Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?

J.E. Lee, J.-S. Kim, Y.-S. Oh, D.-W. Ryu, I.-U. Song, K.-S. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Pathway Selective Deep Brain Stimulation Derived from Patient-Specific Models

K. Gunalan, B. Howell, R. Patriat, Y. Duchin, G. Sapiro, N. Harel, C. McIntyre (Cleveland, OH, USA)

1:45pm-3:15pm: Prof. Wadia’s contributions to neurology and SCA2

F. Tensini, J. Pedroso, O. Barsottini, H. Teive (Curiitiba, Brazil)

1:45pm-3:15pm: ‘It’s not disgraceful to say you can’t cope’ – Understanding the caregivers’ perspective in care home placement for people with Parkinson’s

A. Hand, L. Oates, W. Gray, R. Walker (North Shields, United Kingdom)

1:45pm-3:15pm: “Home made” olfactory spice discrimination test for PD

D. Flisar, M. Trost, M. Brglez (Ljubljana, Slovenia)

1:45pm-3:15pm: [11C]PK11195 PET in Alzheimer’s disease and progressive supranuclear palsy: the NIMROD study

P. Vazquez Rodriguez, J. Rowe, J. O'Brien, F. Aigbirhio, T. Fryer, L. Su, E. Mak, A. Surendranathan, R. Borchert, S. Jones, R. Arnold, R. Bevan-Jones, L. Passamonti, Y. Hong (Cambridge, United Kingdom)

1:45pm-3:15pm: A case of Dementia with Lewy Bodies Co-Occuring with Multiple Sclerosis

A. Hannoun, E. DeGrush, K. Smith, T. Kao, A. Deb (Worcester, MA, USA)

1:45pm-3:15pm: A case of idiopathic adult-onset truncal extension dystonia treated with bilateral pallidal deep brain stimulation

D. Ehrlich, S. Frucht, B. Kopell, P. Greene, R. Ramdhani (New York, NY, USA)

1:45pm-3:15pm: A double-blind, randomized, placebo controlled study of botulinum toxin type A for limb pain in advanced Parkinson’s disease

V. Bruno, M. Freitas, D. Mancini, J. Liu, J. Miyasaki, S. Fox (CABA, Argentina)

1:45pm-3:15pm: A global survey of the use and linguistic translation of the NMSQuest and NMSScale: implications for non-motor studies in Parkinson’s disease

A. Sauerbier, L. Klingelhoefer, R. Banerjee, S. Diaconu, R. Erro, T. Farombi, S. Gangadharan, A. Macerollo, L. Chahine, O. Jitkritsadakul, R. Biundo, M. Grilo, H. Dafsari, G. Pagano, F. Niccolini, N. Titova (London, United Kingdom)

1:45pm-3:15pm: A national Swedish self-management program for people with Parkinson’s disease – patients and relatives view

C. Hellqvist, C. Berterö, M. Levander, N. Dizdar, P. Hagell (Linköping, Sweden)

1:45pm-3:15pm: A new aroma in the new world

H. Fajardo, A. Medina, P. Gomez, r. Medina (tegucigalpa, Honduras)

1:45pm-3:15pm: A Novel Deep Brain Stimulation Programming Paradigm for Essential Tremor

J. Karl, L. Verhagen (Chicago, IL, USA)

1:45pm-3:15pm: A Novel Deep Brain Stimulation Programming Paradigm for Parkinson’s disease

J. Karl, L. Verhagen, D. Ocegueda (Chicago, IL, USA)

1:45pm-3:15pm: A Novel Model of Care for Advanced Parkinson’s Disease and Related Disorders: Interdisciplinary Home Visits

J. Fleisher, W. Barbosa, M. Sweeney, S. Oyler, A. Lemen, A. Fazl, M. Ko, T. Meisel, N. Friede, G. Dacpano, R. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

1:45pm-3:15pm: A pilot study of mindfulness yoga on psychological distress in people with Parkinson’s Disease (PD)

JJ.Y.-Y. Kwok, J.C.-y. Kwan, H.Y.-L. Chan (Hong Kong, Hong Kong)

1:45pm-3:15pm: A PSP-like phenotype accompanies rapidly progressive dementia

M. Dale, D. Erten-Lyons, F. Bittner, H.-Y. Jong, D. Bourdette, R. Woltjer (Charleston, SC, USA)

1:45pm-3:15pm: A registry study of multiple system atrophy in Hokkaido, Japan: HoRC-MSA Project 2014-16

M. Matsushima, K. Sakushima, I. Yabe, Y. Kanatani, Y. Ito, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, M. Mori, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)

1:45pm-3:15pm: AAV-mediated human alpha synuclein overexpression in the locus coeruleus (LC) leads to a neuronal loss in the nucleus ambiguus of mouse.

B. Lee, M. Henrich, W.-H. Chiu, L. Matschke (Marburg, Germany)

1:45pm-3:15pm: Abnormal melatonin secretion rhythm and nocturnal polyuria in patients with Parkinson’s disease

T. Uchiyama, T. Yamamoto, K. Suzuki, T. Kadowaki, A. Numao, H. Fujita, Y. Watanabe, T. Matsubara, M. Miyamoto, K. Kaga, T. Yamanishi, R. Sakakibara, S. Kuwabara, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: Action tremor control with deep brain stimulation in patients with Parkinson’s disease: Specific target associations

K. Nozile-Firth, V. Viswanathan, K. Foote, M. Okun, A. Wagle Shukla (Gainesville, FL, USA)

1:45pm-3:15pm: Acute L-dopa Challenge Test In Early Parkinsonism With Respect To Presence Of Red Flag Signs &MRIAbnormalitis

M. ACHARYA, A. BISWAS, A. Chatterjee, S. DAS (KOLKATA, India)

1:45pm-3:15pm: Advance care planning in advanced Parkinsonian patients in a long-term care hospital

M.-J. Kim, H.J. Kim, J.-K. Kim, H.-R. Na, S.-B. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm: Advanced DBS programming – Multiple Groups : 3yrs experience

g. hosurkar, r. gopalakrishnan (Bengaluru, karnataka, India)

1:45pm-3:15pm: Alien Limb Syndrome Induced by a Dopamine Agonist in a Patient with Parkinsonism and Agenesis of the Corpus Callosum

M. Krause, J. Shou, S. Joy, D. Torres-Russotto (Omaha, NE, USA)

1:45pm-3:15pm: An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease.

Y. Yamanishi, R. Ando, C. Yamasaki, S. Tada, N. Miyaue, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, M. Nomoto (Ehime, Japan)

1:45pm-3:15pm: An auditory biomarker for Parkinson’s Disease ?

K. De Keyser, A. Bockstael, D. Botteldooren, D. Talsma, M. De Letter, P. Santens (Ghent, Belgium)

1:45pm-3:15pm: An evaluation of the diagnostic utility of radiological biomarkers in PSP

J. Whitwell, G. Hoglinger, A. Antonini, Y. Bordelon, A. Boxer, C. Colosimo, R. Dodel, T. van Eimeren, L. Golbe, J. Kassubek, C. Kurz, I. Litvan, A. Pantelyat, G. Respondek, G. Rabinovici, J. Rowe, M. Stamelou, K. Josephs (Rochester, MN, USA)

1:45pm-3:15pm: An Objective Tool to Guide Target Selection for DBS in PD (GPi vs STN)

L. Meytin, T.-W. Liang (Philadelphia, PA, USA)

1:45pm-3:15pm: An unusual mimicker of Lewy Body Dementia: Gliomatosis Cerebri.

H. Oliveira, P. Oliveira, V. Calil, P. Macêdo, N. Canedo, L. Vasconcellos (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Analyses of physical activity on cognitive flexibility, depression and RBD in healthy elderly with high risk for neurodegenerative diseases

S. Lerche, A. Gutfreund, K. Brockmann, I. Wurster, G. Eschweiler, F. Metzger, W. Maetzler, D. Berg (Tuebingen, Germany)

1:45pm-3:15pm: Analysis of related factors of occurrence of dementia in Parkinson’s disease using the application form of Parkinson’s disease provided by the specific diseases treatment research program of Ministry of Health, Labor and Welfare of Japan

K. Konaka, M. Mihara, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Analysis of the exclusion causes for deep brain stimulation in Parkinson’s Disease Center in southern Taiwan

Y.-F. CHEN, Y.-F. CHEN, C.-C. CHANG, Y. LI, Y.-Y. CHANG (Kaohsiung, Taiwan)

1:45pm-3:15pm: Anatomical predictors of survival in PSP: thalamic collapse towards the end of life

W. Bevan-Jones, S. Jones, B. Ghosh, T. Rittman, I. Coyle-Gilchrist, J. Rowe (Cambridge, United Kingdom)

1:45pm-3:15pm: Are a „mathematical brain“ and early childhood adverse events possible risk factors that contribute to Progressive Supranuclear Palsy?

S. Lorenzl (Hausham, Germany)

1:45pm-3:15pm: Are patients with Parkinson’s disease who have either mild to moderate microsmia, severe microsmia or anosmia clinically different?

c. cox, A. Khattab, K. Amar (Bournemouth. Dorset, United Kingdom)

1:45pm-3:15pm: Aspects of Quality of Life in MSA and PSP

L. Wiblin, M. Lee, D. Burn (Newcastle-upon-Tyne, United Kingdom)

1:45pm-3:15pm: Assessing the extent of carer strain in Parkinson’s disease

R. Varadarassou, V. Queen, E. Pearson, F. Murphy, M. Turner, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Assessment of Autonomic Dysfunction in Parkinson’s Disease

K. Karbozova, , (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: Assessment of pain in Parkinson’s disease: comparison between clinical and self-reported measures

C. Rodriguez-Blazquez, R. Balestrino, K. Chaudhuri, J.M. Rojo-Abuin, A. Rizos, C. Trenkwalder, A. Sauerbier, P. Odin, A. Antonini, P. Martinez-Martin (Madrid, Spain)

1:45pm-3:15pm: Assisted Suicide of patients with parkinsonian syndromes in Switzerland – the need of early and continuous integration of palliative care and dignitiy therapy

S. Lorenzl, L. Butzhammer, G. Nübling (Salzburg, Austria)

1:45pm-3:15pm: Association of impaired melatonin secretion with sleep disturbance in Parkinson’s disease

T. Nakamura, M. Suzuki, M. Ueda, E. Imai, G. Tohnai, M. Katsuno (Nagoya, Japan)

1:45pm-3:15pm: Association of Metabolic Syndrome and Change in Unified Parkinson Disease Rating Scale Scores

M. Leehey, S. Luo, S. Sharma, A.-M. Wills, J. Bainbridge, D. Simon, J. Schneider, Y. Zhang, A. Pérez, R. Dhall, C. Christine, C. Singer, F. Cambi (Aurora, CO, USA)

1:45pm-3:15pm: Association of nocturnal stridor with clinical features of patients with multiple system atrophy

H.-S. Ryu, J.-H. Paek, S. You, M.-J. Kim, Y.J. Kim, J. Kim, K. Kim, S.-A. Lee, S.J. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: Association of pain and depression with Parkinson’s disease-osteoarthritis comorbidity.

A.Q. Rana, A.R. Qureshi, Z. Sarfaraz, R. Rana (Toronto, ON, Canada)

1:45pm-3:15pm: Association of pain in Parkinson’s disease with anxiety, depression and sleep quality: a cross-sectional study

A.Q. Rana, U. Saeed, A.R. Qureshi, Z. Sarfaraz, R. Rana (Toronto, ON, Canada)

1:45pm-3:15pm: Associations of probable REM sleep behavior disorder, constipation, and hyposmia with PD

K. Hughes, X. Gao, J. Baker, M. Schwarzschild, A. Ascherio (Boston, MA, USA)

1:45pm-3:15pm: Asymptomatic and transitory postoperative hypodense lesion around deep brain stimulation electrode

M. Sousa, F. Moreira, N. Canário, O. Brito, R. Pereira, M. Rito, C. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Automated DBS Contact Selection using Coherence in Parkinson’s Disease

J. van Zijl, J. Elting, T. van Laar, F. Lange, G. Drost, D. Oterdoom, J. van Dijk, M. Tijssen, M. Beudel (Groningen, Netherlands)

1:45pm-3:15pm: Automatic discrimination between the striatum, Globus pallidus externa and Globus pallidus interna during deep brain stimulation surgery

D. Valsky, H. Bergman, Z. Israel (Jerusalem, Israel)

1:45pm-3:15pm: Autonomic Dysfunction in Early Parkinson’s Disease: Cross-Sectional Study in Hoehn and Yahr Stage 1

I. Stankovic, I. Petrovic, T. Pekmezovic, T. Stojkovic, V. Markovic (Belgrade, Serbia)

1:45pm-3:15pm: Baseline characteristics associated with greatest improvement in HRQL after DBS surgery

P. Schmidt, F. Cubillos, C. Martinez-Rubio, K. Lyons, C. Marras, T. Davis, E. Nelson, M. Okun (Miami, FL, USA)

1:45pm-3:15pm: Baseline risk factors of insomnia symptoms after five years of follow-up: a population-based cohort of incident Parkinson’s disease

A. Duarte Folle, B. Ritz, K. Paul (Los Angeles, CA, USA)

1:45pm-3:15pm: Battery consumption and need for replacement in patients with Parkinson disease treated with interleaved deep brain stimulation

L. Deuel, J. Pilitsis, A. Ramirez-Zamora (Albany, NY, USA)

1:45pm-3:15pm: Body mass index, change in body mass index and risk of Parkinson`s disease

J. Lee, J.H. Kim, J.H. Cho, G.S. Kim, J.H. Lee, P.H. Lee, Y.H. Sohn (Goyang-shi, Republic of Korea)

1:45pm-3:15pm: Brain metabolic patterns in progressive supranuclear palsy phenotypes

M.M. Carmona-Abellan, A. Fontes, E. Prieto, J. Arbizu, R. Luquin, M. Riverol (Pamplona, Spain)

1:45pm-3:15pm: Burden of autonomic neuropathy in Parkinson’s disease patients treated with advanced therapies

A. Romagnolo, A. Merola, M. Rosso, C. Comi, C. Artusi, M. Rizzone, M. Zibetti, S. Maule, L. Lopiano, A. Espay (Turin, Italy)

1:45pm-3:15pm: Calcium Channel Blocking Drugs and Risk of LRRK2 Parkinson’s Disease

C. Marras, K. Marder, R. Alcalay, R. Saunders-Pullman, C. Meng, S. Goldman, A. Lang, M. Korell, M. San Luciano, E. Tolosa, B. Schuele, A. Brice, S. Goldwurm, G. Riboldazzi, C. Klein, G. Mellick, C. Sue, E.K. Tan, K. Brockmann, K. Hasegawa, S. Bressman, J. Ferreira, M. Tazir, W. Langston, D. Berg, C. Tanner (Toronto, ON, Canada)

1:45pm-3:15pm: Can the level of CSF Neurofilament Light Chain predict disease progression in Progressive Supranuclear Palsy?

E. Jabbari, J. Woodside, H. Morris (London, United Kingdom)

1:45pm-3:15pm: Cardiac Autonomic Dysregulation in Probable Multiple System Atrophy

M. Rukmani, R. Yadav, P. Pal, B. Bhaskarapillai, T. Sathyaprabha (Bangalore, India)

1:45pm-3:15pm: Cardiovascular autonomic dysfunction, depression and cognitive disorders in Parkinson’s disease patients

A. Guekht, M. Lebedeva, G. Popov, A. Yakovlev, O. Davidov (Moscow, Russian Federation)

1:45pm-3:15pm: Cause-Specific Hazard of Motor and Nonmotor Long Term Complications of Idiopathic Parkinson’s Disease in a Hospital-based Outpatient Clinic Incident Cohort of 1333 Patients

S. Prange, C. Laurencin, t. danaila, m.-b. delphine, S. Thobois (bron, France)

1:45pm-3:15pm: Causes, Complications and Outcomes of Hospitalization in Patients with Dementia with Lewy Bodies

C. Spears, A. Besharat, D. Martinez-Ramirez, L. Almeida, M. Armstrong (Gainesville, FL, USA)

1:45pm-3:15pm: Central Aortic Pressure in Parkinson’s Disease and Levodopa Effect

M. BALAL, M. DEMIRKIRAN (Adana, Turkey)

1:45pm-3:15pm: Cerebrospinal Fluid Levels of Coenzyme Q10 are Reduced in Multiple System Atrophy

Y. Compta, F. Antonelli, M. Fernandez, P. Bravo, M. Soto, A. Camara, D.M. Giraldo, M.J. Marti, On-behalf-of Catalan-MSA-Registry Group (Barcelona, Spain)

1:45pm-3:15pm: Changes in Functioning Associated with Exercise in Individuals with Parkinson’s

L. Clack, B. Riemann, M. Cohen (Savannah, GA, USA)

1:45pm-3:15pm: Changing patterns of intimate relationships as dementia emerges in Parkinson’s disease

S. Vatter, K. McDonald, S. McCormick, I. Leroi (Manchester, United Kingdom)

1:45pm-3:15pm: Circadian and Homeostatic Modulation of Multi-unit Activity in Dopaminergic and Striatal Structures

K. Fifel (Leiden, Netherlands)

1:45pm-3:15pm: Clean intermittent catheterization in Parkinson’s disease: a case report

M. Tosin, C. Mecone, W. Macedo, A.P. Seabra, A. Barbosa, R. Sakakibara (RIO DE JANEIRO, Brazil)

1:45pm-3:15pm: Clinical characteristics of Parkinson’s disease developed from essential tremor

D.-W. Ryu, J.-S. Kim, K.-S. Lee, J.-W. Park (Seoul, Republic of Korea)

1:45pm-3:15pm: Clinical correlates of severe somnolence in Parkinson’s disease: results from an international naturalistic non-motor symptoms cohort

R. Taddei, A. Sauerbier, M. Qamar, K. Ray Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Clinical Phenotype in Patients with Multiple System Atrophy in the Mexican Population

S. Isais-Millán, C. Perez-Lohman, K. Salinas Barboza, A. Cervantes Arriaga, M. Rodriguez Violante, L. Mendoza Vega, N. Davila Avila, A. DelaCruz Landero (Mexico City, Mexico)

1:45pm-3:15pm: Clinical Predictors of Dementia and Other Non-Motor Symptoms in Parkinson’s Disease

D. Lichter, S. Finnegan (Buffalo, NY, USA)

1:45pm-3:15pm: Clinical utility of chronic directional subthalamic Deep Brain Stimulatoin in Parkinson’s Disease

C. Hartmann, L. Venkatesan, P. Slotty, J. Vesper, A. Schnitzler (Düsseldorf, Germany)

1:45pm-3:15pm: Clinicopathological analysis of corticobasal syndrome: a retrospective study

R. Lamb, J. Rohrer, R. Weil, H. Ling, A. Lees, H. Morris (London, United Kingdom)

1:45pm-3:15pm: Cognitive effects of GPi versus STN deep brain stimulation in Parkinson’s Disease: experience with patients with moderate cognitive impairment

C. Marques-Matos, C. Sousa, J. Lima, P. Monteiro, P. Linhares, R. Vaz, M.J. Rosas (Porto, Portugal)

1:45pm-3:15pm: Cognitive Impairment in MSA Patients from the Catalan Multiple System Atrophy Registry (CMSAR)

D. Giraldo, Y. Compta, F. Antonelli, E. Muñoz, A. Camara, J. Pagonabarraga, O. de Fabregués, J. Hernández-Vara, F. Valldeoriola, E. Tolosa, M.C. Pont, S. Jauma, A. Bayes, N. Caballol, M. Calopa, P. Pastor, L. Planellás, M. Pujol, V. Puente, A. Avila, M.J. Martí (Barcelona, Spain)

1:45pm-3:15pm: Cognitive Mechanisms of Visual Dysfunction in Non-Demented PD Patients (PD-ND)

T. Lin, H. Gibler, S. Rapcsak (Tucson, AZ, USA)

1:45pm-3:15pm: Cognitive profiling in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy: a 15-month longitudinal study

E. Fiorenzato, L. Weis, A. Antonini, R. Biundo (Venice-Lido, Italy)

1:45pm-3:15pm: Cognitive safety of eight-hours adaptive deep brain stimulation (aDBS) in Parkinson’s disease

R. Ferrucci, F. Ruggiero, F. Cortese, T. Bocci, M. Rosa, M. Arlotti, M. Colombo, S. Marceglia, F. Mameli, F. Cogiamanian, G. Ardolino, M. Locatelli, P. Rampini, A. Priori (Milan, Italy)

1:45pm-3:15pm: Combined aerobic and function-based exercise in a group setting improves quality of life and functional mobility in persons with Parkinson disease

J. Russell, L. Wolf, T. McMath, L. Shaffer, C. Collins, A. Mansur, D. Zid, D. Hinkle (Columbus, OH, USA)

1:45pm-3:15pm: Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease

L. Kirkpatrick, Y. Torres-Yaghi, A. Keys, N. Starr, T. Kimbason, C. Moussa, F. Amjad, F. Pagan (Washington, DC, USA)

1:45pm-3:15pm: Comparison of lead localization in postoperative CT versus MRI

R. Nickl, M. Reich, P. Fricke, F. Steigerwald, F. Lange, R.-I. Ernestus, J. Volkmann, C. Matthies (Würzburg, Germany)

1:45pm-3:15pm: Comparison of neuropathology in Parkinson’s disease subjects with and without deep brain stimulation

G. Pal, B. Ouyang, G. Serrano, H. Shill, C. Goetz, G. Stebbins, L. Metman, E. Driver-Dunckley, S. Mehta, J. Caviness, M. Sabbagh, C. Adler, T. Beach (Chicago, IL, USA)

1:45pm-3:15pm: Comparison of pallidal and subthalamic deep brain stimulation in Parkinson’s disease: therapeutic and adverse effects

H.-S. Ryu, M.-S.K. Kim, S. You, M.-J.K. Kim, Y.J. Kim, J. Kim, K. Kim, S.J. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: Comparison of subthalamic and pallidal deep brain stimulation in treatment of Parkinson’s disease: a 5-year follow-up study

A. Gamaleya, A. Tomskiy, A. Dekopov, E. Bril, A. Poddubskaya, N. Fedorova, V. Shabalov (Moscow, Russian Federation)

1:45pm-3:15pm: Contact location and non-motor outcomes in subthalamic nucleus deep brain stimulation for Parkinson’s disease

D. Floden, C. Matias, C. Wathen, G. Ozinga, O. Hogue, A. Machado (Cleveland, OH, USA)

1:45pm-3:15pm: Correlation and impact of non-motor symptoms on intensity of motor symptoms in Parkinson’s Disease

M. Sanoeva, M. Gulova, N. Mansurova (bukhara, Uzbekistan)

1:45pm-3:15pm: Correspondence between MRI borders of the subthalamic nucleus and its electrophysiological borders: a comparison study using intraoperative CT.

S. Bus, P. Van den Munckhof, M. Bot, G. Pal, B. Ouyang, S. Sani, L. Verhagen-Metman (Chicago, IL, USA)

1:45pm-3:15pm: Corticobasal degeneration and frontotemporal dementia – an overlapping continuum

R. Varela, C. Duque, J. Carvalho, A. Moreira, A. Morgadinho, C. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Creutzfeldt-Jakob Disease with Corticobasal Syndrome-Like Onset: Case report

M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)

1:45pm-3:15pm: Deep brain recording and surgical time in stereotactic and functional neurosurgery for movement disorders

J. Teijeiro Amador, R. Macías, C. Maragoto, N. Quintanal (Havana, Cuba)

1:45pm-3:15pm: Deep Brain Stimulation (DBS) for Parkinson Disease in the Philippines: Outcomes and Practice of the First DBS Center

J.D. Diestro, T. Vesagas, J. Aguilar, R. Teleg, J. Anlacan, R.D. Jamora (Manila, Philippines)

1:45pm-3:15pm: Deep Brain Stimulation and Olfactory Function in Parkinson’s Disease

O. Saatci, B. Polat, N. Helvaci Yilmaz, T. Zirh (Istanbul, Turkey)

1:45pm-3:15pm: Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.

d. servello, M. Porta, e. zekaj (Milano, Italy)

1:45pm-3:15pm: Deep Brain Stimulation for Parkinson’s disease: Short-term outcomes, referral patterns and health disparities.

D. Di Luca, V. Aldahondo, W. Jermakowicks, L. Segala, H. Moore, C. Singer, B. Levin, J. Jagid, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: Deep Brain Stimulation in a case with Parkinsonism and SCA2 mutation: case report highlighting challenges and outcome

N. Sarangmat, A. Whone, S. Gill, C. Robbins (Bristol, United Kingdom)

1:45pm-3:15pm: Deep brain stimulation influences on event-related potentials (P300) in Parkinson’s disease

M. Zibetti, S. Palermo, S. Vighetti, A. Romagnolo, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Degree, onset and longevity of benefit achieved with Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) as assessed by the UPDRS.

D. Caputo, O. Mark, D. Schneider, R. DiPaola, S. Danish, E. Hargreaves (New Brunswick, NJ, USA)

1:45pm-3:15pm: Depression, anxiety and quality of life in Multiple System Atrophy

L. Zhang, B. Cao, Q. Wei, R. Ou, B. Zhao, J. Yang, Y. Wu, H. Shang (Chengdu, China)

1:45pm-3:15pm: Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson’s disease inadequately controlled on oral medications

A. Antonini, P. Schmidt, P. Odin, L. Kleinman, A. Skalicky, K. Sail, Y. Jalundhwala, J. Zamudio, K. Onuk, T. Marshall, H. Fernandez (Venice, Italy)

1:45pm-3:15pm: Diabetes Mellitus and Parkinson’s Disease

G. Pagano, S. Polychronis, H. Wilson, F. Niccolini, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Diagnosis of Irritable Bowel Syndrome Increases Risk of Parkinson’s Disease in the Finnish Population

T. Mertsalmi, E. Pekkonen, F. Scheperjans (HUS, Finland)

1:45pm-3:15pm: Differences in the oscillatory activity of the globus pallidus in dystonia, parkinson´s disease and gilles de la tourette syndrome

M.M. Carmona-Abellan, M. Valencia, J. Guridi, R. Luquin, J. Artieda, M. Alegre (Pamplona, Spain)

1:45pm-3:15pm: Differential diagnosis and progress monitoring in Progressive Supranuclear Palsy – a potential role of pulmonary function tests

G. Nuebling, C. Abright, M. Schuberth, S. Schoenecker, K. Boetzel, J. Levin, S. Lorenzl (Munich, Germany)

1:45pm-3:15pm: Differential diagnosis of Parkinson’s Disease and Progressive Supranuclear Palsy

Y. Trufanov (Kyiv, Ukraine)

1:45pm-3:15pm: Differential effects of ventral or dorsal predominant dopaminerjic denervation of striatum on development of dopamine dysregulation syndrome and punding in a rat model of parkinsonism

E. Özkan, G. Çakmaklı, B. Elibol, E. Topçuoğlu (Ankara, Turkey)

1:45pm-3:15pm: Differential microRNA expression in a cohort of Parkinson’s disease patients

A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

1:45pm-3:15pm: Differentiating Parkinsonism with Spatio-temporal dynamics (real-time MRI) and Acoustics of Speech (spectrogram)

S. GUDWANI, S.S. Kumaran, M. Behari (New Delhi, India)

1:45pm-3:15pm: Diffusion-Weighted MRI discriminates Parkinson´s Disease from the Parkinsonian Variant of Multiple System Atrophy: a Meta-analysis

S. Bajaj, F. Krismer, G. Wenning, W. Poewe, K. Seppi (Innsbruck, Austria)

1:45pm-3:15pm: Directional distribution of subthalamic nucleus beta activity in patients with Parkinson’s disease

G. Tinkhauser, A. Pogosyan, I. Debove, A. Nowacki, H. Tan, K. Petermann, K. Seidel, M. Oertel, C. Pollo, P. Brown, M. Schuepbach (Oxford, United Kingdom)

1:45pm-3:15pm: Disparities in Access to DBS Surgery Based on Demographics of Patients with PD Admitted for DBS Surgery in the United States from 2003 to 2013

F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm: Displacement of deep brain stimulation (DBS) lead location after implantation: Preliminary result of a study comparing early Vs late CT findings

X.-L. Zhu, C. Lau, C.-M. Cheung, D. Chan, A. Chan, V. Mok, J. Yeung, W. Poon (Hong Kong, China)

1:45pm-3:15pm: Do median-nerve evoked blink reflexes allow early differentiation between PD and PSP in patients with debuting parkinsonism?

E. Nordh, J. Linder, L. Forsgren (UMEA, Sweden)

1:45pm-3:15pm: Do motor symptoms influence on malnutrition in Parkinson`s disease patients?

S. Tomic, V. Pekic, Z. Popijac, T. Pucic, M. Petek, T. Gilman Kuric (Osijek, Croatia)

1:45pm-3:15pm: Does gender influence the expression of non-motor symptoms in Parkinson’s disease?: An observational study

J. Herreros Rodríguez, A. Esquivel López, R. Gordo Mañas, Á. Sánchez Ferro (Madrid, Spain)

1:45pm-3:15pm: Dr. Paula Coutinho’s Seminal Contributions to the Understanding of Machado-Joseph’s Disease

P. Marques, H. Teive, F. Germiniani, B. Garcia (Curitiba, Brazil)

1:45pm-3:15pm: Dream content in Parkinson’s Disease

V. Malgrati, F. Mancini, L. Manfredi, M. Lacerenza, A. Maggiolini (Milan, Italy)

1:45pm-3:15pm: Driving license and car accidents in patients with Parkinson’s disease

M. Tomiyama, T. Ueno, H. Nishijima, T. Kon, R. Haga, Y. Funamizu, A. Arai, C. Suzuki, J. Nunomura, M. Baba (Aomori, Japan)

1:45pm-3:15pm: Dynamic Instability and Stride Width in Parkinsonism

P. Fino, C. Curtze, M. Mancini, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Dynamic of symptoms of dopamine dysregulation syndrome after deep brain stimulation in patients with Parkinson`s disease

S. Omarova, N. Fedorova, A. Tomskiy, A. Gamaleya, E. Bril, N. Gubareva (Moscow, Russian Federation)

1:45pm-3:15pm: Dynamics of subthalamic nucleus beta bursts in Parkinson’s disease during ON and OFF dopaminergic state

G. Tinkhauser, A. Pogosyan, H. Tan, A. Kühn, P. Brown (Oxford, United Kingdom)

1:45pm-3:15pm: Dysphagia in PSP

H. Clark, J. Whitwell, J. Ahlskog, K. Josephs (Rochester, MN, USA)

1:45pm-3:15pm: Effect of bilateral subthalamic nucleus deep brain stimulation on quality of life in advanced Parkinson’s disease patients

s. tandra, B. ramavath, r.m. kandadai, r. borgohain (hyderabad, India)

1:45pm-3:15pm: Effect of deep brain stimulation of the subthalamic nucleus on cranial tremor in Parkinson’s disease

L. Cameron, C. Kilbane, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: Effect of low frequency stimulation on freezing of gait in a PSP patient with bilateral STN DBS

T. Xie, M. Padmanaban (Chicago, IL, USA)

1:45pm-3:15pm: Effect of Urinary Dysfunction on Depression and Anxiety Development in Parkinson’s Disease

E. Benli, F. Ozer, N. Helvaci Yilmaz, T. Ozcan, O. Arici Duz (Ordu, Turkey)

1:45pm-3:15pm: Effects of bilateral pallidal deep brain stimulation for chorea after pulmonary thromboendarterectomy with deep hypothermia and circulatory arrest: case report

K. Aoyagi, Y. Higuchi, Y. Okahara, Y. Yamanaka, T. Yamamoto, S. Hirano, Y. Iwadate (Ichihara, Japan)

1:45pm-3:15pm: Effects of deep brain stimulation in genetic parkinsonism

L. Oliveira, R. Cury, E. Barbosa (Sao Paulo, Brazil)

1:45pm-3:15pm: Effects of deep brain stimulation on olfactory function in Parkinson’s disease

R. Cury, M. Carvalho, M.g. Santos Ghilardi, A. Estevo, A. de Paiva, F. Lopez, A. Coutinho, M. Teixeira, E. Barbosa, E. Fonoff (São Paulo, Brazil)

1:45pm-3:15pm: Effects of subthalamic and nigral stimulation on gait kinematics in Parkinson’s disease

M. Scholten, J. Klemt, C. Plewnia, B. Bloem, F. Bunjes, R. Krüger, A. Gharabaghi, D. Weiss (Tübingen, Germany)

1:45pm-3:15pm: Efficacy and tolerability of low-frequency deep brain stimulation during daytime only in Parkinson’s disease: a pilot study

F. Dematteis, M. Zibetti, E. Montanaro, L. Rizzi, M. Lanotte, L. Lopiano, M. Rizzone (Torino, Italy)

1:45pm-3:15pm: Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease

C. Kostrub, C. Kenney, C. Riemer, E. Prinssen, A. Flohr, J.-L. Moreau (Ardsley, NY, USA)

1:45pm-3:15pm: Eight contacts with multiple-source current steering in pallidal deep brain stimulation for Parkinson’s disease: a non-randomized, single center, open-lavel study

K. Kimura, H. Kishida, N. Ueda, T. Kawasaki, K. Hamada, F. Tanaka (Yokohama, Japan)

1:45pm-3:15pm: Electrode Impedance as a marker for “on” and “off” states in a Deep Brain Stimulation cohort: A pilot study

W. Deeb, J. Shute, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Emergence of Non-motor Fluctuations with Reference to Motor Fluctuations in Parkinson’s Disease

A. Kim, Y. Kim, A. Kim, C.W. Shin, B. Jeon, H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Epidemiological profile of parkinsonism in a tertiary neurological clinic in the northeast of Brazil.

R. Prado, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

1:45pm-3:15pm: Evaluating Non-Motor Fluctuations in Parkinson’s Disease Using a Visual Analogue Scale

E. Brown, K. Dodenhoff, J. Ostrem, C. Racine (San Francisco, CA, USA)

1:45pm-3:15pm: Evaluating Use of the DBS Patient Programmer

D. Whitney, J. Karl, G. Pal, D. Ocegueda-Ramirez, B. Ouyang, L. Verhagen Metman (Chicago, IL, USA)

1:45pm-3:15pm: Evaluation of a Radiographic Marker as a Diagnostic Tool For Progressive Supranuclear Palsy

P. Dowell, B. Patel, L. Ledbetter, K. Lyons, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluation of mitochondrial dysfunction in fibroblasts and iPSC-derived dopaminergic neurons of patients affected by Multiple System Atrophy

G. Monzio Compagnoni, E. Frattini, F. Fortunato, D. Ronchi, A. Bordoni, M. Garbellini, S. Salani, M. Guida, N. Bresolin, S. Corti, G.P. Comi, A. Di Fonzo (Milano, Italy)

1:45pm-3:15pm: Evolution of Globus Pallidus Internus (GPi) Deep Brain Stimulation Targeting Over 15 Years

V. Holanda, L. Almeida, M. Okun, A. Patterson, W. Deeb, A. Shukla, K. Foote (Gainesville, FL, USA)

1:45pm-3:15pm: Examining the brain reserve hypothesis in Parkinson’s disease

P.C. Lee, F. Artaud, F. Cormier, O. Rascol, F. Durif, P. Derkinderen, F. Bourdain, J.-P. Brandel, F. Pico, L. Lacomblez, C. Bonnet, D. Grabli, S. Klebe, G. Mangone, H. You, V. Mesnage, A. Brice, M. Vidailhet, J.-C. Corvol, A. Elbaz (Taipei, Taiwan)

1:45pm-3:15pm: Excellent Non-motor Responses after Bilateral Subthalamic Deep Brain Stimulation in Parkinson’s Disease Patient with SNCA Duplication

J. Youn, J.W. Cho, J.-I. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Excessive daytime sleepiness in Parkinson’s disease: risk factors and clinical associations

O. Babkina, O. Levin, M. Poluektov (Moscow, Russian Federation)

1:45pm-3:15pm: Expectations and Perceived Outcomes Following DBS for PD: A Case Series

D. Coughlin, M. Hernandez-Con, M. Pavon, M. Spindler, L. Chahine (Philadelphia, PA, USA)

1:45pm-3:15pm: Experience and outcomes of the first Movement Disorders Clinic in Honduras.

J. Ortiz, A. Medina, F. Naranjo (Tegucigalpa, Honduras)

1:45pm-3:15pm: Extrapyramidal involvement in amyotrophic lateral sclerosis: results of a prospective population-based study

M. Rizzone, F. Dematteis, A. Chiò, S. Cammarosano, C. Artusi, M. Pagani, F. Nobili, A. Cistaro, M. Balma, E. Montanaro, B. Iazzolino, A. Canosa, L. Lopiano, A. Calvo (Torino, Italy)

1:45pm-3:15pm: Extreme Premature Ejaculation in Parkinson’s disease

G. Yahalom, G. Bronner, S. Israeli-Korn, S. Hassin-Baer (Ramat-Gan, Israel)

1:45pm-3:15pm: Factors associated with health related Quality of Life (HRQOL) in Korean Parkinson patients

J.H. Kang, S. Jang, J.-s. Kim, S.J. Chung, J.S. Baik, Y.J. Kim, H.-I. Ma (Jeju, Republic of Korea)

1:45pm-3:15pm: Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions

C. Lee, E.J. Choi, S.-C. Park, J.K. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Factors that contribute to the greatest levels of caregiver strain in Parkinson’s

A. Hand, L. Oates, W. Gray, R. Walker (North Shields, United Kingdom)

1:45pm-3:15pm: Feedback Controlled DBS in Parkinson’s Disease using Electrocorticography

N. Swann, C. de Hemptinne, A. Miller, W. Chen, I. Tamir, R Gilron, J. Ostrem, P. Starr (San Francisco, CA, USA)

1:45pm-3:15pm: Female reproductive factors and clinical features of PD

H. Liu, R. Ou, Y. Hou, Q. Wei, W. Song, B. Cao, B. Zhao, H. Shang (Chengdu, China)

1:45pm-3:15pm: First experience with 59 directional leads in deep brain stimulation

R. Nickl, P. Fricke, F. Steigerwald, J. Volkmann, C. Matthies (Würzburg, Germany)

1:45pm-3:15pm: First Report of Clinical Outcomes Resulting from Use of Directional Deep Brain Stimulation in Parkinson’s Disease and Essential Tremor

H. Braass, L. Venkatesan, C.-u. Choe, U. Hidding, B. Schönwald, C. Wargel, C. Buhmann, A. Gulberti, C. Moll, J. Köppen, C. Gerloff, W. Hamel, M. Pötter-Nerger (Hamburg, Germany)

1:45pm-3:15pm: Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression

E. Dalle, D. William, M. Musa (Durban, South Africa)

1:45pm-3:15pm: Focused neuromodulation by short pulse width improves gait ataxia in thalamic DBS

M. Reich, N. Pozzi, G. Brandt, A. Leporini, C. Palmisano, R. Lehrke, J. Volkmann, I. Isaias (Würzburg, Germany)

1:45pm-3:15pm: Freezing of gait is an early clinical feature of progressive supranuclear palsy

Y. Osaki, Y. Morita, Y. Miyamoto, T. Furushima, K. Furuta, H. Furuya (Nankoku, Japan)

1:45pm-3:15pm: From local partnership to national network: the growth of a medically connected, community based program model for Parkinson’s wellness

A. Lemen, P. Schmidt, PhD, R. Hagestuen, RN, V. Edelson, C. Kohles, M. Donovan, T. Elkins, M. Sweeney, LMSW, A. DiRocco, MD (New York, NY, USA)

1:45pm-3:15pm: Gait Analysis in Orthostatic Tremor treated with Thalamic Deep Brain Stimulation

T.K. Tareen, A. Duker, G. Mandybur, J. Tuazon, M. Rosso, A. Espay, A. Fasano, A. Merola (Cincinnati, OH, USA)

1:45pm-3:15pm: Gait and Cognition in Progressive Supranuclear Palsy: A Significant Association

K. Chatterjee, B. Mondal, S. Choudhury, H. Kumar (Kolkata, India)

1:45pm-3:15pm: Gait characteristics in Atypical Parkinsonism

S. Radovanovic, M. Jecmenica-Lukic, I. Petrovic, N. Dragasevic-Miskovic, M. Svetel, V. Kostic (Belgrade, Serbia)

1:45pm-3:15pm: Gait impairment and cognitive changes in a case of thalamic dementia and motor neuron disease.

S. O'Shea, O. Levy, J.P. Vonsattel, E. Cortes, K. Marder, H. Mitsumoto, R. Alcalay (New York, NY, USA)

1:45pm-3:15pm: GammaKnife subthalamotomy for Parkinson’s disease

t. witjas, r. carron, a. eusebio, j.p. azulay, j. regis (marseille, France)

1:45pm-3:15pm: Gastroesophageal dysmotility in advanced Parkinson’s Disease

F. Mancini, M. Lacerenza, L. Manfredi, A. Bestetti (Milan, Italy)

1:45pm-3:15pm: Gastrointestinal transit time in Parkinson’s disease -a novel 3D method

K. Knudsen, T. Fedorova, K. Østergaard, K. Krogh, P. Borghammer (Aarhus, Denmark)

1:45pm-3:15pm: Gender differences in motor and non-motor features across the Parkinson’s disease spectrum

T. Dunne, G. Stebbins, C. Goetz, S. Luo, J. Goldman (Chicago, IL, USA)

1:45pm-3:15pm: General Anesthesia and Parkinson’s Disease

C.-W. CHEN, K.-B. CHEN, Y.-C. KUO (TAICHUNG, Taiwan)

1:45pm-3:15pm: Genetic susceptibility associated to impulse control disorders and compulsive behaviors in Parkinson’s disease from a Spanish population.

S. JESUS, C. TEJERA-PARRADO, C. CORTES, M. BONILLA-TORIBIO, I. BERNAL-BERNAL, M. LABRADOR, L. VARGAS-GONZÁLEZ, M. BERNAL, A. ADARMES, F. CARRILLO, M. CARBALLO, P. GÓMEZ-GARRE, P. MIR (SEVILLA, Spain)

1:45pm-3:15pm: Gut Microbiota in Multiple System Atrophy

A.H. Tan, C.W. Chong, S.-L. Song, C.S.-J. Teh, I.K.-S. Yap, M.F. Loke, Y.Q. Tan, H.S. Yong, S. Mahadeva, A.E. Lang, S.-Y. Lim (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: Health related QoL as measured by the EQ-5D-5L in PD patients after DBS therapy: Preliminary results from the Product Surveillance Registry

M. Schiess, J. Krauss, J.-P. Azulay, E. Cuny, A. Lopez Rios, F. Farrokhi, S. Blond, T. Witt, C. Raftopoulos, J. Vesper, B. Van Dorn, T. Weaver, P. Konrad, S. Falowski, S. Palfi (Houston, TX, USA)

1:45pm-3:15pm: Heart rate variability in Parkinson’s Disease and idiopathic REM sleep behavior disorder and relation with other non-motor symptoms

P. Bugalho, M. Mendonça, T. Lampreia, R. Miguel, R. Barbosa, M. Salavisa (Lisbon, Portugal)

1:45pm-3:15pm: Helicobacter pylori eradication and risk of Parkinson’s disease in patients with peptic ulcers

Y.-P. Chang, G.-F. Chiu, Y.-H. Chang, D.-C. Wu (Kaohsiung, Taiwan)

1:45pm-3:15pm: High-Resolution Manometry (HRM) in Parkinson’s Disease (PD)

S. Brillman, C. Barlow, J. Cedarbaum, R. Gandhy, J. Langston, L. Rees, A. Su, G. Triadafilopoulos (Sunnyvale, CA, USA)

1:45pm-3:15pm: Histological analysis of α-synuclein pathology in the circadian system in Parkinson’s disease

E. De Pablo-Fernandez, J. Holton, T. Warner (London, United Kingdom)

1:45pm-3:15pm: How efficient is subthalamic deep brain stimulation in reducing dyskinesia in Parkinson’s Disease?

N. Kovacs, A. Juhász, I. Balás (Pecs, Hungary)

1:45pm-3:15pm: Impact and communication of OFF periods in Parkinson disease

T. Rastgardani, M. Armstrong, A. Gagliardi, C. Marras (Toronto, ON, Canada)

1:45pm-3:15pm: Impact of Duopa™ on Non-Motor Symptoms of Parkinson’s Patients with Deep Brain Stimulation

A. Wadhwa, R. Govindarajan, I. Asher (Columbia, MO, USA)

1:45pm-3:15pm: Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Buenos Aires, Argentina)

1:45pm-3:15pm: Implanted Brain-Computer Interface for communication in people with motor impairment

E. Pels, E. Aarnoutse, M. Vansteensel, S. Leinders, Z. Freudenburg, M. Branco, M. Vanden Boom, T. Denison, N. Ramsey (Utrecht, Netherlands)

1:45pm-3:15pm: Improved sleep quality evaluated by Parkinson’s disease sleep scale after deep brain stimulation of globus pallidus internus

N. Nishida, H. Toda, H. Saiki, S. Matsumoto, K. Iwasaki (Osaka, Japan)

1:45pm-3:15pm: Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the implantable pulse generator for subthalamic nucleus deep brain stimulation .

T. Kadowaki, K. Suzuki, E. Hoshiyama, T. Uchiyama, T. Shingo, K. Hirata (Mibu, Japan)

1:45pm-3:15pm: Impulse control disorder and associated clinical factors in drug-naïve Parkinson’s disease.

D. Gupta, M. Marano, S. Fahn (New York, NY, USA)

1:45pm-3:15pm: Impulse Control Disorders in Early Onset and Familial PD

R. Rees, N. Williams, Y. Ben-Shlomo, D. Grosset, H. Morris (London, United Kingdom)

1:45pm-3:15pm: Impulse control disorders in Parkinson’s disease; description of a New Zealand cohort

A. Garvey, S. Buchanan, N. Cutfield (Dunedin, New Zealand)

1:45pm-3:15pm: Impulsive-compulsive behaviors in patients with Parkinson´s disease in Kannur, India

N. Svensson, S. Ovallath, R. Constantinescu (Göteborg, Sweden)

1:45pm-3:15pm: Increased BMI May Protect Against Parkinson’s Disease: Evidence From A Mendelian Randomisation Study

A. Noyce, D. Kia, G. Hemani, A. Nicolas, T. Price, E. Fernandez, P. Haycock, P. Lewis, T. Foltynie, G. Davey Smith, A. Schrag, A. Lees, J. Hardy, A. Singleton, M. Nalls, N. Pearce, D. Lawlor, N. Wood (London, United Kingdom)

1:45pm-3:15pm: Influence of major earthquakes and their effects on patients with Parkinson’s disease: A multi-institutional study

R. Kurisaki, H. Ueyama, Y. Maeda, T. Sakamoto, K. Nakahara, S. Nakane, S. Yamashita, Y. Ando (Koshi, Japan)

1:45pm-3:15pm: Interleaved Stimulation for Freezing of Gait in Advanced Parkinson’s Disease: A Pilot Study

R. Rajan, S. Zafer, S. Krishnan, K. Kesavapisharady, A. Kishore (Trivandrum, India, India)

1:45pm-3:15pm: Internet-based Cognitive Behavioral Therapy for general function in patients with Parkinson’s Disease: A randomized controlled trial.

M. Kraepelien, R. Schibbye, P. Svenningsson, N. Lindefors, V. Kaldo (Stockholm, Sweden)

1:45pm-3:15pm: Interrelation between chronic pain syndrome and cognitive and affective disturbances in patients with Parkinson’s disease

K. Stepanchenko (Kharkiv, Ukraine)

1:45pm-3:15pm: Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial

W. Singer, A. Dietz, A. Zeller, T. Gehrking, J. Schmelzer, D. Sletten, J. Gehrking, E. Coon, P. Sandroni, E. Benarroch, R. Fealey, J. Matsumoto, J. Bower, J. Ahlskog, A. Hassan, A. McKeon, B. Klassen, P. Low (Rochester, MN, USA)

1:45pm-3:15pm: Investigating the Association between Anxiety and Cognitive Impairment in Parkinson’s Disease: A Descriptive Study

A. Toft, J. Yang, G. Byrne, J. O'Sullivan, L. Mitchell, D. Copland, N. Dissanayaka (Brisbane, Australia)

1:45pm-3:15pm: Investigation of Non-Motor Symptoms Impacting Care Dependency in Individuals with Parkinson’s Disease

M. Bryant, A. Tan, J.-G. Hou, E. Protas (Houston, TX, USA)

1:45pm-3:15pm: Is cognitive decline similar among Parkinson’s disease motor sub-types? A prospective study examining changes over time in gait, balance and cognition

T. Herman, L. Arie, S. Shema-Shiratzky, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: Is Hypertension and Certain Anti Hypertensive Agents Increase The Risk of Parkinson Disease?

R. Pinzon (Yogyakarta, Indonesia)

1:45pm-3:15pm: Key clinical milestones 15 years and onwards after DBS-STN surgery – a retrospective analysis of patients that underwent surgery between 1993 and 2001

R. Constantinescu, B. Eriksson, Y. Jansson, B. Johnels, B. Holmberg, T. Gudmundsdottir, A. Renck, P. Berglund, F. Bergquist (Göteborg, Sweden)

1:45pm-3:15pm: Levodopa induced dyskinesia in a case of progressive supranuclear palsy.

T. Yamamoto, H. Kawasaki, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, K. Takahashi, N. Tamura, N. Araki (Saitama, Japan)

1:45pm-3:15pm: Lifelong daily workload and postural abnormalities in patients with Parkinson’s disease

T. Maeda (Morioka, Japan)

1:45pm-3:15pm: Lifetime exposure to estrogen and risk for progressive supranuclear palsy

H.K. Park, I. Litvan, S. Ilango (Goyang-si, Republic of Korea)

1:45pm-3:15pm: Long term tremor benefit from cyst formation as a complication of DBS surgery in a patient with Parkinson’s disease

P. Morrison, I. Richard (Rochester, NY, USA)

1:45pm-3:15pm: Long-term Effects of Subthalamic Nucleus Deep Brain Stimulation on Quality of Life, Non-motor and Motor Symptoms

H. Dafsari, J. Petry-Schmelzer, M. Strack, L. Stalinski, V. Visser-Vandewalle, A. Rizos, M. Silverdale, K. Ashkan, M. Samuel, J. Evans, A. Antonini, P. Martinez-Martin, K. Ray Chaudhuri, L. Timmermann (Cologne, Germany)

1:45pm-3:15pm: Long-term levodopa therapy accelerates the circadian rhythm dysfunction in 6-OHDA rat model

D. Lv, Y. Wang, F. Wang, X. Zhang, X. Gu, Y. Yang (Suzhou, China)

1:45pm-3:15pm: Long-term Parkinson’s disease progression in PIGD and TD subtypes in the PPMI cohort

D. Aleksovski, D. Miljkovic, A. Antonini (Ljubljana, Slovenia)

1:45pm-3:15pm: Longitudinal changes in speech and voice functions after subthalamic stimulation in Parkinson’s disease patients

T. Tsuboi, H. Watanabe, Y. Tanaka, R. Ohdake, K. Kawabata, K. Hara, D. Nakatsubo, S. Maesawa, Y. Kajita, T. Wakabayashi, M. Katsuno, G. Sobue (Nagoya, Japan)

1:45pm-3:15pm: Lower education level is associated with greater disability from pain in Parkinson’s disease patients

A.Q. Rana, A.R. Qureshi, Z. Sarfaraz, R. Rana (Toronto, ON, Canada)

1:45pm-3:15pm: Lower urinary tract symptoms in patients with Parkinson’s Disease: findings from a Tunisian cohort

A. Nasri, M. Ben Djebara, Y. Sidhom, K. Achour, I. Kacem, A. Gargouri, R. Gouider (Manouba, Tunisia)

1:45pm-3:15pm: Management of parkinsonism in primary care.

A. Planas-Ballve, M. Muñoz, K. Beyer, L. Ispierto, D. Vilas, A.M. Crespo, L. Abraira, T. Canento, R. Álvarez (Badalona, Spain)

1:45pm-3:15pm: Maximising decrease in Dopaminergic drugs and increase in ON time following Bilateral STN DBS using constant current for Advanced Parkinsons Disease

S. SANYAL (CALCUTTA (KOLKATA), India)

1:45pm-3:15pm: MDS prodromal PD research criteria validation in two independent prospective cohorts

A. Pilotto, S. Heinzel, U. Suenkel, S. Lerche, K. Brockmann, b. Roeben, E. Schaeffer, i. Wurster, R. Yilmaz, I. Liepelt-Scarfone, A. von Thaler, F. Metzger, g. Eschweiler, R. Postuma, W. Maetzler, D. Berg (Tuebingen, Germany)

1:45pm-3:15pm: Meta-analysis of mortality following Subthalamic and Pallidal deep brain stimulation for patients with Parkinson’s disease

A. Negida (Zagazig, El-Sharkia, Egypt)

1:45pm-3:15pm: Metabolomics study in a group of Parkinson’s disease patients from Northern India

G.N. Babu, M. Gupta, V.K. Paliwal, S. Singh, R. Roy (Lucknow, India)

1:45pm-3:15pm: Mindfulness for People with Parkinson’s: Emotional Well Being, Social Support and Group Effect

B. Pickut, S. Woolner, R. Nyenhuis, D. Nyenhuis (Grand Rapids, MI, USA)

1:45pm-3:15pm: Motor and non-motor symptoms in old-age onset Parkinson’s Disease patients

M. Mendonça, T. Lampreia, R. Miguel, A. Caetano, R. Barbosa, P. Bugalho (Lisboa, Portugal)

1:45pm-3:15pm: Motor complications and others of therapy but not non-motor symptoms burden predict short-term mortality in non-demented Parkinson´s disease patients

D. Santos García, E. Suárez Castro, I. Expósito Ruíz, C. Tuñas Gesto, M. Aneiros Díaz, M. López Fernández, T. de Deus, D. Núñez Arias, J. Ernández (Ferrol, Spain)

1:45pm-3:15pm: Motor performance measured with the UPDRS in PD patientswith varying degrees of smell loss

c. cox, A. Kahttab, K. Amar (Bournemouth. Dorset, United Kingdom)

1:45pm-3:15pm: Movement Disorder Society – Clinical Diagnostic Criteria for Progressive Supranuclear Palsy

G. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K. Josephs, A. Lang, B. Mollenhauer, U. Müller, C. Nilsson, J. Whitwell, A. Boxer, L. Golbe, I. Litvan (Munich, Germany)

1:45pm-3:15pm: Movement disorders caused by benign brain tumor

A.M. Magnerou, P.E. Sounga Bandzouzi, H.F. Ngoungoure, M.M. Ndiaye (DAKAR, Senegal)

1:45pm-3:15pm: Mutational analysis of COQ2 in Chinese patients with multiple-system atrophy

J. Zhang, Y. Hao, Y. Chen, M. Ding, X. Zhang, W. Gu (Beijing, China)

1:45pm-3:15pm: Neuroactive steroids reverse the dopaminergic neurotransmission defectiveness in chronic hepatic (HE) encephalopathy: a possible involvement in HE related parkinsonism

O. El Hiba, A. EL Khiat, H. Gamrani (EL Jadida, Morocco)

1:45pm-3:15pm: Neuroanatomical correlates of depressive symptoms in newly diagnosed Parkinson’s disease patients

S.J. Kim (Busan, Republic of Korea)

1:45pm-3:15pm: Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson’s disease and multiple system atrophy

K.J. Kim, J.-M. Kim (Seongnam-Si, Republic of Korea)

1:45pm-3:15pm: Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms

D. Claassen, C. Adler, C. Gibbons, L.A. Hewitt (Nashville, TN, USA)

1:45pm-3:15pm: Neuropsychiatric and Cognitive Predictors of Early Diagnosis of Progressive Supranuclear Palsy

C. Pellicano, F. Assogna, N. Cellupica, M. Pierantozzi, A. Stefani, R. Cerroni, B. Mercuri, C. Caltagirone, F. Pontieri, G. Spalletta (Rome, Italy)

1:45pm-3:15pm: Neuropsychiatric symptoms after bilateral stimulation in Parkinson’s disease: subthalamic nucleus versus globus pallidus internus.

F. Fonoff, E. Fonoff, R. Machado, R. Cury, M.G. dos Santos, E. Barbosa (São Paulo, Brazil)

1:45pm-3:15pm: Neuropsychological predictors of patient-reported cognitive outcomes following deep brain stimulation

K. Mills, K. Donohue, A. Swaminathan, J.-M. Leoutsakos, J. Brandt (Baltimore, MD, USA)

1:45pm-3:15pm: Non-motor features of p.A53T α-synuclein mutation carriers compared to sporadic Parkinson’s disease in a PPMI cohort .

M. Stamelou, C. Koros, A. Simitsi, I. Beratis, X. Geronicola Trapali, D. Papadimitriou, N. Papagiannakis, A. Prentakis, D. Kontaxopoulou, S. Fragkiadaki, R. Antonelou, S. Papageorgiou, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: Non-motor symptoms and gender differences in multiple system atrophy

S. Eschlboeck, T. Benke, S. Bösch, M. Delazer, A. Djamshidian-Tehrani, A. Fanciulli, R. Granata, B. Högl, C. Kaindlstorfer, G. Kiss, F. Krismer, K. Mair, M. Nocker, C. Raccagni, C. Scherfler, K. Seppi, A. Stefani, W. Poewe, G. Wenning (Innsbruck, Austria)

1:45pm-3:15pm: Non-motor symptoms in a cross section of PD patients with varying degrees of smell loss

c. cox, A. Khattab, K. Amar (Bournemouth. Dorset, United Kingdom)

1:45pm-3:15pm: Non-motor symptoms in Parkinsons’s disease patients treated with levodopa-carbidopa intestinal gel infusion- the follow up study

A. Križnar, N. Zupančič Križnar, M. Kramberger, J. Bon, R. Rajnar, L. Ocepek, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: Non-motor symptoms in patients with Parkinson’s disease, essential tremor and both diseases – a group comparison

I. Wurster, A. Abaza, K. Brockmann, M. Rüdiger-Albers, S. Lerche, D. Berg (Tübingen, Germany)

1:45pm-3:15pm: Non-motor symptoms in the first neurology consultation in Cali – Colombia

J. Valderrama-Chaparro, J. Sanchez-Morante, Y. Ariza-Araujo, A. Enriquez-Marulanda, B. Munoz, J. Orozco (cali, Colombia)

1:45pm-3:15pm: NonMotor and Motor symptoms in Idiopathic Parkinson´s Disease and Secondary parkinsonism The “Parkinsons Well-Being MapTM” – a useful instrument in Clinical praxis.

Ö. Skogar, M. Nilsson, S. Morberg (Jönköping SWEDEN, Sweden)

1:45pm-3:15pm: Nonmotor disorders in Parkinsonism: Experience in Kyrgyz Republic

C. Shambetova (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: Nonpharmacological therapies for sleep disturbances in Parkinson’s disease patients: A Systematic review

J. Lee, Y. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Occupational Therapy for patients with Parkinson’s disease in the context of Bangladesh

R. Hoque (Dhaka, Bangladesh)

1:45pm-3:15pm: Occupational trichloroethylene exposure and Parkinson’s disease risk

S. Goldman, P. Quinlan, C. Meng, K. Comyns, G.W. Ross, K. Marek, C. Tanner (San Francisco, CA, USA)

1:45pm-3:15pm: Olfaction and gustation in patients with Parkinson’s Disease

A. Tautscher-Basnett, V. Tomantschger, M. Freimueller (Hermagor, Austria)

1:45pm-3:15pm: Olfactory deficits in the cognitive impaired de novo patients with Parkinson’s disease

J.S. Baik, H.I. Ma (Seoul, Republic of Korea)

1:45pm-3:15pm: Olfactory dysfunction in patient of Scans Without Evidence of Dopaminergic Deficit with parkinsonian bradykinesia

S.J. Kang, J.Y. Ahn, H.-T. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Optimising STN-DBS frequency parameters for improvement of gait with dual tasking in PD patients

R. Borgohain, R. Kandadai, R.P. Peddisetty, J. Kovvuru, S.S. Meka, R. Alagolu, M. Kannan (Hyderabad, India)

1:45pm-3:15pm: Oral health-related quality of life and dental care among Parkinson’s disease patients and Care givers of South India.

E. Aluckal (Ernakulam, India)

1:45pm-3:15pm: Pain and Parkinson’s disease

H. Wilson, T. Yousaf, G. Pagano, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Palliative Care in Parkinson Disease

A. Patterson, L. Almeida, M. Okun, I. Malaty (Gainesville, FL, USA)

1:45pm-3:15pm: Pancreatic polypeptide plasma levels in Parkinson’s disease – a marker of parasympathetic denervation

K. Knudsen, T. Fedorova, K. Østergaard, P. Borghammer (Aarhus, Denmark)

1:45pm-3:15pm: Parkinson Disease-Associated Polyneuropathy: A Biomarker of Disease Severity?

M. Rosso, A. Merola, A. Romagnolo, C. Comi, A. Fasano, M. Zibetti, R. Lopez-Castellanos, D. Cocito, L. Lopiano, A. Espay (Cincinnati, OH, USA)

1:45pm-3:15pm: Parkinson’s Disease and Urogenital Dysfunction

N. Sözer, M. Yenice, H. Erdogan, E. Demir, I. Yiğitbaşı, V. Tuğcu, V. Yayla (Istanbul, Turkey)

1:45pm-3:15pm: Parkinson’s disease patients with cognitive impairment more sensitive to pain?

K. Abe, K. Fukushima, K. Ando, Y. Maeda, R. Ishikura, H. Yoshikawa (Nishinomiya, Japan)

1:45pm-3:15pm: Parkinson’s disease and progressive dysphagia – consider myasthenia gravis

P. Urban (Hamburg, Germany)

1:45pm-3:15pm: Parkinson’s Disease from the Patient Perspective

L. Mischley, G. Canada, R. Lau (Kenmore, WA, USA)

1:45pm-3:15pm: Parkinson’s disease phenotype across different ethnic groups: Comparison of non-motor symptoms in patients living in the United Kingdom and Mexico

A. Sauerbier, M. Rodriguez Violante, A. Cervantes Arriaga, A. Rizos, D. Trivedi, P. Martinez-Martin, M. Parry, M. Rosa-Grilo, R. Brown, K. Ray Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Parkinsonism in Human African Trypanosomiasis: Clinical course, imaging findings and treatment-related challenges.

A. Aggarwal, T. Singhal, P. Borade, L. Hachaambwa, M. Munshi, D. Sanghvi, P. Dutta, A. Shrivastava (Mumbai, India)

1:45pm-3:15pm: Parkinsonism in Patients with Alzheimer Disease and Epileptic Seizures

I. Petrov (Skopje, The former Yugoslav Republic of Macedonia)

1:45pm-3:15pm: Parkinsonism Revealing Cerebral Hematoma with Moya Moya Disease

z. brahem, i. bedoui, a. riahi, m. mansour, j. zaouali, r. mrissa (tunis, Tunisia)

1:45pm-3:15pm: Parkinsonism through astrocytic GABA induce motor symptoms

M.J. Lee, Y. Jang, J. Han, S.J. Kim, J. Kim, I. Ryu, X. Ju, M.J. Ryu, S.-Y. Choi, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: Pathological crying induced by deep brain stimulation of the subthalamic nucleus in Parkinsons’ disease

M. Wolf, M. Abdallat, C. Blahak, J. Krauss (Mannheim, Germany)

1:45pm-3:15pm: Patient characteristics that impact caregiver burden in Parkinson’s disease in Singapore

K. Prakash, E.-K. Tan (Singapore, Singapore)

1:45pm-3:15pm: Patient characteristics vary by DBS indication in Parkinson disease patients

A. Pusso, S. Sperling, M. Harrison, F. Wooten, J. Elias, B. Shah, M. Barrett (Charlottesville, VA, USA)

1:45pm-3:15pm: Patient-Reported Outcomes in a Prospective Real-World Study of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension

S. Kymes, C. François, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, C. Shibao, B. Yue, I. Biaggioni (Deerfield, IL, USA)

1:45pm-3:15pm: PD Check-In: Supporting people with Parkinson’s Disease in self-managed maintenance of communication following intensive speech treatment

A. Finnimore, D. Theodoros, A. Rumbach (Brisbane, Australia)

1:45pm-3:15pm: Perceived facilitators and barriers in communicating with family member among people with Parkinson’s Disease: A focus group study

J. Lee, Y. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Perceptual and acoustical analysis of speech in multiple system atrophy and progressive supranuclear palsy.

S. Contardi, A. Gessani, F. Cavallieri, C. Budriesi, A. Bernardi, M. Tondelli, E. Menozzi, A. Chiari, P. Nichelli, F. Valzania (Modena, Italy)

1:45pm-3:15pm: PET-MRI Imaging in Parkinson Dementia Complex of Guam: A Case Report

A. Tran, K. Chan, V. Kharidi, E. Goldstein, R. Burns, P. Reyes (Phoenix, AZ, USA)

1:45pm-3:15pm: Pharmaeconomic study of the treatment of advanced Parkinson’s disease.

F. VIVANCOS-MATELLANO, A. SANZ, J.U. MIRÓ, J. CADAVID, A. RUÍZ, N. SOLER (Madrid, Spain)

1:45pm-3:15pm: Phasic activity during non REM sleep

R. Miguel, I. Arnulf (Lisboa, Portugal)

1:45pm-3:15pm: Phenotypic Heterogeneity in PSP Variants – A Case Series

S. BHADRAN, S. ABRAHAM, B. NATARAJAN, A. MEKKATTUKUNNEL, J. KRISHNAN, R. ISAAC, P.K. PAL (THRISSUR, India)

1:45pm-3:15pm: Physical Activity and Quality of Life in People with Parkinson’s Disease – A Long-term Follow-up Study

I-F. Shih, K. Paul, J. Bronstein, B. Ritz (Los Angeles, CA, USA)

1:45pm-3:15pm: Physical but not mental aspects of health-related quality of life are improved in 10-year long-term follow-up of deep brain stimulation for segmental dystonia

C. Blahak, M. Wolf, A. Saryyeva, H. Baezner, J. Krauss (Mannheim, Germany)

1:45pm-3:15pm: Postoperative Cognitive Impairment Following Deep Brain Stimulation Surgery

A. Whyte-Rayson, P. Hickey, M. Berger (Durham, NC, USA)

1:45pm-3:15pm: Postoperative delirium after deep brain stimulation surgery for Parkinson’s disease

F. Sasaki, G. Oyama, M. Ito, S. Sekimoto, R. Nakamura, T. Jo, Y. Simo, A. Umemura, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Pre-synaptic dopaminergic deficit in a patient with familial FTD

M. Sousa, R. Varela, C. Januário, A. Morgadinho (Coimbra, Portugal)

1:45pm-3:15pm: Predicting the onset of freezing of gait: A longitudinal study

K. Ehgoetz Martens, E. Lukasik, M. Georgiades, M. Gilat, J. Hall, C. Walton, S. Lewis (Camperdown, Australia)

1:45pm-3:15pm: Predictors of cognitive impairment in multiple system atrophy

M. Hatakeyama, T. Sato, T. Takahashi, M. Kanazawa, O. Onodera, M. Nishizawa (Niigata, Japan)

1:45pm-3:15pm: Predictors of Patient Satisfaction with Rechargeable Deep Brain Stimulator Implantable Pulse Generators

K. Mitchell, M. Volz, S. Wang, A. Lee, J. Ostrem (San Francisco, CA, USA)

1:45pm-3:15pm: Preoperative slowing of EEG and neurocognitive changes following subthalamic nucleus deep brain stimulation in Parkinson’s disease

Y. Higuchi, M. Yakufujiang, Y. Okahara, K. Aoyagi, M. Abe, T. Yamamoto, Y. Yamanaka, S. Hirano, Y. Iwadate (Chiba, Japan)

1:45pm-3:15pm: Prevalence of burning mouth syndrome in Parkinson disease

X.X. Yu, H. Fernandez (Cleveland, OH, USA)

1:45pm-3:15pm: Primary progressive apraxia: an unusual ideomotor syndrome

Y. Fernandez, S. Frucht (New York, NY, USA)

1:45pm-3:15pm: Probabilistic mapping of deep brain stimulation in Parkinson’s disease.

T. Dembek, J. Roediger, V. Visser-Vandewalle, L. Timmermann, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: Probiotic correction of intestinal dysbiosis in Parkinson’s disease

I. Miliukhina, E. Ermolenko, A. Ivanova, M. Kotyleva, A. Suvorov (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Profiling the Non Motor Symptoms burden in Parkinson’s disease patients in Nigeria

T. Farombi, A. Ogunniyi (Ibadan, Nigeria)

1:45pm-3:15pm: Profound reduction of DAT-SPECT signal in multiple system atrophy (MSA)

I. Toyoshima, T. Hatakeyama, E. Abe, C. Wada, M. Kobayashi, K. Obara (Yurihonjo, Japan)

1:45pm-3:15pm: Programming deep brain stimulation in the globus pallidus internus for treatment of idiopathic Parkinson’s disease: experience at the University of Kentucky

J. Gurwell, J. Quintero, J. Lamm, J. Slevin, G. Gerhardt, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: Progression of milestones by clinical types in progressive supranuclear palsy: a longitudinal observational study of a cohort of patients with PSP/CBD (the JALPAC project)

I. Aiba, T. Ikeuchi, H. Takigawa, T. Shimohata, T. Tokuda, M. Morita, O. Onodera, S. Murayama, K. Hasegawa, K. Nakashima (Nagoya, Japan)

1:45pm-3:15pm: Progressive Supranuclear Palsy : About one case at the Neurology Department – Dakar

L. Belarabi, K. Toure, M. Ndiaye (Dakar, Senegal)

1:45pm-3:15pm: Progressive supranuclear palsy presenting with corticobasal syndrome: a case report

M. Sousa, R. Varela, C. Januário, A. Morgadinho (Coimbra, Portugal)

1:45pm-3:15pm: Psychological distress among caregivers of Parkinson’s patients assessed with the SCL-90-R self-reported questionnaire

B. Ozdilek, S. Bozkurt Zincir, D. Ince Gunal (Istanbul, Turkey)

1:45pm-3:15pm: Psychosocial evaluation in caregivers of patients with Parkinson’s disease: analysis of a cohort of Rio de Janeiro / Brazil

V. Carvalho Neri, C. Teixeira Muratori, P. Portes Ferreira, P. Sandin, G. Licassali, S. Barbosa Gomes, E. Reynaldo (Campos dos Goytacazes, Brazil)

1:45pm-3:15pm: Psychosocial Impact of X-Linked Dystonia Parkinsonism (XDP) of Panay

J.N. Ong, C. Go, G. Solinap, P. Acuna (Manila, Philippines)

1:45pm-3:15pm: Quality of life and its influencing factors in a local population of advanced geriatric Parkinson´s Disease patients

M. Klietz, A. Tulke, C. Schrader, L. Diekstall, L. Müschen, D. Dressler, F. Wegner (Hannover, Germany)

1:45pm-3:15pm: Quality of Life in Homebound People with Advanced Parkinson’s Disease: Feasibility and Outcomes of an Interdisciplinary Home Visit Program

J. Fleisher, M. Sweeney, S. Oyler, A. Lemen, A. Fazl, M. Ko, T. Meisel, N. Friede, G. Dacpano, R. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

1:45pm-3:15pm: Quantitative measures of brain MRI as a predictive factor of cognitive outcomes after Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s disease

L. Weinkle, J. Tanabe, B. Hoyt, J. Thompson, J. Honce, O. Klepitskaya (Aurora, CO, USA)

1:45pm-3:15pm: Randomize study of occurrence of Parkinson’s syndrome in patients with rheumatoid arthritis.

M. Mavlanov, S. Aslanova, G. Rakhimbaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Rare presentation of acute secondary parkinsonism in the post partum period.

D. Desai, S. Desai (Anand, India)

1:45pm-3:15pm: Real-world non-motor score changes in Parkinson’s disease patients with motor fluctuations: The J-FIRST study

H. Watanabe, H. Saiki, S.-W. Chiu, T. Yamaguchi, K. Kashihara, Y. Tsuboi, M. Nomoto, N. Hattori, T. Maeda, Y. Shimo (Nagoya, Japan)

1:45pm-3:15pm: Redefining social work for Parkinson’s: the development of a model of care for specialized support in the clinic, community and home

A. Lemen, LCSW, M. Sweeney, LMSW, V. Luce, LCSW, D. Rayment, LMSW, A. Di Rocco (New York, NY, USA)

1:45pm-3:15pm: Relationship between neuropsychological functioning and subjective measures of sleep quality in Parkinson Disease

E. Montanaro, M. Zibetti, F. Dematteis, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Relationship between sleep profiles and clinical features in Parkinson’s disease

Y.-Y. Lin, R.-S. Chen, C.-S. Lu, Y.-Z. Huang, Y.-H. Weng, T.-H. Yeh, W.-Y. Lin, J. Hung (Taoyuan, Taiwan)

1:45pm-3:15pm: REM sleep behavior disorder: Is it useful to differentiate between Parkinson disease and Progressive Supranuclear Palsy?

H. Gupta, S. Mehta, J. Hentz, H. Shill, E. Driver-Dunckley, M. Sabbagh, C. Belden, B. Dugger, T. Beach, G. Serrano, L. Sue, C. Adler (Scottsdale, AZ, USA)

1:45pm-3:15pm: Research participants are not representative of the population age distribution of PD

A. Macleod, R. Henery, P. Nwajiugo, C. Counsell (Aberdeen, United Kingdom)

1:45pm-3:15pm: Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design

N. Mendonca, T. West, J. Braunstein, I. Fogelman, Y. Bordelon, I. Litvan, E. Roberson, H. Hu, P. Verghese, R. Bateman, H. Florian, D. Wang, D. Ryman, L. Gault, K. Budur, B. Rendenbach-Mueller, D. Kerwin, A. Boxer, D. Holtzman (Ludwigshafen, Germany)

1:45pm-3:15pm: Riding the puzzle: deep brain stimulation and the non-motor symptoms in Parkinson’s disease

A.C. Campos, E. Talamoni Fonoff, C. Hamani, R. Lima Pagano (São Paulo, Brazil)

1:45pm-3:15pm: Rolipram, a PDE-IV inhibitor protects against experimental Parkinsonism in mice

N. KUMAR, R. Khanna (Jaipur, India)

1:45pm-3:15pm: Safe Functional MR Imaging in STN-DBS implanted Parkinson’s disease

M. Saxena, C. McIntyre, B. Walter (Cleveland, OH, USA)

1:45pm-3:15pm: Safety and tolerability of deep brain stimulation in early stage Parkinson’s disease: Five-year follow-up of medication use and adverse events

A. Currie, M. Turchan, L. Heusinkveld, S. Millan, M. Hacker, A. Molinari, C. Gill, T. Davis, P. Konrad, F. Phibbs, P. Hedera, D. Charles (Memphis, TN, USA)

1:45pm-3:15pm: Safety of Unilateral and Bilateral DBS implants in ET: Preliminary results from Product Surveillance Registry

M. Schiess, S. Falowski, G. Plotkin, S. Palfi, T. Witt, E. Cuny, T. Theys, K. Martinez, R. Plunkett, Y. Temel, G. Johnson, T. Weaver, J. Krauss, P. Konrad (Houston, TX, USA)

1:45pm-3:15pm: Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.

C. Cattaneo (Bresso (Milan), Italy)

1:45pm-3:15pm: Saliva changes and the oral health in Parkinson´s disease

J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)

1:45pm-3:15pm: Secondary Vascular Parkinsonism in Uzbekistan: Hormonal Pathogenetic Effects and Vascular-Immunological Basics.

D. Akramova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Self-rated burden grading of nonmotor symptoms identifies landmarks and subtypes of Parkinson’s disease: first report from a Moscow-Madrid-London collaboration

N. Titova, S. Cankaya, F. Spinnato, E. Katunina, P. Martinez-Martin, M. Qamar, K.R. Chaudhuri (Moscow, Russian Federation)

1:45pm-3:15pm: Semiquantitative analyses of DAT-SPECT imaging with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism

N. Morimoto, M. Takamiya, M. Morimoto (Takamatsu, Japan)

1:45pm-3:15pm: Serum cholesterol levels over time and risk of Parkinson’s disease

V. Rozani, T. Gurevich, N. Giladi, B. El-Ad, J. Tsamir, B. Hemo, C. Peretz (Tel A viv, Israel)

1:45pm-3:15pm: Serum Mir-30c as a Potential Biomarker to Discriminate MSA from PD Patients: A Pilot Study.

A. Vallelunga, M. Sessa, D. Giovanna, M. Picillo, P. Barone, M.T. Pellecchia (Salerno, Italy)

1:45pm-3:15pm: Sex Differences in Homebound Advanced Parkinson’s Disease Patients

L. Nwabuobi, W. Barbosa, M. Sweeney, S. Oyler, A. Lemen, T. Meisel, A. Di Rocco, J. Chodosh, J. Fleisher (New York, NY, USA)

1:45pm-3:15pm: Sexual Dysfunction in Women with Parkinson’s Disease

A. Hannoun, E. Adams, K. Smith, N. Cohen, A. Deb (Worcester, MA, USA)

1:45pm-3:15pm: Sleep quality in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel infusion

O. De Fabregues, A. Ferré, O. Romero, J. Dot, M. Abu-Suboh, M. Quintana, J.R. Armengol, J. Alvarez-Sabin (Barcelona, Spain)

1:45pm-3:15pm: Sleepiness and depression in Korean patients with Parkinson’s disease treated with ropinirole and levodopa

S.Y. Kang, H.-S. Ryu, M.-K. Sunwoo, S.-J. Kim, J.-S. Baik, M.-Y. Park, H.-E. Park, J.-S. Kim, K.-Y. Kwon, S.-B. Koh, Y.-E. Kim, M.-K. Lee, J.-M. Kim, S.J. Chung, Y.-H. Sohn (Hwaseong, Republic of Korea)

1:45pm-3:15pm: Somnolence as untoward stimulation effect in subthalamic deep brain stimulation (STN DBS) for Parkinson’s disease (PD)

F. Danisi, C. Miller (Poughkeepsie, NY, USA)

1:45pm-3:15pm: Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge

M. Fabbri, I. Guimarães, M. Coelho, R. Cardoso, L. Guedes, M. Rosa, C. Godinho, A. Antonini, J. Ferreira (Lisbon, Portugal)

1:45pm-3:15pm: Speech Markers Estimate Motor Severity and Global Cognition in Parkinson’s Disease

K. Smith, T. Quatieri, J. Williamson (Worcester, MA, USA)

1:45pm-3:15pm: Spinal cord stimulation reduces freezing of gait and improves gait in advanced Parkinson’s disease

O. Samotus, N. Kumar, S. Memar, M. Jog (London, ON, Canada)

1:45pm-3:15pm: Status dystonicus treated by Deep Brain Stimulation in Niemann Pick type C

V. Gonzalez, L. Cif, X. Ayrignac, F. Cyprien, E. Nerrant, E. Sanrey, E. Chan seng, M. Koenig, P. Coubes (Montpellier, France)

1:45pm-3:15pm: STN DBS can temporarily improve balance disorders in Parkinson’s disease (PD) patients.

S. Szlufik, M. Kloda, I. Potrzebowska, K. Gregier, A. Friedman, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Bialoszewski, D. Koziorowski (Warsaw, Poland)

1:45pm-3:15pm: Study of an early wellness program in Parkinson’s disease: impact on quality of life and early intervention guidance

B. Page, H. Shill (Phoenix, AZ, USA)

1:45pm-3:15pm: Subjective visual vertical in patients with early Parkinson’s disease

H.S. Kim, H. Lee, S. Chu (Kyunggi-do, Republic of Korea)

1:45pm-3:15pm: Subthalamic nucleus local field potential activity during the sleep-wake cycle

A. Tekriwal, J. Thompson, A. Abosch (Aurora, CO, USA)

1:45pm-3:15pm: Successful deep brain stimulation treatment of incapacitating tremor resulting from bilateral thalamic infarcts complicating surgery for Arnold Chiari malformation/syringomyelia.

S. Alusi, M. Bonello, K. Das, L. Lowry, P. Eldridge (Liverpool, United Kingdom)

1:45pm-3:15pm: Sudden onset of parkinsonism in a case of dural arteriovenous fistula

H. Kawasaki, T. Yamamoto, A. Miyake, K. Ikeda, T. Mistuhuji, Y. Ito, K. Takahashi, N. Tamura, N. Araki (Moroyama, Japan)

1:45pm-3:15pm: Suicide in Parkinson disease

W. Li, H. Seah, L. Ng, Y. Tay, L. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: SweetSpot of antidystonic effect in pallidal neurostimulation: a European multicentre imaging study

M. Reich, L. Lange, J. Roothans, A. Horn, F. Wodarg, J. Runge, M. Aström, F. Steigerwald, K. Witt, R. Nickl, P. Plettig, M. Wittstock, V. Coenen, P. Mahlknecht, W. Poewe, W. Eisner, C. Matthies, A. Kühn, J. Krauss, G. Deuschl*, J. Volkmann* (Wuerzburg, Germany)

1:45pm-3:15pm: Tau Network Genes in a Genome Wide Association Study of Progressive Supranuclear Palsy

T. Chang (Los Angeles, CA, USA)

1:45pm-3:15pm: Tear tumor necrosis factor-alpha levels in patients with Parkinson’s disease: The effect of deep brain stimulation

B. Kocer, S. Comoglu, H. Guven, M. Acar, G. Ozturk (Ankara, Turkey)

1:45pm-3:15pm: The battery longevity of implantable pulse generators (IPG) in Parkinson’s disease (PD) is affected by IPG model, number of previous IPG replacements and stimulation energy delivered.

S. Israeli-Korn, T. Fay-Karmon, S. Tessler, G. Yahalom, S. Benizri, H. Strauss, Z. Zibly, R. Spiegelmann, S. Hassin (Ramat Gan, Israel)

1:45pm-3:15pm: The clinical phenotype of progressive supranuclear gaze palsy with predominant cerebellar ataxia (PSP-C): a case series

Z. Xu, T. Lim, W.L. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: The complex relationship between olfactory and cognitive impairment in Parkinson’s disease

J. Djordjevic, N.S. Saadat, A. Sadikot, T. White (Montreal, QC, Canada)

1:45pm-3:15pm: The DBS response ratio: An individual benchmark parameter of DBS quality

L. Lange, M. Reich, R. Nickl, F. Steigerwald, C. Matthies, J. Volkmann (Wuerzburg, Germany)

1:45pm-3:15pm: The diagnostic challenges of patients with possible multiple system atrophy

M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)

1:45pm-3:15pm: The effect and mechanism of acupuncture for pain in Parkinson’s disease

S.-W. Yu, Y.-R. Wu, J.-J. Wang, C.-C. Tsai (Taoyuan, Taiwan)

1:45pm-3:15pm: The effect of deep brain stimulation in a computational model of essential tremor

N. Yousif, M. Mace, N. Pavese, S. Al-Rasheed, R. Borisyuk, P. Bain, D. Nandi (Hatfield, United Kingdom)

1:45pm-3:15pm: The environmental and genetic risk factors in multiple system atrophy in a Taiwanese population

M.-C. Kuo, Y.-C. Lu, M.-L. Chen, C.-H. Tai, C.-H. Lin, R.-M. Wu (Taipei, Taiwan)

1:45pm-3:15pm: The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.

D. Stephenson, A. Porter, K. Romero, G. Podskalny, E. Bastings, B. Dunn, S. Goldstein, T. Mullin (Tucson, AZ, USA)

1:45pm-3:15pm: The impact of divided attention in dual task conditions on drooling in Parkinson’s Disease (PD): a pilot study

H. Reynolds, N. Miller, R. Walker (Gateshead, United Kingdom)

1:45pm-3:15pm: The impact of intensive voice treatment on swallowing in Parkinson disease

D. McFarland, L. Ramig, B. Martin-Harris, K. Humphries, J. Logemann, K. Freeman, A. Halpern, J. Spielman (Montréal, QC, Canada)

1:45pm-3:15pm: The impact of Parkinson’s disease on faith and spirituality

A. Weldehana (Addis Ababa, Ethiopia)

1:45pm-3:15pm: The influence of sleep disordered breathing in REM sleep behavior disorder associated symptoms

P. Bugalho, M. Mendonça, M. Salavisa, R. Barbosa (Lisbon, Portugal)

1:45pm-3:15pm: The Life Style and Risk of Parkinson Disease

R. Pinzon (Yogyakarta, Indonesia)

1:45pm-3:15pm: The non-motor symptoms in Parkinsons’s disease patients treated with STN DBS: the follow up study

M. Mencinger, M. Červek, T. Rus, G. Jakob, D. Georgiev, D. Flisar, R. Rajnar, M. Benedičič, K. Boetzel, J. Mehrkens, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: The Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale for use in Sweden

P. Hagell, M. Nilsson, R. Chaudhuri, P. Odin (Kristianstad, Sweden)

1:45pm-3:15pm: The phenotypic spectrum of patients with progressive supranuclear palsy

M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)

1:45pm-3:15pm: The predictor factors for survival in Chinese Multiple System Atrophy patients

B. Cao, L. Zhang, Y. Zou, Q. Wei, R. Ou, Y. Chen, J. Yang, Y. Wu, H. Shang (Chengdu, China)

1:45pm-3:15pm: The Relationship between Olfactory Function and Clinical Subtypes of Parkinson’s Disease

D.-Y. Kwon (Ansan, Republic of Korea)

1:45pm-3:15pm: The Role of Social Work in Improving Comprehensive Care for Parkinson’s Disease

E. Book, A. Lemen (Vancouver, BC, Canada)

1:45pm-3:15pm: The Roles of Diet, Exercise, & Supplements in Parkinson’s Disease Progression

L. Mischley, R. Lau (Kenmore, WA, USA)

1:45pm-3:15pm: The secular change of quality of life in patients with Parkinson’s disease.

A. Kumon, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)

1:45pm-3:15pm: The Superior Colliculus is impaired in de novo Parkinson’s disease patients

E. BELLOT, E. BELLOT, V. COIZET, S. MEONI, P. PELISSIER, B. DEBU, M. DOJAT, E. MORO (LA TRONCHE, France)

1:45pm-3:15pm: The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)

1:45pm-3:15pm: The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease

T. Yamamoto, M. Asahina, Y. Yamanaka, T. Uchiyama, S. Hirano, M. Fuse, Y. Koga, R. Sakakibara, S. Kuwabara (Chiba, Japan)

1:45pm-3:15pm: The Value of Follow Up: The Role of Social Work and Nursing Calls in an Interdisciplinary Home Visit Program for Advanced Parkinson’s Disease Patients

S. Oyler, M. Sweeney, A. Lemen, A. Di Rocco, J. Fleisher (New York, NY, USA)

1:45pm-3:15pm: The value of various risk factors in the manifestation of Parkinson’s disease in the southern part of Uzbekistan.

S. Lukmonov (Tashkent, Uzbekistan)

1:45pm-3:15pm: To Study the Role of Biomarkers DJ-1 and Apo A1 in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in Indian Population

M. Modi, R. Shree, S. Mehta, M. Goyal, B. Medhi, V. Lal, B. Mittal (Chandigarh, India)

1:45pm-3:15pm: Tongue Strength in PSP

H. Clark, J. Whitwell, J. Ahlskog, K. Josephs (Rochester, MN, USA)

1:45pm-3:15pm: Tonsillectomy and risk of Parkinson’s disease: A Danish nationwide population-based cohort study

E. Svensson, V. Henderson, S. Szépligeti, M. Stokholm, T. Klug, H. Sørensen, P. Borghammer (Aarhus, Denmark)

1:45pm-3:15pm: Transient loss of psychic self-activation following bilateral thalamic ventral intermediate nucleus stimulation for essential tremor

C. Marques-Matos, L. Braz, P. Monteiro, M. Mota-Oliveira, C. Reis, P. Linhares, R. Vaz, M.J. Rosas (Porto, Portugal)

1:45pm-3:15pm: Translation and validation of the Filipino version of the wearing-off questionnaire-19 (F-WOQ-19)

K. Remigio, R.D. Jamora (Manila, Philippines)

1:45pm-3:15pm: Treatment Outcomes for Deep Brain Stimulation in Sex-Linked Dystonia Parkinsonism (XDP, DYT3) Up To 60 Months Follow-up – A Case Series

J.E. Abejero, J. Aguilar, T. Vesagas, R. Teleg, J. Anlacan, R.D. Jamora (Manila, Philippines)

1:45pm-3:15pm: Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease

B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)

1:45pm-3:15pm: Twiddler Syndrome in Deep Brain Stimulation

N. Durmaz Celik, M. Vural, S. Ozkan (Eskişehir, Turkey)

1:45pm-3:15pm: Two ethnic clusters with Huntington’s disease in Israel – The case of Mountain Jews and Karaites

J. Zitser, A. Thaler, N. Inbar, S. Naor, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Two patients with dystonia treated with internal globus pallidus deep brain stimulation (GPi-DBS) using a multiple independent source current-controlled system,long term results,a case report 

O. Morsi, J. Jimenez, J. Lopez, B. Cuartero, J. Zamarro, R. Sanchez, M. Felipe, J.J. Martin (Murcia, Spain)

1:45pm-3:15pm: Two-year prospective study reveals that gut dysbiosis predicts progression of Parkinson’s disease

M. Hirayama, T. Minato, Y. Fujisawa, H. Tsuji, T. Asahara, K. Nomoto, T. Maeda, K. Ohno (Nagoya, Japan)

1:45pm-3:15pm: Tyrosine kinase inhibition clears Tau and reserves neuropathology and motor symptoms in a novel model of progressive supranuclear palsy

Y. Torres-Yaghi, F. Pagan, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, M. Javidnia, M. Hebron, C. Moussa (Washington, DC, USA)

1:45pm-3:15pm: Understanding the illness experience of people living with Parkinson’s disease: A mixed methods study

JJ.Y.-Y. Kwok, M.M. AuYeung, H.Y.-L. Chan (Hong Kong, Hong Kong)

1:45pm-3:15pm: UPDRS benefit from dual frequency DBS fields sculpted by intentionally overlapped interleaving

Y. Fernandez, D. Caputo, D. Schneider, R. Dipaola, S. Danish, E. Hargreaves (New York, NY, USA)

1:45pm-3:15pm: UPDRS III score and RS latency can determine the possible neuromodulative role of STN DBS in Parkinson’s disease (PD) patients

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

1:45pm-3:15pm: Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment

D. Weintraub, J. Norton, D. Fredericks, B. Coate, C. Andersson, C. Ballard (Philadelphia, PA, USA)

1:45pm-3:15pm: Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

M. Jecmenica Lukic, T. Pekmezovic, I. Petrovic, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)

1:45pm-3:15pm: Utility of THK-5351 tau-PET for differential diagnosis in patients with hypokinetic-rigid syndromes.

G. Rohrer, S. Schönecker, M. Brendel, J. Havla, G. Höglinger, S. Lindner, C. Zach, F. Vettermann, C. Prix, G. Nübling, P. Bartenstein, K. Furukawa, A. Ishiki, N. Okamura, K. Bötzel, A. Rominger, J. Levin (Munich, Germany)

1:45pm-3:15pm: Validation of the performance based Erlangen Test of Activities of Daily Living in PD

I. Liepelt-Scarfone, L. Liebig, P. Sulzer, D. Berg (Tübingen, Germany)

1:45pm-3:15pm: Validation of the Utility of Brief Smell Identification Test Simplified Chinese Version 2 in Chinese Parkinson’s disease

M. Cao (Beijing, China)

1:45pm-3:15pm: Vascular Parkinsonism, an underdiagnosed Parkinsonian variant : An outpatient study from a South Indian Superspeciality Private Hospital

S. Jaiswal, M. Reddy (Hyderabad, India)

1:45pm-3:15pm: Videoendoscopy study of swallowing in Parkinson’s disease

J. Fukae, Y. Tsuboi, S. Fujioka, G. Umemoto (Fukuoka, Japan)

1:45pm-3:15pm: Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy

W. Meissner, F. Bassil, P. Guerin, N. Dutheil, Q. Li, M. Klugmann, E. Bezard, P.-O. Fernagut (Bordeaux, France)

1:45pm-3:15pm: Vmat2 heterozygote mice display motor dysfunction and progressive depressive-like behaviors

K. Ma, J. Huang, L. Liu, C. Han, X. Guo, S. Guo, L. Wang, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

1:45pm-3:15pm: Weight Changes in STN and GPi Deep Brain Stimulation: Long Term Follow up

S. Shah, L. Almeida, A. Patterson, J. Hilliard, A. Wagle Shukla, K. Foote, M. Okun, D. Martinez-Ramirez, P. Zeilman (Gainesville, FL, USA)

1:45pm-3:15pm: Weight loss in Parkinson’s disease (PD)

K. Khalid, D. Linsky, H. Khan, S. Pradhan, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: What does the severity of hemifacial spasm mean to us?

J. Youn, J.W. Cho (Seoul, Republic of Korea)

1:45pm-3:15pm: What impacts relationship satisfaction in Parkinsonian dementias?

S. Vatter, K. McDonald, S. McCormick, I. Leroi (Manchester, United Kingdom)

1:45pm-3:15pm: Where Are The Main Lesions That Cause Orthostatic Hypotension In Parkinson’s Disease ?

R. Sengoku, M. Shibukawa, M. Yamazaki, K. Eguchi, M. Higashihara, D. Kaneda, Y. Nishina, K. Kanemaru, S. Murayama (Tokyo, Japan)

1:45pm-3:15pm: Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review

G. Respondek, C. Kurz, T. Arzberger, E. Gelpi, D. Irwin, W. Meissner, A. Pantelyat, A. Rajput, J. Van Swieten, C. Troakes, K. Josephs, A. Lang, U. Mueller, C. Nilsson, Y. Bordelon, J.-C. Corvol, A. Boxer, L. Golbe, I. Litvan, M. Stamelou, G. Hoeglinger (Munich, Germany, Germany)

1:45pm-3:15pm: α-Synuclein Preformed Fibrils Induce Disruption of Myelin Basic Protein Expression in Primary Oligodendrocyte Culture; Deciphering Glial Pathology in Multiple System Atrophy

S. Kaji, T. Maki, N. Uemura, R. Takahashi (Kyoto, Japan)

1:45pm-3:15pm: “Essential tremor” as a presenting symptom of neuronal intranuclear inclusion disease (NIID).

Z. Xu, W.-Y. Yu, J. Tan, H.-Y. Lee, Q. Cheng, T. Lim (Singapore, Singapore)

1:45pm-3:15pm: A Descriptive Analysis of a Real-World Population With Huntington Disease-Associated Chorea (HDAC) Treated With Tetrabenazine: Findings From an Electronic Medical Records (EMR) Database

R. Iver, D. Alevras, S. Gandhi, T. Schilling, V. Abler, F. Cao, K. Johnson, K. Anderson (Frazer, PA, USA)

1:45pm-3:15pm: A model community neurofitness and wellness center for people with Parkinson disease. 1-year group pilot data

E. Borchers, B. Farley, D. Snider, T. McIsaac, J. Bazan-Wigle (Tucson, AZ, USA)

1:45pm-3:15pm: A modified model for prediction of Huntington disease age of onset based on length of CAG repeat expansion

Y. Seliverstov, E. Shulgina, S. Illarioshkin, M. Belyaev (Moscow, Russian Federation)

1:45pm-3:15pm: A new neurophysiological tool for differential diagnosis in tremor syndromes: The Tremor Stability Index

L. di Biase, J.-S. Brittain, S.A. Shah, D.J. Pedrosa, H. Cagnan, A. Mathy, C.C. Chen, L. Timmerman, P. Schwingenschuh, K. Bhatia, V. Di Lazzaro, P. Brown (Oxford, United Kingdom)

1:45pm-3:15pm: A novel cause for unpredictable response to levodopa

J. Staisch, G. Bakis, J. Nutt (Portland, OR, USA)

1:45pm-3:15pm: A Pair of Brothers with Aceruloplasminemia Due to a Novel Nonsense Mutation: Unusual Phenotype and Neurological Improvement After Iron-Chelation Therapy with Deferasirox.

F. Valzania, F. Cavallieri, M. Fiorini, S. Contardi, F. Ferrara, E. Menozzi, S. Scarlini, F. Cavalleri, M. Molinari, A. Pietrangelo, E. Corradini (Modena, Italy)

1:45pm-3:15pm: A qualitative study of the views and experience of people with Parkinson’s disease regarding their footwear

A. Ashburn, M. Donnovan-Hall, J. Robison, M. Cole, C. Bowen, M. Burnett, L. Mamode, R. Pickering, D. Bader, D. Kunkel (Southampton, United Kingdom)

1:45pm-3:15pm: A retrospective analysis of clinical forms and age of onset of biallelic Huntington disease patients from an Argentinean Center

M. Cesarini, V. Parisi, G. Persi, J. Etcheverry, A. Sanguinetti, F. Squitieri, E. Gatto (Buenos Aires, Argentina)

1:45pm-3:15pm: A review of telemedicine for Parkinson’s disease: But what’s happen in Asia??

W. Rattanachaisit, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: A Service Evaluation of the Clinical Use of Parkinson’s KinetiGraph (PKG) Movement Recording System in the Assessment of Parkinson’s Disease Patients with Tremor

J. Price, H. Martin, L. Ebenezer (Bronllys, United Kingdom)

1:45pm-3:15pm: A survey-based analysis of abnormal movements in patients with Postural Tachycardia Syndrome (PoTS)

R. Pyda, A. Hohler (Boston, MA, USA)

1:45pm-3:15pm: A Swedish family with Paroxysmal Kinesigenic Dyskinesia due to p.Arg217Profs*8 truncation in the proline-rich transmembrane protein 2 gene

P. Tsitsi, M. Paucar Arce, P. Svenningsson (Stockholm,, Sweden)

1:45pm-3:15pm: a-synuclein neurotoxicity and spreading using Lewy Body extracts from Parkinson Disease Brains: In vitro screening by cell-based assays

E. Bezard, F. Cavaliere, L. Cerf, B. Dehay, P. Ramos-Gonzalez, F. De Giorgi, M. Bourdenx, A. Bessede, J. Obeso, F. Ichas, C. Matute (Bordeaux, France)

1:45pm-3:15pm: AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content

T. Falk, M. Bartlett, D. Muller, B. Silashki, D. Farrell, K. Parent, M. Heien, S. Sherman (Tucson, AZ, USA)

1:45pm-3:15pm: Abnormal activity in reward system in Parkinson’s disease patients with rapid eye movement sleep behavior disorder

C. BEAL, M.L. FANTINI, G. SESCOUSSE, M. ULLA, C. CHASSAIN, A. Marques, B. Pereira, N. VITELLO, P. BEUDIN, R. Colamarino, F. DURIF (Clermont-Ferrand, France)

1:45pm-3:15pm: Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm: Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Tardive Dyskinesia (TD)

J. Jimenez-Shahed, H. Fernandez, R. Hauser, M. Davis, S. Factor, J. Isojärvi, W. Ondo, D. Stamler, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm: Admission Diagnoses and Eventual Discharge Dispositions for Hospitalized Huntington’s Disease Patients: Results of a Nationwide Survey

S. Gupta, F. Benesh, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm: Admixing augments nigral dopaminergic correlates during development to impart resistance to MPTP-toxicity at adulthood

V. D J, Y. H, R. T R, P. Anand Alladi (Bangalore, India)

1:45pm-3:15pm: Alpha-synuclein enhances histone H3 lysine-9 dimethylation

N. Sugeno, S. Jäckel, A. Voigt, T. Hasegawa, P. Kahle (Tübingen, Germany)

1:45pm-3:15pm: Alpha-Synuclein knock-out mouse brain shows significant dysregulation of c-Fos expression

M. Overhoff, J. Canet-Pons, D. Meierhofer, S. Gispert, G. Auburger (Frankfurt am Main, Germany)

1:45pm-3:15pm: Alpha-synuclein protein homeostasis and oligomerization in iron-overloaded cells expressing mutant HFE

Y. Kim, J. Connor, M. Stahl (Hershey, PA, USA)

1:45pm-3:15pm: Alpha-synucleinopathy and mitochondrial dysfunction in a cell based model of neurodegeneration: Implications in the pathogenesis of sporadic Parkinson’s disease

U. Ganguly, O. Sen, A. Ganguly, S. Chakrabarti (Kolkata, India)

1:45pm-3:15pm: Altered somtatosensory cortex neuronal activity in a rat model of Parkinson`s disease and levodopa-induced dyskinesias

K. Schwabe, X. Jin, J. Krauss, M. Alam (Hannover, Germany)

1:45pm-3:15pm: Alternative Apomorphine Challenge Test

J.C. Martinez Castrillo, A. Alonso Canovas, C. Estevez Fraga, G. Sanchez Diez, I. Avilés Olmos, J. Lopez Sendon, P. Garcia Ruiz, L. Vela Desojo (Madrid, Spain)

1:45pm-3:15pm: An Evaluation of the Parkinson’s Kinetigraph (PKG) as a Tool to Support Deep Brain Stimulation Eligibility Assessment in Patients with Parkinson’s Disease

M. Horne, J. Volkmann, C. Sannelli, P.-P. Luyet, E. Moro (Parkville, Australia)

1:45pm-3:15pm: An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia

M. Stacy, R. Kurlan, J. Burke, S. Siegert, G. Liang, C. O'Brien (Durham, NC, USA)

1:45pm-3:15pm: An Unusual Cause of Rhabdomyolysis in Parkinson’s disease

Y. Pitakpatapee, C. Satukijchai, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm: An unusual presentation of tyrosine hydroxylase deficiency

L. Katus, S. Frucht (New York, NY, USA)

1:45pm-3:15pm: Analysis of serum non-mercaptoalbumin in patients with Parkinson’s disease

S. Ueno, T. Hatano, Y. Ouji, S. Saiki, H. Ikeda, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD).

A. Boika, V. Ponomarev, H. Ivanchik (Minsk, Belarus)

1:45pm-3:15pm: Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy

T. Yamasaki, A. Welleford (Lexington, KY, USA)

1:45pm-3:15pm: Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity

D. Dressler, F. Adib Saberi (Hamburg, Germany)

1:45pm-3:15pm: Antisense oligonucleotides containing amido-bridged nucleic acid downregulate SNCA expression and improve motor function in Parkinson’s disease mouse models.

T. Uehara, C.-J. Choong, H. Hayakawa, Y. Kasahara, T. Nagata, T. Yokota, K. Baba, M. Nakamori, S. Obika, H. Mochizuki (Suita-Shi, Osaka, Japan)

1:45pm-3:15pm: Ascertainment of Impaired Balance in Orthostatic Tremor Patients

D. Bhatti, R. Thompson, x. yiwen, A. Hellman, J. Mckune, L. Schmaderer, K. Suing, C. Penke, R. Iske, B.J. Roeder, K.-C. Siu, J. Bertoni, D. Torres-Russotto (Omaha, NE, USA)

1:45pm-3:15pm: Assessing Parkinson’s disease motor symptoms using supervised learning algorithms

P. Angeles, Y. Tai, N. Pavese, R. Vaidyanathan (London, United Kingdom)

1:45pm-3:15pm: Assessment of graphomotor impairment in patients with Spinocerebellar ataxia and Parkinson’s disease

M. Thomas, A. Stezin, A. Lenka, N. Thota, P. Pal, R. Yadav (Bengaluru, India)

1:45pm-3:15pm: Assessment of neurodegeneration and spreading of α-synuclein pathology induced by structurally defined α-synuclein assemblies in wild-type mice

E. Bezard, M. Bourdenx, L. Arcuri, L. Bousset, R. Melki, B. Dehay (Bordeaux, France)

1:45pm-3:15pm: Assessment of new technology in deep brain stimulation technology: what are the anticipated benefits?

C. Butson (Salt Lake City, UT, USA)

1:45pm-3:15pm: Assessments of Movement Disorder Symptoms and Functional Impacts in Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

A. Bowden, S. Blair, K. Wesdock, M. Haller, M. Brandabur, P. Collins, A. Skrinar, J. Mayhew (Novato, CA, USA)

1:45pm-3:15pm: Association analysis of single nucleotide polymorphisms near the DYT3 locus to dystonic symptoms in X-linked dystonia-parkinsonism

G. Saranza, D. Sumalapao, A. Domingo, P. Pasco, R.D. Jamora, L. Lee, A. Westenberger, C. Klein (Manila, Philippines)

1:45pm-3:15pm: Association of CSF biomarkers with motor and non-motor features in moderately advanced Parkinson’s disease cohort: the BioFIND study

J. Goldman, A. Amara, L. Shaw, P. Taylor, H. Andrews, R. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, S. Frank, M.-H. Saint Hilaire, A. Naito, M. Frasier, V. Arnedo, A. Reimer, M. Sutherland, C. Swanson-Fischer, K. Gwinn, U. Kang (Chicago, IL, USA)

1:45pm-3:15pm: Ataxia and increased cerebrospinal fluid phosphate associated with a mutation in the SLC20A2 gene

M. Paucar, H. Almqvist, V. Jelic, G. Hagman, G. Jörneskog, S. Holmin, I. Björkhem, P. Svenningsson (Stockholm, Sweden)

1:45pm-3:15pm: Atypical and slowly progressive FTDP-17 caused by MAPT p.R406W mutations – similarities to AD and PSP.

E. Ygland, D. van Westen, E. Englund, R. Rademakers, Z. Wszolek, K. Nilsson, C. Nilsson, O. Hansson, L. Gustafson, A. Puschmann (Lund, Sweden)

1:45pm-3:15pm: Autonomous Tracking of Body Bradykinesia during Unconstrained Activities in Parkinson’s Disease

S. Roy, B. Shiwani, J. Kline, M. Saint-Hilaire, C. Thomas, M. Gennert, G. De Luca (Natick, MA, USA)

1:45pm-3:15pm: Axial signs in early-stage Parkinson’s disease : an influence of the genotype ?

G. BAILLE, D. DEVOS, V. HUIN, T. PEREZ, B. SABLONNIERE, L. DEFEBVRE, C. MOREAU (CHRU Lille, France)

1:45pm-3:15pm: Barriers to exercise in newly diagnosed Parkinson’s disease

I. Argyropoulos, E. Pearson, F. Murphy, V. Queen, J. Rideout, C. Carrollq (Plymouth, United Kingdom)

1:45pm-3:15pm: Baseline multimodal information predicts future motor impairment in premanifest Huntington’s disease

E. Castro, P. Polosecki, I. Rish, G. Cecchi (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD)

S. Park, S. Nam, A. Nathan, A. Haque, A. Haque, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

1:45pm-3:15pm: Beneficial and Protective Effects of Withania Someniferais On Mice Brain: A Therapeutic Potential Drug for Parkinson’s Disease

S. Rajput, S. Sinha (New Delhi, India)

1:45pm-3:15pm: Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

1:45pm-3:15pm: Brain insulin resistance in Parkinson’s disease

F. Bassil, M.-H. Canron, N. Dutheil, A. Vital, E. Bezard, P.-O. Fernagut, W. Meissner (Bordeaux, France)

1:45pm-3:15pm: C19orf12 p.Thr11Met mutation is frequent among adult Turkish patients with MPAN

M. Quadri, S. Olgiati, O. Doğu, Z. Tufekcioglu, Y. Diler, E. Saka, M. Gultekin, H. Kaleagasi, D. Kuipers, J. Graafland, G. Breedveld, R. Sürmeli, G. Sünter, T. Doğan, A.D. Yalçın, B. Bilgiç, B. Elibol, M. Emre, H. Hanagasi, V. Bonifati (Rotterdam, Netherlands)

1:45pm-3:15pm: Can three-dimensional visual cues delivered via smart glasses reduce freezing of gait in patients with Parkinson’s Disease?

S. Janssen, J. Nonnekes, B. Bolte, M. Bittner, T. Heida, Y. Zhao, R. van Wezel (Enschede, Netherlands)

1:45pm-3:15pm: Cannabis and Parkinson’s Disease Tremor

L. Mischley, R. Bennett, M. Sexton, G. Ricciardi, J. McNames (Kenmore, WA, USA)

1:45pm-3:15pm: Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker

B. McMicken (Irvine, , CA, USA)

1:45pm-3:15pm: Catecholamines’ concentration ratio in plasma of early diagnosed treatment-naive patients with Parkinson disease

Z. Zalyalova, D. Khasanova (Kazan, Russian Federation)

1:45pm-3:15pm: CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons

R. Zhu (Shanghai, China)

1:45pm-3:15pm: Cerebello-cortical loops differ between Essential-, Parkinsonian- and voluntary tremor

J. Raethjen, M. Muthuraman, S. Groppa, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Cerebrospinal fluid biomarkers in Huntington’s disease – a longitudinal study

V. Niemelä, J. Sundblom, A.-M. Landtblom, S. Herman, K. Kultema, D. Nyholm, K. Blennow (Uppsala, Sweden)

1:45pm-3:15pm: Cerebrotendinous xanthomatosis without tendon xanthoma: a diagnostic challenge.

S. Souki, L. Vasconcellos, M. Spitz, J. Pereira, V. Marussi, A. Carrié, P. Couvert (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Changes in saccade performance with oculomotor task repetition in neurological disorders

Y. Terao, H. Fukuda, S.-i. Tokushige, S. Inomata-Terada, Y. Ugawa (Tokyo, Japan)

1:45pm-3:15pm: Characteristics of tremor caused by non-olivary lesion of the medulla oblongata

A. Kovács, N. Pintér, L. Halász, A. Kamondi (Budapest, Hungary)

1:45pm-3:15pm: Characterization of GNB1 mutations as a cause of global developmental delay in combination with dystonia, ataxia, or chorea in children

H. Baumann, I. Masuho, D. Patil, S. Steinruecke, E. Hebert, V. Dobricic, I. Huening, G. Gillessen-Kaesbach, A. Westenberger, D. Savic-Pavicevic, A. Muenchau, C. Klein, A. Rolfs, K. Martemyanov, K. Lohmann (Luebeck, Germany)

1:45pm-3:15pm: Characterizing the Bcl-2 Associated Athanogene 5 Interactome

E. Friesen, X. Wang, D. Williams, H. Chau, M. De Snoo, O. Pellerito, L. Kalia, G. Schmitt-Ulms, S. Kalia (Toronto, ON, Canada)

1:45pm-3:15pm: Citrus extract A protects dopaminergic neuron by modulating mitochondrial respiration and reactive oxygen species

Y. Jang, J. Han, S.J. Kim, M.J. Lee, I. Ryu, X. Ju, H. Chu, M.J. Ryu, E.S. Oh, S.-Y. Choi, W. Chung, J.Y. Heo, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: Clinical and genetic analysis of ataxic patients with CACNA1A mutations in Taiwan

P.-Y. Fong, S.-C. Lai, T.-H. Yeh, C.-S. Lu (Taoyuan City, Taiwan)

1:45pm-3:15pm: Clinical and genetic characterization of Huntington’s disease in relation to the age and type of onset.

L. Mendoza Vega, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. De-la-Cruz-Landero, N. Davila-Avila, K. Salinas-Barboza, S. Isais-Millan (Mexico City, Mexico)

1:45pm-3:15pm: Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment

P. Dowell, K. Lyons, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Clinical feasibility of a wearable, conformable, sensor patch to monitor motor symptoms in Parkinson’s disease

B. Boroojerdi, K. Claes, R. Ghaffari, N. Mahadevan, M. Markowitz, K. Melton, B. Morey, C. Otoul, S. Patel, J. Phillips, E. Sen-Gupta, O. Stumpp, D. Tatla, J. Wright Jr, N. Sheth (Monheim am Rhein, Germany)

1:45pm-3:15pm: Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm

S. Pandey, S. Jain (New Delhi, India)

1:45pm-3:15pm: Closed Loop STN DBS for Tremor in Parkinson’s disease using a Neural or Kinematic Signal

A. Velisar, J. Herron, J. SYRKIN-NIKOLAU, Z. Blumenfeld, M. TRAGER, T. MARTIN, H. CHIZECK, H. Bronte-Stewart (Palo Alto, CA, USA)

1:45pm-3:15pm: Co-speech gestures in Parkinson’s disease (PD)

M. Bacigalupe (La Plata, Argentina)

1:45pm-3:15pm: Cognitive Dysfunction is Associated with Greater Imbalance and Falls in Patients with Essential Tremor

E. Louis, K. Collins, S. Kellner, S. Morgan, B. Rohl, E. Huey, S. Cosentino (New Haven, CT, USA)

1:45pm-3:15pm: Combined Motor and Cognitive Training Improves Motor and Cognitive Function in People with Parkinson’s Disease and Freezing of Gait

C. Fearon, I. Killane, L. Newman, R. Beck, T. Munteanu, D. Birsanu, J. Butler, B. Magennis, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:45pm-3:15pm: Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

F. Adib Saberi, D. Dressler (Hamburg, Germany)

1:45pm-3:15pm: Comparison of neurotoxic potency of a newly produced Botulinum Neurotoxin Type A with onabotulinumtoxinA, incobotulinumtoxinA and BotulinumtoxinA

Y. Feng, W. Liu, L. Pan, Z. Nie (Shanghai, China)

1:45pm-3:15pm: Congenital mirror movements: When the left hand doesn’t know what the right is doing

M. Boca, A. Whone (Bristol, United Kingdom)

1:45pm-3:15pm: Correction of minimal oculomotor disorders improves forward and lateral axial dystonia in Pakinson’s disease

S. Varanese, M. Meglio, M. Bologna, M. Santilli, G. Grillea, F. Lena, L. Meglio, N. Modugno (Pozzilli, Italy)

1:45pm-3:15pm: Cortico-thalamic Biomarkers for a Responsive Deep Brain Stimulation: an enhanced Treatment of Essential Tremor.

E. Opri, J. Shute, R. Molina, K. Foote, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:45pm-3:15pm: CR6-interacting factor1 Deficiency in Dopamine Neurons Triggers Early-onset Parkinsonism in Mice

I. Ryu, J. Han, Y. Jang, S.J. Kim, j. Kim, M.J. Lee, X. Ju, M.J. Ryu, S.-Y. Choi, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: D2 receptor mediated DARPP32/PP1α signaling is responsible for cadmium induced Parkinson’s like behavioral alterations in rats

R. Gupta, R. Shukla, V. Khanna (Luckno, India)

1:45pm-3:15pm: Deep Brain Stimulation (DBS) battery longevity of Medtronic Activa SC is briefer than preceding Soletra models, a within subject analysis

E. Hargreaves, R. Patel, R. DiPaola, S. Wong, D. Caputo, S. Danish (New Brunswick, NJ, USA)

1:45pm-3:15pm: Deferiprone combined with phlebotomy for aceruloplasminemia

L.H.P. Vroegindeweij, J.G. Langendonk, J.H.P. Wilson, A.J.W. Boon (Rotterdam, Netherlands)

1:45pm-3:15pm: Demographic and Clinical Characteristics and Tetrabenazine (TBZ) Persistence in Patients With Huntington Disease (HD)-Associated Chorea

V. Sung, R. Iyer, S. Gandhi, V. Abler, B. Davis, D. Irwin, K. Anderson (Birmingham, AL, USA)

1:45pm-3:15pm: Depression among Inpatients with Huntington’s Disease: Patient Characteristics and Outcomes

F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm: Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

A. Verma, V. Kumar, U. Singh (Allahabad, India)

1:45pm-3:15pm: Design and personalisation of new upper-limb dynamic orthoses for dystonia and dyskinesia

L. Garavaglia, M. Ferari, A. Lo Mauro, E. Pagliano, G. Baranello, B. Bassi, A. Aliverti, S. Pittaccio (Lecco, Italy)

1:45pm-3:15pm: Design of a randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxin treatment for cervical dystonia (StimTox-CD)

H. Drechsel, U. Malzahn, C. Roeser, P. Heuschmann, J. Volkmann (Würzburg, Germany)

1:45pm-3:15pm: Detection of Early Changes in Microbiota Composition in Prodromal Parkinson’s Disease

J. Boertien, T. Van Laar (Groningen, Netherlands)

1:45pm-3:15pm: Determinant factors of treatment adherence in Parkinson’s disease

I. Estrada-Bellmann, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías, P. Cortés-Estrada (Monterrey, Mexico)

1:45pm-3:15pm: Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm: Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm: Development of a Paroxysmal Movement Disorder Diary for Patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

R. Hall, S. Kilgariff, P. Collins, M. Brandabur, R. Arbuckle, A. Bowden (Macclesfield, United Kingdom)

1:45pm-3:15pm: Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

1:45pm-3:15pm: Development of nano-formulation containing crocetin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds

V. Kumar, A. Verma, P. Bhatt (Allahabad, India)

1:45pm-3:15pm: Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.

M. Marano, M. Marano, L. di Biase, R. Arca, G. Cossu, E. Coletta, V. Di Lazzaro, A. Fasano, P. Marano (Rome, Italy)

1:45pm-3:15pm: Direct dopaminergic responsiveness of activity performance

P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

1:45pm-3:15pm: Disappearance of the clinical and imaging manifestations in Wilson’s disease after controlled therapy with tetrathiomolybdate and zinc

I. Posada, C. Garfia, F. Ostos, A. Ramos (Madrid, Spain)

1:45pm-3:15pm: Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil

L. Tönges, L. Tatenhorst, J. Koch, T. Outeiro, M. Zweckstetter, M. Bähr, P. Lingor (Bochum, Germany)

1:45pm-3:15pm: Does cerebellar dysfunction contribute to tremor in Parkinson’s disease?

E. Batzianouli, M. Pagliaro, D. Benninger (Lausanne, Switzerland)

1:45pm-3:15pm: Does Parkinsons KinetiGraph (PKG) recording help in clinical decision making? A local experience

N. Wilson, R. Mappilakkandy, M. Smith, K. Nithi (Northampton, United Kingdom)

1:45pm-3:15pm: Dopamine Agonists and Postural Disorders in Parkinson’s disease

L. Ameghino, V. Bruno, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm: Dopamine replacement medication improves acquisition, retention, and transfer of skilled upper extremity movement in people with Parkinson Disease.

S. Paul, C. Walter, G. Olivier, L. Dibble, S. Schaefer (Salt Lake City, UT, USA)

1:45pm-3:15pm: Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease

P. Loehrer, F. Nettersheim, F. Jung, I. Weber, C. Huber, T. Dembek, E. Pelzer, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

1:45pm-3:15pm: Dopamine transporter scan finding in patients with chorea.

K. Kawabe, K. Miura, K. Ikeda, Y. Iwasaki (Tokyo, Japan)

1:45pm-3:15pm: Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s Disease patients

K.-H. Chang, Y.-R. Wu, C.-M. Chen (Taoyuan County, Taiwan)

1:45pm-3:15pm: Drug-induced movement disorders: not a typical problem

A. Vives-Rodriguez, A. Patel (New Haven, CT, USA)

1:45pm-3:15pm: Dural lymphatic vasculature in human superior saggital sinus: the brain drain

N. Visanji, A. Lang, D. Munoz (Toronto, ON, Canada)

1:45pm-3:15pm: Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach

K. Li, E. Furr Stimming, S. Luo, K. Li (Houston, TX, USA)

1:45pm-3:15pm: Dynamic stability during turning in people with Parkinson’s disease

C. Curtze, P. Fino, S. Smith, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Effect of Deutetrabenazine by Body Region Score of the Abnormal Involuntary Movement Scale in Tardive Dyskinesia: ARM-TD and AIM-TD Studies

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm: Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm: Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study

S. Factor, K. Anderson, D. Stamler, M. Davis, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Atlanta, GA, USA)

1:45pm-3:15pm: Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): Results of a Cohort Comparison of Open-HART and Historical Placebo Subjects

A. McGarry, V. Abler, P. Auinger, I. Grachev, S. Gandhi, S. Papapetropoulos (Camden, NJ, USA)

1:45pm-3:15pm: Effectiveness of lead position with MER to determine STNs: A study of MER with DBS for quantifying the effects of DBS in Parkinson`s disease

V. Rama Raju, R. Borgohain (HYDERABAD, India)

1:45pm-3:15pm: Effects of different intensity exercises on motor function of PD rats as well as the regulation of DA

x. Liu, p. Chen, d. Qiao, m. wang (Beijing, China)

1:45pm-3:15pm: Effects of non-invasive electrical and magnetic stimulation to improve motor and cognitive function in Parkinson’s disease: a meta-analytical review

A. Goodwill, J. Lum, A. Hendy, M. Muthalib, L. Johnson, N. Albein-Urios, W.-P. Teo (Burwood, Australia)

1:45pm-3:15pm: Effects of thalamic deep brain stimulation on posture and balance in patients with essential tremor

K. Lizarraga, A. Farooqi, A. Rasul, J. Jagid, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: Effects of the administration of levodopa on postural control under visual tasks

C. Bonnet, A. Delval, L. Defebvre (Lille, France)

1:45pm-3:15pm: Efficacy of Smartphone-enabled Active Tests in Automated PD Severity Assessment

A. Zhan, S. Mohan, M. Elson, E. Dorsey, A. Terzis, S. Saria (Baltimore, MD, USA)

1:45pm-3:15pm: Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD

R. Reilmann, A. McGarry, G. Landwehrmeyer, K. Kieburtz, I. Grachev, E. Eyal, J. Savola, B. Borowsky, S. Papapetropoulos, M. Hayden (Münster, Germany)

1:45pm-3:15pm: Efficient control of dopamine neuron physiology for rescuing disease phenotypes

T. Rumbell, J. Kozloski (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Eight contact LFP recordings in the Subthalamic region localize beta source to the dorsal STN

I. Tamir, C. de Hemptinne, J. Ostrem, P. Starr (San Francisco, CA, USA)

1:45pm-3:15pm: Electronic stethoscope in the diagnosis of orthostatic tremor

J. Tashiro, H. Otsuka, M. Hirotani, S. Hamada, H. Soma, M. Nonaka, S. Honma, K. Hamada, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

1:45pm-3:15pm: Epitope mapping of CSF auto-antibodies to alpha-synuclein

R. Akhtar, J. Licata, K. Luk, D. Covell, J. Trojanowski, V. Lee (Philadelphia, PA, USA)

1:45pm-3:15pm: Essential Tremor and Depression

S. Aslam, N. Zhang, C. Adler, J. Caviness, E. Driver-Dunckley, S. Mehta, M. Sabbagh, T. Beach, H. Shill (Phoenix, AZ, USA)

1:45pm-3:15pm: Estimation of Tardive Dyskinesia Incidence and Prevalence in the United States

A. Dhir, T. Schilling, V. Abler, R. Potluri, B. Carroll (New York, NY, USA)

1:45pm-3:15pm: Evaluating the Clinical Efficacy of the Personal KinetiGraph Movement Recording System

A. Fowler, K. Lyons, V. Sharma, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluating wearable sensors for objective measurement of motor features in Parkinson disease and Huntington disease – a pilot study

J. Adams, M. Xiong, K. Dinesh, C. Tarolli, S. Sharma, N. Sheth, A.J. Aranyosi, W. Zhu, S. Goldenthal, K. Biglan, R. Dorsey, G. Sharma (Rochester, NY, USA)

1:45pm-3:15pm: Evaluation of CSF cytokine profiles in people with Parkinson disease and age-matched controls.

G. Crotty, D. Vaughan, G. Moloney, G. O'Keeffe, S. O'Sullivan, A. Sullivan (Cork, Ireland)

1:45pm-3:15pm: Evaluation of Patient-Reported Outcomes in Tardive Dyskinesia Patients With Underlying Psychotic and Mood Disorders in the ARM-TD and AIM-TD Trials

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm: Evaluation of serum sestrin protein in Parkinson’s disease: a plausible diagnostic marker

S. Dey, N. Rai, A. Singh, S. Shekhar, A. Dey (New Delhi, India)

1:45pm-3:15pm: Evaluation of spike sorting algorithms applied to artificial spikes and to spikes recorded from the Subthalamic Nucleus of PD patients

J. Sukiban, N. Voges, I. Weber, T. Dembek, M. Denker, M. Barbe, S. Grün, L. Timmermann (Cologne, Germany)

1:45pm-3:15pm: Evaluation of Swallowing Function in Parkinson’s Disease Patients with and without Dysphagia Complaints

E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, A. Cakci, B. Gonenli, Y. Eren (Ankara, Turkey)

1:45pm-3:15pm: Evaluation of the short-term and long-term effects of an intensive multidisciplinary collective rehabilitation program over 5 weeks in Parkinson’s patients followed in Lyon

T. DANAILA, C. LAURENCIN, P. ROCHE, S. THOBOIS, M. CHEMINON, J. LUAUTE (BRON, France)

1:45pm-3:15pm: Evidence-based Brazilian Physicaltherapy Guideline for Huntington´s Disease

T. Capato, M. Haddad, E. Barbosa, M.E. Piemonte (Sao Paulo, Brazil)

1:45pm-3:15pm: Examining central cognitive processing speed as an early marker of Huntington’s disease (HD) onset

A. Nathan, S. Park, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

1:45pm-3:15pm: Exercise preferences of people with Parkinson’s disease: preliminary findings of a discrete choice experiment

C. Canning, C. Canning, S. Paul, J. Bampton, C. Sherrington, K. Howard (Lidcombe, Sydney, Australia)

1:45pm-3:15pm: Exercise Trends Reported in Parkinson’s Patients

P. Raje, C. Branson, M.P. de Leon, M. Saint-Hilaire, A. Hohler, S. Ning (Boston, MA, USA)

1:45pm-3:15pm: Explicit movement control in functional movement disorders is characterized by reduced lateralized beta desynchronisation

T. Teodoro, A. Meppelink, S. Little, A. Macerollo, R. Grant, M. Edwards (London, United Kingdom)

1:45pm-3:15pm: Exploiting sequence data of genes involved in synthesis of plant derived enzyme inhibitors of Acetylcholinesterase that involve in antineurodegenerative acitivity.

N. No surname, M. Abdin (New Delhi, India)

1:45pm-3:15pm: Exploratory Clinical study of role of cerebral dopamine neurotrophic factor (CDNF) mediating endoplasmic reticulum stress (ERS) in Parkinson Disease

K. Terpstra, R. Mishra, S. Chiu (Hamilton, ON, Canada)

1:45pm-3:15pm: Exposure to bifenthrin contributes to Parkinson’s disease in mouse model

C. Han, S. Liu, J. Huang, L. Liu, K. Ma, X. Guo, S. Guo, L. Wang, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

1:45pm-3:15pm: Expression of late cell cycle markers in Parkinson Disease and Lewy Body Dementia

I. Martinez-Valbuena, R. Valenti-Azcarate, M.M. Carmona-Abellan, I. Marcilla-Garcia, I. Gaston-Zubimendi, G. Marti-Andres, M.-T. Tuñon-Alvarez, M.-R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter

J. Kobayashi, T. Hasegawa, N. Sugeno, S. Yoshida, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

1:45pm-3:15pm: Factors Influencing Completion of Predictive Testing for Huntington’s Disease (HD)

M. Patel, V. Sung (Birmingham, AL, USA)

1:45pm-3:15pm: Familial Creutzfeldt-Jakob Disease with an E200K Mutation in Peru: A Case Report

H. Sarapura-Castro, C. Cosentino, L. Torres-Ramirez, P. Parchi, A. Vishnevetsky, M. Inca-Martinez, E. Figueroa-Ildefonso, P. Mazzetti, M. Cornejo-Olivas (Lima, Peru)

1:45pm-3:15pm: Familial idiopathic basal ganglia calcification with novel SLC20A2 gene variant

B. Barton (Chicago, IL, USA)

1:45pm-3:15pm: Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

C. Linder, B. Mollenhauer, C. Coffey, T. Beach, T. Foroud, C. Adler, H. Riss, D. Ecklund, C. Caspell-Garcia, K. Dave, S. Deshpande, S. Lasch, V. Arnedo, L. Riley, C. Kopil, D. Jennings, L. Chahine (Philadelphia, PA, USA)

1:45pm-3:15pm: Fibroblasts Implanted in Internal Pallidum of Parkinsonian Macaques Exert L-Dopa-Sparing Activity

E. Bezard, J. Finberg, W.K. Ko, Q. Li, B. Dehay, E. Pioli, Y. Yair (Bordeaux, France)

1:45pm-3:15pm: Final validation of an electronic diary for motor fluctuations and dyskinesias evaluation in PD patients: Comparison with paperback diary.

C. Terroba, A. Medina, F. Nanni, V. Bruno, D. Cerquetti, M. Rossi, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm: Firing rate and proportion of subthalamic oscillatory neurons increase associated with more advanced Parkinson’s Disease

P. Zhuang, M. Hallett, Y. Wen, Y. Zhang, J. Li, Y. Li (Beijing, China)

1:45pm-3:15pm: Focused ultrasound subthalatomy restores intracortical inhibition in PD

M. Dileone, R. Martinez-Fernandez, M. Del Alamo, R. Rodriguez, J. Pineda-Pardo, F. Hernandez-Fernandez, J. Obeso, G. Foffani (Mostoles, Spain)

1:45pm-3:15pm: Forehead Tremor: a clinical presentation of ocular Myasthenia Gravis?

G. Sciacca, E. Reggio, G. Donzuso, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Fragile X Gray Zone Alleles are associated with Higher Global Motor Function in an Elderly Community Population

D. Hall, A. Ali, D. Bennett, B. Ouyang, A. Buchman, L. Zhou, E. Berry-Kravis (Chicago, IL, USA)

1:45pm-3:15pm: Freezing of gait in Parkinson’s disease consists of unique pressure-based gait phase transitions

L. Luo, D. Zanotto, F. Maget, B. Xu, S. Agrawal, P. Mazzoni (New York, NY, USA)

1:45pm-3:15pm: Functional lesional neurosurgery for tremor – a systematic review and meta-analysis

S. Schreglmann, J. Krauss, J. Chang, K. Bhatia, G. Kägi (London, United Kingdom)

1:45pm-3:15pm: Fundamental limit of the alpha-synuclein immunohistochemistry using the endoscopic biopsy from the gastrointestinal tract as a biomarker for Parkinson disease: a case-control study

C.W. Shin, S.-H. Park, J.Y. Yun, J.H. Shin, H.-K. Yang, H.-J. Lee, S.-H. Kong, Y.J. Jung, G. Shen, H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: FXTAS, PD, and ET subjects demonstrate distinct gait, balance and tremor deficits under normal, environmentally challenging, and dual-task conditions

E. Robertson, D. Hall, A. McAsey, M. Swanson, A. Bery, C. Huml, E. Berry-Kravis, J. O'Keefe (Chicago, IL, USA)

1:45pm-3:15pm: Gait analysis as a complementary tool in the levodopa dose decision in Vascular Parkinson’s Disease

M. Gago, F. Ferreira, N. Mollaei, M. Rodrigues, N. Sousa, E. Bicho, P. Rodrigues (Braga, Portugal)

1:45pm-3:15pm: Gait Analysis in Patients with Huntington’s Disease

Y.-M. Park, S. Pyo, H.-M. Lee, M.-J. Kim, S.-B. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm: Gait disturbance and olfactory dysfunction is associated with central cholinergic dysfunction in early Parkinson’s disease

E. Oh, Y. Lim, S. Park (Daejeon, Republic of Korea)

1:45pm-3:15pm: Gait, Freezing of Gait and Falls detection using wearable sensors; a systematic review

A.L. Silvade Lima, L.JW. Evers, T. Hahn, L. Bataille, J.L. Hamilton, M.A. Little, B.R. Bloem, M.J. Faber (Nijmegen, Netherlands)

1:45pm-3:15pm: GBA mRNA is diminished in brain and blood of Lewy body diseases

K. Beyer, J. Campdelacreu, L. Ispierto, D. Vilas, R. Reñé, R. Alvarez (Badalona, Spain)

1:45pm-3:15pm: Genetic and Clinical Analysis of Cerebral Calcifications

V. Chelban, R. Kaiyrzhanov, H. Houlden (London, United Kingdom)

1:45pm-3:15pm: Genetic knock-down of HDAC4 attenuates rotenone-induced abnormal expression of α-synuclein by affecting autophagic flux in SH-SY5Y Cells

L. Wang, J. Huang, L. Liu, C. Han, K. Ma, X. Guo, S. Guo, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

1:45pm-3:15pm: Glucocerebrosidase mutations in idiopathic REM sleep disorder

K. Beyer, M. Serradell, J. Santamaria, C. Gaig, R. Alvarez, A. Iranzo (Badalona, Spain)

1:45pm-3:15pm: Glut-1 deficiency: a case report

P. Marques, H. Teive, F. Germiniani, V.C. Terra, C.E. Silvado, M. Canever, G. Tansini, L. Oliveira (Curitiba, Brazil)

1:45pm-3:15pm: Goal-Directed Movement in Idiopathic Parkinson’s Disease and the effect of Parkin Mutations

C. Fearon, T. Munteanu, D. Birsanu, L. Newman, B. Quinlivan, i. killane, B. Magennis, J. Butler, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:45pm-3:15pm: Gray Matter Density in Essential Tremor: A Lobule by Lobule Analysis of the Cerebellum

E. Louis, J. Dyke, E. Cameron, N. Hernandez, U. Dydak (New Haven, CT, USA)

1:45pm-3:15pm: Haploinsufficiency of KMT2B causes myoclonus-dystonia with impaired psychomotor ability

T. Kawarai, R. Miyamoto, H. Mure, R. Morigaki, R. Oki, A. Orlacchio, R. Koichihara, E. Nakagawa, T. Sakamoto, Y. Izumi, S. Goto, R. Kaji (Tokushima, Japan)

1:45pm-3:15pm: Head tremor in supine position does not differentiate essential tremor and cervical dystonia

E. Ruzicka, R. Krupicka, T. Duspivova, O. Ulmanova, P. Holly, V. Cejka, J. Rusz, R. Jech (Praha, Czech Republic)

1:45pm-3:15pm: Healthcare Utilization and Costs for Patients With Tardive Dyskinesia

B. Carroll, T. Park, D. Irwin, S. Gandhi (Frazer, PA, USA)

1:45pm-3:15pm: Hemidystonia Associated with Alexander Disease

D. Vijayakumar, R. Lewis, G. Fuller, S. Dhar, K. Machol, L. Robak, J. Jankovic (Houston, TX, USA)

1:45pm-3:15pm: Hereditary spastic paraplegia type 31: a novel splice site donor mutation and intra-familial phenotypic variability

M. Kamada, T. Kawarai, R. Miyamoto, Y. Tojima, A. Orlacchio, R. Kaji (Kita-gun, Japan)

1:45pm-3:15pm: High-mobility group box 1 from astrocytes upregulates TH expression to maintain dopaminergic neurons via JNK pathway in human Parkinson’s disease patients and MPTP induced mouse model

S.J. Kim, M.J. Ryu, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?

E. Okuyucu, M. Uzel, S. Colakoglu Yesıldag, M. Guntel (Hatay, Turkey)

1:45pm-3:15pm: Hung up knee jerk reflex in Huntington’s disease: A clinical and neurophysiological study

J. Perez-Perez, J. Diaz-Manera, J. Pagonabarraga, S. Martinez-Horta, M. Carceller, A. Horta, J. Marin, H. Bejr-Kasen, A. Guerrero, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Huntington’s disease in the Republic of Tatarstan, epidemiological features

S. Munasipova, Z. Zalyalova (Kazan, Russian Federation)

1:45pm-3:15pm: Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model

N. Gonçalves, J. Mendes, J. Ferreira, C. Sampaio (Lisbon, Portugal)

1:45pm-3:15pm: Idiopathic acquired sporadic (non-wilsonian) Hepatocerebral degeneration

S. Desai, P. Thakkar, S. Seth, b. vaishnav, P. Buch, J. Mannari (Anand, India)

1:45pm-3:15pm: Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.

P. Fazio, C. Fittzer-Attas, J. Bronzova, S. Nag, J. Warner, B. Landwehrmeyer, N. Al-Tawil, C. Halldin, L. Mrzljak, C. Sampaio, A. Varrone (Stockholm, Sweden)

1:45pm-3:15pm: Imbalance between dopaminergic and cholinergic neurotransmission following rotenone administration suggestive of Parkinson’s-like symptoms in male rats

S. Madiha, S. Haider (Karachi, Pakistan)

1:45pm-3:15pm: Impact of weekly dance classes on quality of life of individuals with Parkinson’s Disease.

L. Krejcova, J. Brito, W. Cohen, C. Bahia (Belem, Brazil)

1:45pm-3:15pm: Impacts of CSF kynurenine pathway on neuroinflammaion in patients with Parkinson’s disease

K. Iwaoka, T. Maeda, Y. Terayama (Morioka, Japan)

1:45pm-3:15pm: Impaired cerebral and systemic endothelial dysfunction in patients with restless legs syndrome

M.S. Kim, J.H. Yoon (Suwon, Republic of Korea)

1:45pm-3:15pm: Impaired intracortical inhibition is associated with reduced hand dexterity in Parkinson’s disease patients

S. Filipović, A. Kačar, S. Milanović, M. Ljubisavljević, V. Kostić (Beograd, Serbia)

1:45pm-3:15pm: Impaired stress-induced mitophagy in parkinsonian LRRK2(R1441G) knockin mutant mice

P.W.-l. Ho, C.S.-c. Lam, H.-f. Liu, G.C.-t. Leung, L. Li, M.H.-w. Kung, D. Ramsden, S.-l. Ho (Hong Kong, Hong Kong)

1:45pm-3:15pm: Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial

S. Papapetropoulos, S. Fine, E. Cohen, C. Admati, Y. Dolan, I. Grachev, I. Grossman, M. Hayden (Petach Tikva, Israel)

1:45pm-3:15pm: Improved Detection of Gait Abnormalities in Parkinson’s disease using an IMU Sensor-based System

B. Shiwani, S. Roy, J. Kline, M. Saint-Hilaire, C. Thomas, M. Gennert, G. De Luca (Natick, MA, USA)

1:45pm-3:15pm: Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm: Improving Nursing Education on the care of those with Parkinson’s disease

G. Vernon (Philadelphia, PA, USA)

1:45pm-3:15pm: In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease

N. Visanji, A. Lacoste, S. Spangler, E. Argentinis, S. Ezell, C. Marras, L. Kalia (Toronto, ON, Canada)

1:45pm-3:15pm: Increased and symmetric expression of rigidity in early Parkinson’s disease with abnormal REM sleep without atonia

M. Petrucci, S. Amundsen Huffmaster, C. Lu, P. Tuite, M. Howell, C. MacKinnon (Minneapolis, MN, USA)

1:45pm-3:15pm: Increased appendicular lean body mass is associated with increased cerebral cholinergic innervation in Parkinson disease

J. Chua, M. Müller, M. Beaulieu, S. Nejad-Davarani, N. Bohnen (Ann Arbor, MI, USA)

1:45pm-3:15pm: Increased bilirubin levels in Parkinson’s disease from southern Spain.

D. Macias Garcia, D. Macias Garcia, C. Mendez Barrio, S. Jesus, M.A. Labrador Espinosa, M. Bernal Escudero, L. Vargas Gonzalez, A. Adarmes Gomez, F. Carrillo, M. Carballo, P. Gómez-Garre, P. Mir (Seville, Spain)

1:45pm-3:15pm: Inferring the presence of Parkinsonian rest tremor from subthalamic local field potential recordings

J. Hirschmann, J.-M. Schoffelen, A. Schnitzler, M. van Gerven (Düsseldorf, Germany)

1:45pm-3:15pm: Information transfer between subthalamic area and forearm muscles during tonic muscle activity in Parkinson’s patients

I. Weber, E. Florin, M. von Papen, L. Timmermann (Marburg, Germany)

1:45pm-3:15pm: Infusion Rate Dependent Acute Neuropathic Pain with Duopa™ in a Patient with Parkinson’s disease and Pre-Existing Neuropathy

A. Shukla, R. Govindarajan, I. Asher (Columbia, MO, USA)

1:45pm-3:15pm: Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity

E. Bezard, J. Bauffreton, Q. Li, G. Porras, W.K. Ko, E. Pioli, M. Cazalon, S. Morin, G. Farjot, J. Pype, B. Bessiere (Bordeaux, France)

1:45pm-3:15pm: Inhibiting sphingosine-1-phosphate lyase as a possible therapy in Huntington’s disease

E. Furr Stimming, J.F. Manchon, A. Tsvetkov (Houston, TX, USA)

1:45pm-3:15pm: Inhibition of long term memory and induction of biochemical deficits in rats following protofibrillar Aβ 1-42 injection

B. Nehru, S. Sharma (Chandigarh, India)

1:45pm-3:15pm: Inhibition of mitochondrial complex I synthesis by chloramphenicol mitigates dopaminergic neuronal cell loss in PQ-induced parkinsonism

S.J. Kim, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, M.J. Ryu, W. Chung, J.Y. Heo (Daejeon, Republic of Korea)

1:45pm-3:15pm: Instrumental Measurement of Stepping in Place – Detection of Asymmetry and Freezing of Gait

K. Otte, T. Vater, T. Ellermeyer, L. Rasche, G. Wenzel, B. Kayser, S. Mansow-Model, A. Kühn, F. Paul, A. Brandt, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Insulin Resistance In Non-Diabetic People With Parkinson’s Disease

M. Tagliati, E. Tan, J. Eskenazi, C. Basile, E. Hogg (Los Angeles, CA, USA)

1:45pm-3:15pm: Interaction between PLK2 ( Polo-like kinase-2) and alpha-synuclein in the non-human primate MPTP model of Parkinson disease

R. Valenti-Azcarate, I. Martinez-Valbuena, M.-M. Carmona-Abellan, I. Marcilla-Garcia, G. Marti-Andres, M.R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Interaction of dietary protein with levodopa in Parkinson disease.

B. Sharma, A. Rassmann, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?

C. LALOUX, F. GOUEL, C. LACHAUD, K. Timmerman, A. Jonneaux, C. Moreau, R. BORDET, J.-c. DEVEDJIAN, D. DEVOS (LILLE, France)

1:45pm-3:15pm: Intracortical plasticity is preserved in de novo Parkinson’s disease: a tSMS study.

M. Dileone, V. Catanzaro, J. Obeso, G. Foffani (Mostoles, Spain)

1:45pm-3:15pm: Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience

P. Podgorny, P. McCann, K. Toore, G. Tremain, A. Lazarescu, O. Suchowersky (Edmonton, AB, Canada)

1:45pm-3:15pm: Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

M. Bhargava, S. Bhargava, V. Bhargava (Kanpur, India)

1:45pm-3:15pm: Is the GBA2 a new modifier for Gauchers’s disease and GBA1-related Parkinson’s disease?

E. Nakanishi, N. Uemura, H. Akiyama, M. Kinoshita, H. Yamakado, S. Takeda, Y. Hirabayashi, R. Takahashi (kyoto, Japan)

1:45pm-3:15pm: Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis

W. Sako, N. Murakami, K. Motohama, Y. Izumi, R. Kaji (Tokushima, Japan)

1:45pm-3:15pm: Juvenile Huntington Disease (JHD) subjects’ stratification according to the mutation-length

M. Marano, M. Marano, S. Migliore, S. Maffi, F. Consoli, A. Ciammola, E. Gatto, F. Squitieri (Rome, Italy)

1:45pm-3:15pm: Large CAG expansions in Huntington disease children: the RAREST-JHD initiative

F. Squitieri, M. Marano, S. Migliore, S. Maffi, F. consoli, E. Bidollari, J. Rosati, A. Ciammola, E. Gatto, E. Cortes, A. Ilari, J. Vonsattel, U. Sabatini (Rome, Italy)

1:45pm-3:15pm: Laryngeal Tardive Dyskinesia in a Patient treated with Haldol

R. Joseph, F. Amjad (Columbus, OH, USA)

1:45pm-3:15pm: Listen to your heart: ordinal pattern statistics reveal altered cardiac rhythm dynamics in LRRK2-nonmanifesting carriers

C. Carricarte Naranjo, C. Marras, N. Visanji, A. Lang, L. Sanchez-Rodriguez, A. Machado García (La Habana, Cuba)

1:45pm-3:15pm: Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm: Longitudinal Study of Cortico-Striatal Functional Connectivity in Huntington’s Disease Measured with High-Field Functional MRI.

M. Kronenbuerger, M. Kronenbuerger, J. Hua, X. Mia, P. Unschuld, P. van Zijl, C. Ross (Baltimore, MD, USA)

1:45pm-3:15pm: Longitudinal study of freezing of gait in patients with Parkinson’s disease

M. Sawada, K. Wada-Isoe, S. Tagashira, K. Nakashima (Tottori, Japan)

1:45pm-3:15pm: Low frequency Deep Brain stimulation for Parkinson’s disease – Effect on freezing of gait.

R. Gopalakrishnan, G. Hosurkar (Bangalore, India)

1:45pm-3:15pm: Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment

S. Lessig, R. Kurlan, S. Factor, J. Burke, C. Wright, R. Jimenez, G. Liang (La Jolla, CA, USA)

1:45pm-3:15pm: Low-frequency repetitive transcranial cerebellar magnetic stimulation as an ‘add-on’ therapy in patients with Essential Tremor

H.-W. Shin, M. Hallett, Y. Sohn (Bethesda, MD, USA)

1:45pm-3:15pm: Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion

B. Cruse, D. Tsui, J. Griffith, H. Morales-Briceno, F. Chang, A. Ha, S. Kim, N. Wolfe, V. Kwan, N. Mahant, V. Fung (Westmead, Australia)

1:45pm-3:15pm: Manifestations of restless legs syndrome and its influence on the clinical course of associated migraine

M. Sanoeva (Bukhara, Uzbekistan)

1:45pm-3:15pm: Measuring temporal irregularity in spiral drawings of patients with Parkinson’s disease

S. Aghanavesi, M. Memedi, J. Westin (Borlange, Sweden)

1:45pm-3:15pm: Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition

J. Zhang, Q. Cai, M. Jiang, Y. Liu, H. Gu, J. Guo, H. Sun, J. Fang (Shanghai, China)

1:45pm-3:15pm: Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating HSP70 in SHSY-5Y cells

H. Sun, M. Jiang, J. Zhang, L. Feng, Y. Liu, Z. Nie, J. Fang, L. Jin (Shanghai, China)

1:45pm-3:15pm: Metabolic syndrome: Its link with motor function of Parkinson’s disease (PD)

H. Chan, Y. Cheung, D. Chau, V. Lo, C. Woo, S. Tse, T. Fung, W. Fong (Hong Kong, Hong Kong)

1:45pm-3:15pm: Metabolomic biomarkers strongly differentiate PD from healthy controls (HCs) in BioFIND study* specimens

P. LeWitt, J. Li, M. Lu, K.-H. Wu, Y. Zhou, I. Datta, L. Guo, B. Investigators (West Bloomfield, MI, USA)

1:45pm-3:15pm: Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain

P. Thakur, L. Breger, M. Lundblad, O. Wan, B. Mattsson, K. Luk, V. Lee, J. Trojanowski, A. Björklund (Frankfurt, Germany)

1:45pm-3:15pm: More effective rTMS site for the freezing of gait in Parkinson’s disease

S.Y. Kang, S.J. Kim (Hwaseong, Republic of Korea)

1:45pm-3:15pm: Motor dysfunctions in rats following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin

R. Shukla, R. Gupta, A. Pant, V. Khanna (Lucknow, India)

1:45pm-3:15pm: Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.

L. Andreoli, C. Alcacer, I. Sebastianutto, A. Cenci Nilsson (Lund, Sweden)

1:45pm-3:15pm: Movement Disorders Tele-Education program for undergraduate medical students in low-middle, high income countries.

E. Cubo, J. Doumbe, E. Lopez, C. Kuate, E. Gatto, B. Epundugu, G. Persi, G. Lopez (Burgos, Spain)

1:45pm-3:15pm: Multidisciplinary Parkinson rehabilitation delays nursing home admission and is cost-effective.

E. Steendam-Oldekamp, W. Rutgers, T. van Laar (Groningen, Netherlands)

1:45pm-3:15pm: Multiple myeloma induced parkinsonism

H. DS, V. Paramanandam, P.c. N (Chennai, India)

1:45pm-3:15pm: Multivariate analysis of writer`s cramp: a study with advanced multi-channel microelectrode recording system

V. Rama raju, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Mutant DNAJC13 modulates accumulation and toxicity of alpha-synuclein through altered endosomal trafficking in cell and fly models of Parkinson’s disease

T. Hasegawa, S. Yoshida, M. Suzuki, J. Kobayashi, N. Sugeno, K. Sekiguchi, M. Edura, A. Kikuchi, A. Takeda, Y. Nagai, M. Aoki (Sendai, Japan)

1:45pm-3:15pm: Myoclonus in adult onset Huntington’s disease

S. McAllister, S. Shipley, J. Shah, R. Fekete (New York, NY, USA)

1:45pm-3:15pm: Myths and Misconceptions Regarding Huntington’s Disease in Peru

A. Vishnevetsky, M. Illanes-Manrique, M. Inca-Martinez, M. Cornejo-Olivas (Philadelphia, PA, USA)

1:45pm-3:15pm: Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration

M. Duffy, T. Collier, K. Luk, M. Tansey, K. Paumier, D. Fischer, N. Polinski, C. Kemp, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Neurological worsening in patients undergoing treatment for Wilson disease: Frequency, causes and outcomes.

A. Aggarwal, M. Bhatt (Mumbai, India)

1:45pm-3:15pm: Neuroprotection and Alleviation of Parkinsonian Phenotypes by Ayurvedic Herbs

S. Singh, J. Prakash, S. Yadav (Varanasi, India)

1:45pm-3:15pm: Neuroprotective effect of α-Mangostin in restoration mitochondrial function in MPTP-Induced Parkinson’s disease in mice

A. Prakash, A.B. Majeed, K. Ramasamy, M. Hasan (Baltimore, MD, USA)

1:45pm-3:15pm: Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

1:45pm-3:15pm: New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients

K. Ikenaka, K. Araki, M. So, S. Hashimoto, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Non-Invasive Assessment of Swallowing and Respiration Coordination in Early Parkinson’s Disease

Y.R. Wu, C.-M. Wang, W.-Y. Shieh, Y.-H. Weng, Y.-H. Hsu (Taoyuan, Taiwan)

1:45pm-3:15pm: Non-motor symptoms in ACDY5-associated disease

C. Amlang, M. Vidailhet, M. Amlang (Bronx, NY, USA)

1:45pm-3:15pm: Novel Programming Strategy to Overcome Loss of Efficacy in Essential Tremor

S. Farris, M. Giroux (Englewood, CO, USA)

1:45pm-3:15pm: Novel TUBB4A variants in idiopathic dystonia

S. Camargos, C. Dos Santos, F. Silva Junior, E. Barbosa, S.M. Azevedo Silva, V. Borges, J.C. Limongi, M.S. Rocha, H. Ferraz, F. Cardoso, P. Carvalho Aguiar (Belo Horizonte, Brazil)

1:45pm-3:15pm: Number and characteristics of people who requested the Portuguese Version of the European Physiotherapy Guideline for Parkinson’s Disease: a one-year follow-up

L. Almeida, T. Capato, J. Domingos (Salvador, Brazil)

1:45pm-3:15pm: Objective gait parameters as a noninvasive biomarker for freezing of gait in Parkinson’s disease patients

J. Shah, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Objective identification of freezing of gait in Parkinson’s disease patients using a triaxial accelerometer

Y. Okuma, H. Mitoma, M. Yoneyama (Izunokuni-city, Japan)

1:45pm-3:15pm: Objective Measurement in Clinical Care of Patients with Parkinson’s disease: an RCT using the PKG

P. Farzanehfar, M. Braybrook, K. Kotschet, M. Horne (Parkville, Australia)

1:45pm-3:15pm: Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Optimization of Synucleinopathy and Nigrostriatal Degeneration Induced by Injection of Alpha-Synuclein Preformed Fibrils into Rat Striatum

C. Sortwell, T. Collier, M. Duffy, K. Luk, C. Kemp, N. Kanaan, K. Paumier, J. Patterson (Grand Rapids, MI, USA)

1:45pm-3:15pm: Pairing TMS and physical therapy for treatment of gait and balance disorders in Parkinson’s Disease: a randomized pilot trial

A. Cucca, H. Migdadi, T. Biller, S. Agarwal, P. Kumar, A. Son, M. Ko, E. Gallo, S. Fisher, A. Di Rocco, M. Biagioni (New York, NY, USA)

1:45pm-3:15pm: Parkinson ‘ s disease and Peripheral Nervous System : Wax and Waning Non-motor offs and Levodopa-use Topics

s.g. echebarria mendieta (-, Spain)

1:45pm-3:15pm: Parkinson Syndrome associated with inositol-1,4,5-triphosphate receptor antigen type 1 (ITPR1) antibodies

B. Wimmer, K. Fuchs, U. Bogdahn, A. Heimeroth (Regensburg, Germany)

1:45pm-3:15pm: Parkinson’s disease disrupts motor skill learning that requires improvement of a speed-accuracy trade-off

C. Kim, A. Zimnik, U. Kang, P. Mazzoni (New York, NY, USA)

1:45pm-3:15pm: Parkinson’s disease and comorbidity: A US national perspective

A. Mithal, B. Lingala, A. Niyazov, A. Guo, C. Marras, G. Singh (Woodside, CA, USA)

1:45pm-3:15pm: Parkinson’s Disease Medications Availability in Each Philippine Region

S. Villaraza, C. Go (Manila, Philippines)

1:45pm-3:15pm: Parkinson’s Disease-Like Pathology in the Rat Brain and Colon Following Methamphetamine Self-Administration

B. Bradaric, A. Persons, S. Kousik, L. Kelly, S. Graves, T.C. Napier (Chicago, IL, USA)

1:45pm-3:15pm: Parkinsonism in the very old – A clinicopathological study

A. Rajput, E. Rajput (Saskatoon, SK, Canada)

1:45pm-3:15pm: Patient Clustering through a Mobile-based PD Severity Score

A. Zhan, S. Mohan, M. Elson, E. Dorsey, A. Terzis, S. Saria (Baltimore, MD, USA)

1:45pm-3:15pm: Patients with Essential Tremor Live Longer than their Relatives

C. Akbostanci, K. Doğanyiğit, M. Şen, E. Onat, A. Tekinay, T. Özçelik, M. Akbostanci (Snoqualmie, WA, USA)

1:45pm-3:15pm: Patients’ Perspective of Physicians’ Counseling on Exercise in Parkinson’s Disease (PD)

J.Y. Park, V. Shanker (New York, NY, USA)

1:45pm-3:15pm: PDSS: A Novel Mobile-based Parkinson Disease Severity Score

A. Zhan, S. Mohan, M. Elson, E. Dorsey, A. Terzis, S. Saria (Baltimore, MD, USA)

1:45pm-3:15pm: Perceptual decision making and reflection impulsivity in drug naïve and treated patients with restless legs syndrome

B. Heim, M.-T. Pertl, A. Stefani, A. Heidbreder, L. Zamarian, E. Brandauer, B. Averbeck, M. Delazer, K. Seppi, B. Högl, W. Poewe, A. Djamshidian (Innsbruck, Austria)

1:45pm-3:15pm: Perrault syndrome: CLPP-Knock-Out mouse brain shows accumulation of mitoribosomes

J. Key, J. Heidler, S. Torres-Odio, G. Auburger, I. Wittig, S. Gispert (Frankfurt am Main, Germany)

1:45pm-3:15pm: Personal KinetiGraph (PKG) for Parkinson’s Disease: Experience at a Tertiary Care Center

V. Sharma, A. Fowler, K. Lyons, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Personal KinetiGraph Devices Assessing Efficacy of Continuous Enteral Carbidopa/Levodopa Infusion Therapy

J. Margolesky, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.

I. Sebastianutto, N. Maslava, L. Di Menna, F. Nicoletti, M. Cenci (Lund, Sweden)

1:45pm-3:15pm: Phenotype of PLP1-related disorder caused by novel mutation: a case report

N. Kresojevic, I. Petrovic, V. Dobricic, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)

1:45pm-3:15pm: Phosphodiesterases and striatal pathways in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, A. Tziortzi, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Plasma Biomarkers in Idiopathic Normal Pressure Hydrocephalus

P.-W. Ko, K. Kang, S.Y. Kim, H.-W. Lee (Daegu, Republic of Korea)

1:45pm-3:15pm: Potential of non-invasive brain stimulation to ameliorate freezing of gait in Parkinson’s disease: A deep repetitive TMS randomized, double-blinded, cross-over pilot study

M. Dagan, T. Herman, A. Mirelman, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.

N. Rocha, E. Furr-Stimming, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm: Premovement betaband event-related desynchronization related to simple lower limb movement and simulated gait initiation in Parkinson’s disease patients: MEG study

J.Y. Yun, J.S. Kim, H.W. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Prescription pattern of treatment in Mexican patients with Huntington’s Disease.

A. De-la-Cruz, L. Mendoza Vega, N. Davila Avila, K. Salinas Barboza, S. Isais Millan, A. Cervantes Arriaga, M. Rodriguez Violante (Ciudad de Mexico, Mexico)

1:45pm-3:15pm: Prevalence of Parkinson’s disease and Drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)

H.-I. MA, S. Jang, J.-s. Kim, S.J. Chung, J.S. Baik, Y.J. Kim (Anyang, Republic of Korea)

1:45pm-3:15pm: Prevalence of Restless Legs Syndrome in hemodialyzed patients

I. Estrada-Bellmann, S. Castillo-Torres, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías (Monterrey, Mexico)

1:45pm-3:15pm: Prevalence of substance abuse in Huntington´s disease patients and its relationship with neuropsychiatric symptoms

K. SALINAS BARBOZA, L. MENDOZA VEGA, A. CRUZ LANDERO, S. ISAIS MILLAN, M. RODRIGUEZ VIOLANTE, A. CERVANTES ARRIAGA, N. DAVILA AVILA (MEXICO, Mexico)

1:45pm-3:15pm: Prevalence of tremor in Multiple Sclerosis in Isfahan, Iran

M. Salari, M. Etemadifar, O. Mirmosayyeb (Isfahan, Islamic Republic of Iran)

1:45pm-3:15pm: Prism adaptation and cerebellar inhibition were impaired in essential tremor

R. Hanajima, R. Tsutsumi, Y. Shirota, T. Shimizu, N. Tanaka, Y. Ugawa (Kanagawa, Japan)

1:45pm-3:15pm: Prognostic relevance and predictive ability of data-driven PD subtypes in the Longitudinal and Biomarker Studies in Parkinson’s disease (LABS-PD)

T. Mestre, S. Eberly, C. Tanner, D. Grimes, A. Lang, D. Oakes, C. Marras (Ottawa, ON, Canada)

1:45pm-3:15pm: Progressive microstructural abnormalities of the occipital cortex in Huntington’s disease

O. Odish, R. Reijntjes, S. van_den Bogaard, R. Roos, A. Leemans (Leiden, Netherlands)

1:45pm-3:15pm: Prominent extensor truncal and cervical dystonia induced by mirtazapine

W.T. Yoon (Seoul, Republic of Korea)

1:45pm-3:15pm: Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data

L. Garavaglia, E. Pagliano, A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

1:45pm-3:15pm: Psychiatric comorbidities are common in patients with Orthostatic Tremor

D. Bhatti, R. Thompson, K. Malgireddy, B. Bayer, D. Bessette, M. Fleisher, D. Murman, D. Torres-Russotto (Omaha, NE, USA)

1:45pm-3:15pm: Psycho-behavioral profile of Parkinson’s disease patients with RLS: a cross sectional-study

A. MARQUES, M. Figorilli, B. Pereira, P. Derost, B. Debilly, P. Beudin, T. Vidal, F. Durif, M. Fantini (Clermont-Ferrand, France)

1:45pm-3:15pm: Putaminal Atrophy Gradient in X-linked Dystonia-Parkinsonism

H. Hanßen, M. Heldmann, C. Diesta, R. Rosales, A. Domingo, T. Münte, C. Klein, N. Brüggemann (Luebeck, Germany)

1:45pm-3:15pm: Quantifying postural stability differences in people with Parkinson’s disease with and without freezing of gait, using body-worn sensors

P. Carlson-Kuhta, M. El-Gohary, M. Mancini, F. Horak, J. Huisinga (Portland, OR, USA)

1:45pm-3:15pm: Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates

A. Singh, S. Papa (Minneapolis, MN, USA)

1:45pm-3:15pm: Relation between REM-Sleep Behaviour Disorder and dysautonomic symptoms in Essential Tremor patients

R. Barbosa, M. Mendonça, F. Ladeira, R. Miguel, P. Bugalho (Lisboa, Portugal)

1:45pm-3:15pm: Relationship between the presence of colonic a-synuclein and MDS research criteria for prodromal PD in patients without manifest motor parkinsonism (PARCAS study)

M. Skorvanek, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, B. Kolarova, B. Repkova, Z. Urbancikova, A. Vargova, L. Gombosova, M. Zakuciova, E. Veseliny, F. Trebuna, E. Mechirova, Z. Gdovinova (Kosice, Slovakia)

1:45pm-3:15pm: Relationship of metabolic markers in Parkinson’s disease

N. Alsomali, A. Mujtaba, A. AlSamrani, S. Marar, T. Mohammad (Riaydh, Saudi Arabia)

1:45pm-3:15pm: Reliability of Continuous Parkinson’s Assessment Using Wearables

D. Heldman, E. Urrea Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, A. Hadley, Z. Mari, M. Burack, I. Itin, F. Revilla (Cleveland, OH, USA)

1:45pm-3:15pm: Reproducibility of data-driven Parkinson’s disease subtypes for clinical research using a Delphi process for expert-based consensus.

T. Mestre, S. Eberly, C. Tanner, A. Lang, D. Grimes, D. Oakes, C. Marras (Ottawa, ON, Canada)

1:45pm-3:15pm: Restless Legs Syndrome in Functional Movement Disorders

T. Serranova, M. Slovak, D. Kemlink, K. Sonka, E. Ruzicka (Prague, Czech Republic)

1:45pm-3:15pm: Restless Legs Syndrome in hemodialyzed patients: a case-control study.

I. Estrada-Bellmann, S. Castillo-Torres, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías (Monterrey, Mexico)

1:45pm-3:15pm: Restless legs syndrome in pregnancy: frequency and impact on quality of life and sleep

S. Telarovic, L. Condic, I. Telarovic (Zagreb, Croatia)

1:45pm-3:15pm: Reversible progressive supranuclear palsy-mimic induced by risperidone

H.J. Kim, J.H. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Reviewing the Clinical and Mutational Spectrum of SLC20A2 Mutations in Primary Familial Brain Calcification (PFBC) for MDSGene

A. Balck, S. Schaake, C. Marras, C. Lill, A. Westenberger, C. Klein (Luebeck, Germany)

1:45pm-3:15pm: Rice bran extract against animal model of Huntington’s disease: Possible role of neurotransmitters

P. Kumar, N. Kaur (Bathinda, Punjab, India)

1:45pm-3:15pm: Risk of Parkinson’s disease in zolpidem user: A systematic review and meta-analysis

S. Hussain, A.K. Najmi, D. Anil (New Delhi, India)

1:45pm-3:15pm: Role of the subthalamic nucleus and globus pallidus internus in response inhibition during masked prime tasks in human

A. Singh, I. Niazi, V. Sharma, K. Boetzel (Minneapolis, MN, USA)

1:45pm-3:15pm: Saccadic impairment in patients with Gaucher’s disease type 3

J. Blume, C. Kämpe Björkvall, M. Machaczka, P. Svenningsson (Stockholm, Sweden)

1:45pm-3:15pm: Salivary Alpha-Synuclein in Aging

G. Vivacqua, A. Fabbrini, A. Suppa, R. Mancinelli, G. Fabbrini, C. Colosimo, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Salivary biomarkers for Huntington’s disease (HD)

J. Corey-Bloom, A. Aikin, S. Park, A. Haque, A. Nathan, D. Granger, S. Granger, E. Thomas (La Jolla, CA, USA)

1:45pm-3:15pm: Saving Veterans Time, Miles, and Money: Cost Analysis of Video Telemedicine Evaluation of Deep Brain Stimulation (DBS) candidacy at the VA

N. Witek, S. Heath, C. Tanner, N. Galifianakis (San Francisco, CA, USA)

1:45pm-3:15pm: Screening of cognitive impairment in Huntington’s disease with the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)

S. Martinez-Horta, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Sensory modulation of postural control in Huntington’s disease

F. Porciuncula, K. Marder, P. Wasserman, A. Rao (New York, NY, USA)

1:45pm-3:15pm: Serum lipid profile in Parkinsons disease patients from Southern Spain

C. Mendez Barrio, D. Macias Garcia, S. Jesus, M.A. Labrador Espinosa, L. Vargas Gonzalez, M. Bernal Escudero, A. Adarmes Gomez, F. Carrillo Garcia, M. Carvallo Cordero, P. Gomez Garr, P. Mir (Seville, Spain)

1:45pm-3:15pm: Serum soluble transferrin receptor levels correlate with the Hoehn & Yahr stage of Parkinson disease progression

P. Costa-Mallen, S.-C. Hu, P. Agarwal (Kenmore, WA, USA)

1:45pm-3:15pm: Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder.

E. Antelmi, V. Donadio, G. Plazzi, R. Liguori (Bologna, Italy)

1:45pm-3:15pm: Social hindrances for diagnosing Huntington’s disease

A. Alboudi, P. Sarathchandran, A.B. Almadani (Dubai, United Arab Emirates)

1:45pm-3:15pm: Spanish Primary Familial Brain Calcification caused by SLC20A2 mutation

N. Caballol, E. Peral, M. Balague, E. Moral, L. Vila, G. Celma, L. Vives, I. Royo, A. Ferran, A. Torrents, E. Gean, A. Ávila (Sant Joan Despí, Spain)

1:45pm-3:15pm: Spasmodic Dysphonia in Hereditary Spastic Paraplegia Type 7

D. Hall, N. Stong, N. Lippa, M. Pitman, S. Pullman, O. Levy (New York, NY, USA)

1:45pm-3:15pm: Spastic paraplegia type 4: a novel SPAST splice site donor mutation and expansion of the phenotype variability

A. Orlacchio, C. Montecchiani, R. Miyamoto, M. Mearini, L. D'Onofrio, M. Miele, F. Gaudiello, Y. Izumi, C. Caltagirone, R. Kaji, T. Kawarai (Rome, Italy)

1:45pm-3:15pm: Spectrum of non-motor symptoms in essential tremor in a Tunisian population

M. Ben Djebara, I. Kacem, S. Mrabet, Y. Sidhom, B. Saguem, A. Nasri, A. Gargouri, R. Gouider (Manouba, Tunisia)

1:45pm-3:15pm: Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline.

S. Desai, S. Singh, V. Patel, J. Sheth (Anand, India)

1:45pm-3:15pm: Substantia nigra hyperechogenicity in male methamphetamine users

G. Todd, V. Pearson-Dennett, B. Collie, J. White (Adelaide, Australia)

1:45pm-3:15pm: Successful passive monitoring of early-stage Parkinson’s disease patient mobility in Phase I RG7935/PRX002 clinical trial with smartphone sensors

F. Lipsmeier, I. Fernandez Garcia, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Eriksen, W.-Y. Cheng, J. Siebourg-Polster, L. Jin, J. Soto, L. Verselis, M. Martin Facklam, F. Boess, M. Koller, M. Grundman, M. Little, A. Monsch, R. Postuma, A. Gosh, T. Kremer, K. Taylor, C. Czech, C. Gossens, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

R. Bansal, R. Singh (Chandigarh, India)

1:45pm-3:15pm: Tacrolimus induced parkinsonism presenting as freezing of gait and speech

V. Paramanandam, H. DS, P.C. N (Chennai, India)

1:45pm-3:15pm: Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study

S. Factor, M. Stacy, J. Burke, C. Yonan, H. Le, G. Liang (Atlanta, GA, USA)

1:45pm-3:15pm: Tardive syndromes induced by coadministration of tramadol and sertralin

H. Sarac, N. Bozina, N. Henigsberg, L. Bagaric-Krakan (Zagreb, Croatia)

1:45pm-3:15pm: Targeted overexpression of A53T-alpha-synuclein induces progressive neurodegeneration and electrophysiological changes of noradrenergic locus coeruleus neurons – a preclinical model of Parkinson’s disease

M. Henrich, L. Matschke, A. Stoehr, W.-H. Chiu, B. Lee, F. Geibl, J. Koprich, N. Decher, W. Oertel (Marburg, Germany)

1:45pm-3:15pm: Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

1:45pm-3:15pm: TETRAS applicability and study design in randomized, placebo controlled clinical trial of Cav3 modulation for essential tremor patients.

Y. Maricich, E. Newbold, R. Elble (Charlottesville, VA, USA)

1:45pm-3:15pm: The Accreditation and Certification of the Movement Disorders Subspecialty

S. O'Shea, L. Gutmann, L. Faulkner (New York, NY, USA)

1:45pm-3:15pm: The AppTUG : a new application for analyzing the Timed Up and Go task in patients with neurological disorders

G. Yahalom, Z. Yekutieli, S. Korn-Israeli, S. Elincx-Benizri, V. Livneh, T. Fay-Karmon, Y. Rubel, S. Hassin-Baer (Ramat-Gan, Israel)

1:45pm-3:15pm: The comparison of urine microvesicle reflecting gut microbiome between Parkinson’s disease and healthy control

J. Park, S. Park, W. Jang, J.S. Kim, J. Yoon, E. Oh (Busan, Republic of Korea)

1:45pm-3:15pm: The effects of dual task on the finger tapping performance of Parkinson’s disease.

A. Miyake, T. Yamamoto, H. Kawasaki, T. Furuya, T. Fukuoka, K. Takahashi, N. Tamura, N. Araki (irumagun moroyama town, Japan)

1:45pm-3:15pm: The Huntington’s Disease Health Index Study (HD-HI)

A. Glidden, E. Luebbe, M. Elson, S. Goldenthal, R. Dorsey, C. Heatwole (Rochester, NY, USA)

1:45pm-3:15pm: The influence of neurorehabilitation on Parkinson medication

V. Tomantschger, A. Tautscher-Basnett, M. Freimueller (Hermagor, Austria)

1:45pm-3:15pm: The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

1:45pm-3:15pm: The nature of postural tremor in Parkinson’s disease

M. Dirkx, H. Zach, M. Hallet, R. Helmich (Nijmegen, Netherlands)

1:45pm-3:15pm: The neural correlates of apathy in premanifest and manifest Huntington’s disease: A cross-sectional multimodal imaging study

S. Martinez-Horta, J. Perez-Perez, F. Sampedro, M. Carceller, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

1:45pm-3:15pm: The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease

E. Tan, M. Tagliati, E. Hogg, M. Horne (Los Angeles, CA, USA)

1:45pm-3:15pm: The predominant parkinsonian phenotype in beta propeller associated neurodegeneration (BPAN)

H. Morales, B. Sanchez-Hernandez, R. Leal-Ortega, M. Rodriguez-Violante, M. Kurian, V. Fung (Westmead, NSW, Australia)

1:45pm-3:15pm: The Role of Clinical Outcome Assessment (COA) Data in the Drug Approval Process of Medicines for the Treatment of Restless Legs Syndrome (RLS): A Review of the Labels of Medicines Approved by the FDA and the EMA

M.-P. Emery, C. Anfray, L.-L. Perrier, C. Acquadro (Lyon, France)

1:45pm-3:15pm: The therapeutic effects of cortical electrical stimulation in an animal model of Parkinson’s disease

T.-H. Hsieh, W.-S. Chang Chien, C.-W. Peng, Y.-Z. Hunag, J.-J. Chen (Taoyuan, Taiwan)

1:45pm-3:15pm: The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

1:45pm-3:15pm: The value of the Tau/α-synuclein ratio and TNF-α in cerebrospinal fluid, and of plasma IL-6, in the diagnosis and prognosis of Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jimenez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro-Gómez, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, P. Martínez-Lage, A. Izagirre, M. Rodríguez-Oroz (San Sebastián, Spain)

1:45pm-3:15pm: Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations

J. Mitsui, K. Koguchi, T. Momose, M. Takahashi, T. Matsukawa, T. Yasuda, S.-i. Tokushige, H. Ishiura, J. Goto, S. Nakazaki, T. Kondo, H. Ito, Y. Yamamoto, S. Tsuji (Tokyo, Japan)

1:45pm-3:15pm: Topography of essential tremor

W. Chen, F. Hopfner, S. Szymczak, O. Granert, S.H. Müller, G. Kuhlenbäumer, G. Deuschl (Shanghai, China)

1:45pm-3:15pm: Transcranial sonography in the prognosis of drug-induced parkinsonism

Y.-S. Oh, D.-Y. Kwon (Seoul, Republic of Korea)

1:45pm-3:15pm: Treadmill training, Tai Chi, dance and more: a meta-analysis on the effectiveness of different physiotherapy modalities in Parkinson’s disease

D. Radder, N. de Vries, M. Faber, M. van Nimwegen, S. Keus, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Treatable Rare Movement Disorders

E. Gatto, H. Jinnah, A. Espay, J. Jankovic, K. Bhatia, M. Rodriguez, V. Fung, F. Cardoso, M. Rodriguez Oroz, A. Albanese, A. Muenchau, A. Chade, M. de Koning-Tijssen, M. Stamelou, P. Garcia Ruiz, C. Uribe Roca, F. Morgante, A. Dela Cerda, L. Schoels, J. Miyasaki, J. Ferreira (Buenos Aires, Argentina)

1:45pm-3:15pm: Treatment of secondary movement disorders related to midbrain cavernomas

K. Karpinska, A. Smolanka (Uzhgorod, Ukraine)

1:45pm-3:15pm: Tremor Characteristics in Essential Tremor and Dystonic Tremor

P. Panyakaew, H.J. Cho, M. Hallett (Bangkok, Thailand)

1:45pm-3:15pm: Tremor in motorneuron disease: central or peripheral origin?

A. Latorre, M. Stamelou, L. Rocchi, M. Ciocca, K. Sidle, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Ultrasonography-guided Botulinum Toxin Type-A Injection in Tremor. An open-label Study

H. Shehata, N. Shalaby, M. Basheer, A. Elmazny, S. Eljaafary (Cairo, Egypt)

1:45pm-3:15pm: Unusual facial synkinesia after Bell’s palsy: interactive Marin-Amat syndrome proven by surface electromyogram, successfully treated with low dose botulinum toxin A.

H. Mori (Kurashiki, Japan)

1:45pm-3:15pm: Update on the MDS-Sponsored Systematic Review On Clinical Rating Scales for Huntington’s Disease: motor, cognitive, functional ability and quality of life domains

T. Mestre, C. Sampaio, C. Goetz, P. Martinez-Martin, G. Stebbins (Ottawa, ON, Canada)

1:45pm-3:15pm: Using measurements from wearable sensors for automatic scoring of Parkinson’s disease motor states

I. Thomas, F. Bergquist, R. Constantinescu, D. Nyholm, M. Senek, M. Memedi (Falun, Sweden)

1:45pm-3:15pm: Using the power of a Network to accomplish a Countrywide Review of Acute Parkinson’s Disease management

E. Peter, B. Mohamed, C. Thomas (Bridgend, United Kingdom)

1:45pm-3:15pm: Validation of actigraphy-derived sleep metrics in Parkinson’s disease (PD) patients and elderly controls, taking into account clinical and physiological status

J. Munro, R. Wolz, D. Hill, Y. DAUVILLIERS (London, United Kingdom)

1:45pm-3:15pm: Variability of spiral tremor during daily life of subjects with Essential Tremor

J. Thompson-Westra, T. Wu, H. Cao, A. Pigg, G. Leodori, F.A. Vial Undurraga, M. Hallett, D. Haubenberger (Bethesda, MD, USA)

1:45pm-3:15pm: Variations in ANO3 gene in patients with cervical dystonia

V. Han, V. Habalova, L. Klimcakova, J. Zidzik, M. Skorvanek, Z. Gdovinova (Kosice, Slovakia)

1:45pm-3:15pm: Verticality Perception Differentially Correlates with Pisa Syndrome in Parkinson’s Disease

Y.E. Huh, W.-H. Chung, K. Kim, J.W. Cho (Seongnam-si, Republic of Korea)

1:45pm-3:15pm: Vitamin D in the Parkinson’s Associated Risk (PARS) Study

M. Fullard, S. Xie, K. Marek, M. Stern, D. Jennings, A. Siderowf, A. Chen-Plotkin (Philadelphia, PA, USA)

1:45pm-3:15pm: Wearable motion quantification and electronic diaries for long-term monitoring of Parkinson’s disease

A. Hadley, E. Mendoza, N. Mennucci, C. Zimmerman, J. Giuffrida, Z. Mari, M. Burack, I. Itin, F. Revilla, D. Heldman (Cleveland, OH, USA)

1:45pm-3:15pm: Wearable sensor-based therapy titration for Parkinson’s Disease

R. Schmidt, D. Heldman, A. Hadley, D. Riley (Cleveland, OH, USA)

1:45pm-3:15pm: Whole Exome Sequencing (WES) identifies a TUBB4A Mutation in two Saudi siblings with hypomyelinating leukodystrophy associated with atrophy of basal ganglia and cerebellum.

Z. Aldaajani, E.-S. Ali (Dhahran, Saudi Arabia)

1:45pm-3:15pm: Whole exome sequencing in essential tremor.

I. Alfradique-Dunham, L. Robak, A. Kaw, O. Fagbongbe, Z. Coban Akdemir, E. Young, J. Lupski, J. Jankovic, J. Shulman (Houston, TX, USA)

1:45pm-3:15pm: WILSON’S DISEASE: A Mongolian case

U. Dashdorj, S. Jambal (Ulaanbaatar 51, Mongolia)

1:45pm-3:15pm: Сase of myotonic dystrophy

A. Jusupova (Bishkek, Kyrgyzstan)

1:15pm-2:45pm: [11C]PK11195 PET Imaging Reveals Neuroinflammation in Dementia with Lewy Bodies: NIMROD Study

A. Surendranathan, L. Su, L. Passamonti, Y. Hong, W. Bevan-Jones, R. Arnold, P. Vázquez Rodríguez, E. Mak, T. Fryer, F. Aigbirhio, J. Rowe, J. O'Brien (Cambridge, United Kingdom)

1:15pm-2:45pm: 99mTc -TRODAT- 1 SPECT SHOWING DOPAMINERGIC DEFICIENCY IN A PATIENT WITH SPINOCEREBELLAR ATAXIA TYPE 10 AND PARKINSONISM.

G. Fabiani, R. Filho, T. Ashizawa, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: A case report: a primary progressive multiple sclerosis (PPMS) with adolescent-onset of progressive cerebellar ataxia

S.-K. Yang, J.-J. Lin (Changhua county, Taiwan)

1:15pm-2:45pm: A comparative study between OCT in SCA3 and 10

F. Tensini, M. Sato, N. Shiokawa, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B

F. Amjad, F. Pagan, A. Lax, C. Moussa (Washington DC, DC, USA)

1:15pm-2:45pm: A member of the HSP40/DNAJ family is a novel gene for early-onset parkinsonism

L. Straniero, I. Guella, V. Rimoldi, L. Parkkinen, A. Young, R. Asselta, J. Follett, G. Soldà, E. Saba, V. Sossi, J. Stoessl, K. Nishioka, N. Hattori, A. Rajput, R. Cilia, S. Goldwurm, M. Farrer, G. Pezzoli, A. Rajput, S. Duga (Rozzano-Milano, Italy)

1:15pm-2:45pm: A neuronal model of PARK20 (SYNJ1 mutation) using patient derived iPSCs

R. Masius, M. Minneboo, M. Grochowska, M. Quadri, M. Picillo, P. Barone, V. Bonifati, W. Mandemakers (Rotterdam, Netherlands)

1:15pm-2:45pm: A new psychosocial intervention for people with Parkinsonian dementias: Adherence, barriers and facilitators

S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

1:15pm-2:45pm: Absence of depression in de novo Parkinson’s disease: a benign motor phenotype?

H.S. YOO, Y. Lee, J.J. Lee, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

1:15pm-2:45pm: Accuracy measures of imbalance bedside examination

y. xia, R. Thompson, D. Bhatti, A. Hellman, J. McKune, K. Suing, L. Schmaderer, K.-C. Siu, D. Torres-Russotto (omaha, NE, USA)

1:15pm-2:45pm: Action Verb Generation as a marker of cognitive function in Parkinson disease

O. Yerokhin, K. Smith (Worcester, MA, USA)

1:15pm-2:45pm: Action Verbal Fluency is Related to the Functional Integrity of the Cognitive Cortico-Striatal Loop in Parkinson’s Disease

N. Auclair-Ouellet, A. Hanganu, E. Mazerolle, J. Sarna, M. Kibreab, J. Cheetham, I. Kathol, A. Haffenden, B. Pike, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Adding cues to a rat gambling task potentiates the increase in premature responding in response to chronic D2/3 agonist ropinirole without mitigating preference for risk

M. Tremblay, M. Barrus, P. Cocker, S. Kaur, C. Winstanley (Vancouver, BC, Canada)

1:15pm-2:45pm: All-trans-retinoic Acid pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced hemi-parkinsonian rats

A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

1:15pm-2:45pm: Allelic CACNA1A disorders: a retrospective cohort analysis on clinical course and overlapping features

W. Nachbauer, P. Dorin, E. Indelicato, A. Eigentler, S. Boesch (Innsbruck, Austria)

1:15pm-2:45pm: Alteration of early endosomal trafficking causes neurodegeneration in PARK20

C. Criscuolo, D. Fasano, V. Coppola, G. Amodio, M. Picillo, A. De Rosa, V. Bonifati, P. Barone, M. Pellecchia, G. De Michele, P. Remondelli, S. Paladino (Naples, Italy)

1:15pm-2:45pm: Alterations in lipid metabolism modify GBA1-mediated neurodegeneration in a Drosophila model of Parkinson’s disease

M. Davis, R. Thomas, A. Germanos, S. Yu, B. Whitley, L. Pallanck (Seattle, WA, USA)

1:15pm-2:45pm: Altered brain network measures in patients with Primary Writing Tremor

A. Lenka, K. Jhunjhunwala, R. Panda, R. Yadav, J. Saini, R. Bharath, P. Pal (Bangalore, India)

1:15pm-2:45pm: An unusual case of hemichorea in a woman with newly discovered renal cell carcinoma and inconclusive LGI-1 antibody

K. Colletta, N. Kartha, J. Chawla (Maywood, IL, USA)

1:15pm-2:45pm: An unusual case of sporadic Creutzfeld Jacob disease presenting as acute neuropathy

R. Hanumanthu, A. Alchaki, A. Nyaboga, H. Ghuman, J. Chen, E. Feinstein (Newark, NJ, USA)

1:15pm-2:45pm: Anosognosia for Levododopa-induced Dyskinesias in PD – Frequency

R. Doyle Maia, F. Cardoso, P. Caramelli (Vitória, Brazil)

1:15pm-2:45pm: Antiphospholipid syndrome presenting with craniocervical dystonia: A case study

C. Dietiker, C. Clelland, S. Gupta, M. Richie, M. Shah, I. Bledsoe (San Francisco, CA, USA)

1:15pm-2:45pm: Antisense FMR1 splice variant and loss of AGG interruptions are predictors of Fragile X-associated tremor/ataxia syndrome (FXTAS)

P. Vittal, S. Pandya, K. Sharp, E. Berry-Kravis, L. Zhou, B. Ouyang, J. Jackson, D. Hall (Winfield, IL, USA)

1:15pm-2:45pm: Apathy in adolescents with Tourette syndrome (TS), more than a teenager attitude

W. Deeb, M. Hensley, A. Bernier, I. Malaty (Gainesville, FL, USA)

1:15pm-2:45pm: APOE4+ status increases rate of longitudinal cognitive decline in Parkinson Disease patients with low CSF Aβ42

K. Leaver, T. Hendershott, D. Zhu, L. Tian, K. Poston (Stanford, CA, USA)

1:15pm-2:45pm: Apolipoprotein E ε4 allele frequency in Korean Patients with Parkinson’s disease Dementia

M. Park (Daegu, Republic of Korea)

1:15pm-2:45pm: Apomorphine infusion does not impair cognitive action control in Parkinson’s disease

J. Duprez, J.-F. Houvenaghel, S. Drapier, D. Drapier, M. Vérin, P. Sauleau (Rennes, France)

1:15pm-2:45pm: Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.

C. Friedrich, W. Zago, S. Gardai, G. Tonn, M. Reed (Cupertino, CA, USA)

1:15pm-2:45pm: Are there genotype-phenotype correlations in Perrys syndrome?

J. Panicker, M. Bonello, R. Ellis, A. Randall, L. Fratalia, S. Alusi (Liverpool, United Kingdom)

1:15pm-2:45pm: Assessing Bone Health in Parkinson’s – When and how?

A. Dzharif, E. Thomas, B. Mohamed, T. Williams, S. Mahon (Cardiff, United Kingdom)

1:15pm-2:45pm: Assessing the response to L-dopa/carbidopa intestinal gel infusion (Deudopa) based on genetic status.

A. Thaler, A. Hillel, H. Shabtai, N. Giladi, T. Gurevich (Tel-Aviv, Israel)

1:15pm-2:45pm: Assessment of cognitive impairment using FP-CIT SPECT

N. Egawa, A. Kokuryu, Y. Inoue, A. Kuzuya, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: Association analyses of three susceptibility loci for Alzheimer’s disease in Parkinson’s disease, amyotrophic lateral sclerosis, and multiple system atrophy

Y. Chen, R. Ou, X. Chen, B. Cao, Q. Wei, B. Zhao, Y. Wu, H. Shang (Chengdu, China)

1:15pm-2:45pm: Association of arterial stiffness with cognition in patients with Lewy body disorder

J.Y. LEE, D.-W. Ryu, J.-S. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm: Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease

B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)

1:15pm-2:45pm: Association of the GBA T369M polymorphism with motor and cognitive symptoms in Parkinson’s disease

A. Julius, Y.-H. Lin, M. Smith, J. Leverenz, D. Weintraub, J. Trojanoswski, V. Van Deerlin, B. Ritz, R. Rausch, J. Quinn, K. Chung, S. Factor, L. Rosenthal, T. Dawson, M. Albert, A. Espay, F. Revilla, J. Devoto, J. Goldman, G. Stebbins, B. Bernard, Z. Zbigniew, O. Ross, D. Dickson, D. Yearout, S.-C. Hu, C. Johnson, B. Cholerton, T. Montine, K. Edwards, C. Zabetian (Seattle, WA, USA)

1:15pm-2:45pm: Astasia, reach and grasp deficits following bilateral medio-dorsal pulvinar lesions

M. Wilke, M. Baehr, I. Kagan, P. Dechent, Y. Cabral-Calderin, L. Schneider, A.-U. Dominguez-Vargas, K. Miloserdov, C. Schmidt-Samoa, H. Scherberger (Göttingen, Germany)

1:15pm-2:45pm: Asymmetric Orthostaic Myoclonus – A Case Series

Y.-c. Tai, J.-c. Tsou, S.-P. Hsu (Kaohsiung City, Taiwan)

1:15pm-2:45pm: Ataxia asociated to neuromyelitis optica spectrum disorder

D. Pereira (Quezaltepeque, El Salvador)

1:15pm-2:45pm: Ataxia-Teleangiectasia-Mutated-Knock-Out mouse cerebellum shows significant reduction of calcium homeostasis factors

J. Canet-Pons, R. Schubert, U. Warnken, M. Schnoelzer, S. Zielen, G. Auburger (Frankfurt am Main, Germany)

1:15pm-2:45pm: Ataxia, opsoclonus and peripheral neuropathy induced by chronic toluene intoxication.

L. Beltrami, T. Araujo, C. Borges, F. Germiniani,, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Audiological Evaluation in Sporadic Ataxia

B. Zeigelboim, H. Teive, A. Scheidt, K. Kronbauer, J. Faryniuk, T. Oliveira, F. Fernandes (Curitiba, Brazil)

1:15pm-2:45pm: Autosomal Dominant Spinocerebellar Ataxia Secondary to CACNA1G in a Patient of German Ancestry

E. Call, V. Santini (Stanford, CA, USA)

1:15pm-2:45pm: Axial Myoclonus in a Patient with PSP

R. Passo, T. Clark (Portland, OR, USA)

1:15pm-2:45pm: Balance in Spinocerebellar Ataxia (SCA): Comparison Between Type 10 and Type 3

H. Teive, K. Konno, M. Zonta, A. Guimarães (Curitiba, Brazil)

1:15pm-2:45pm: Basal Ganglia and Limbic Striatal Regions are Differentially Affected by Pramipexole: D3 receptor – Mediated Changes in Markers of Synaptic Strength

M. Bailey, A. Persons, T.C. Napier (Chicago, IL, USA)

1:15pm-2:45pm: Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease

M. Barrett, M. Smolkin (Charlottesville, VA, USA)

1:15pm-2:45pm: Behavioral and psychological symptoms in Parkinson’s disease with SWEDDs

J. Ahn, H. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm: Beyond shuffling: Gait phenotypes in Parkinson’s Disease

L. Solis-Cohen, C. Ashton, D. Simon, M. Fox, D. Tarsy, R. Alterman, V. Vanderhorst, L. Shih (Boston, MA, USA)

1:15pm-2:45pm: Blink reflex recovery cycle in patients with genetically determined ataxias

S. Tunc, A. Weissbach, E. Werner, N. Baginski, J. Lubs, A. Münchau, T. Bäumer (Luebeck, Germany)

1:15pm-2:45pm: Blink reflex recovery cycle to differentiate Progressive Supranuclear Palsy from Corticobasal Degeneration

G. Sciacca, A. Nicoletti, G. Mostile, A. Luca, L. Raciti, V. Dibilio, F. Le Pira, M. Zappia (Catania, Italy)

1:15pm-2:45pm: Brain iron accumulation in Wilson disease measured by quantitative susceptibility mapping

P. Dusek, M. Dezortova, V. Herynek, J. Acosta-Cabronero, L. Kotackova, D. Zahorakova, S. Robinson, F. Jiru, R. Bruha, Z. Marecek, M. Hajek (Praha, Czech Republic)

1:15pm-2:45pm: Brainstem reflexes in patients with neuroleptic-induced akathisia

A. Gunduz, B. Metin, S. Metin, B. Poyraz, M. Özmen, G. Kiziltan, M. E. Kiziltan, D. Karadeniz (Istanbul, Turkey)

1:15pm-2:45pm: Caffeinated Drinks, LRRK2 Genotype and PD

C. Tanner, C. Marras, C. Meng, K. Marder, S. Bressman, R. Saunders-Pullman, R. Alcalay, E. Tolosa, A. Brice, S. Goldman, B. Schuele, A. Lang, S. Goldwurm, G. Riboldazzi, J. Ferreira, C. Klein, D. Berg, K. Brockmann, M. Tazir, J. Aasly, J. Marti-Masso, J. . Marti-Masso, R. Munhoz, C. Rieder, M. San Luciano, G. Mellick, C. Sue, K. Hasegawa, E. Tan, J. Langston, M. LRRK2 Cohort-Consortium (San Francisco, CA, USA)

1:15pm-2:45pm: Can glabellar and palmomental reflexes differentiate neurodegenerative from non-neurodegenerative parkinsonism?

X.X. Yu, X. Garcia, S. Patel, H. Fernandez (Cleveland, OH, USA)

1:15pm-2:45pm: Capgras syndrome in advanced Parkinson disease

C. Groth, A. Pusso, D. Huss, S. Sperling, B. Shah, M. Harrison, W.J. Elias, G.F. Wooten, M. Barrett (Charlottesville, VA, USA)

1:15pm-2:45pm: CAPN1 mutations are associated with a syndrome of combined spasticity and ataxia

N. Brüggemann, V. Tadic, C. Klein, A. Münchau, K. Lohmann (Lübeck, Germany)

1:15pm-2:45pm: Cefepime-induced encephalopathy and myoclonus

T. Rasameesoraj, X.x. Yu, A. Ahmed, H. Fernandez (Cleveland, OH, USA)

1:15pm-2:45pm: Cerebellar Ataxia – The First Symptom of HIV Infection

L. Beltrami, J. Kristochik, M. Novaes, G. Tansini, F. Germiniani, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Cerebrospinal fluid lysosomal enzymes and cognition in Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, P. Martínez-Lage, A. Izagirre, S. Paciotti, L. Parnetti, P. Calabresi, T. Beccari, M. Rodriguez-Oroz (San Sebastián, Spain)

1:15pm-2:45pm: Changes in motor subtype designation of early Parkinson’s disease patients

R. Eisinger, D. Martinez-Ramirez, C. Hess, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:15pm-2:45pm: Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.

J. Vance, K. Nuytemans, D. Gveric, L. Gomez, G. Beecham, E. Martin, W. Scott (Miami, FL, USA)

1:15pm-2:45pm: Cholinergic activity, mobility, and attention in mild cognitive impairment

D. Martini, K. Smulders, A. Hiller, K. Chung, J. Quinn, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: Chorea and psychosis as stroke presentation : report and brief review

F. RADJI (AGEN, France)

1:15pm-2:45pm: Classification of neurocognitive impairment in Spanish speaking Parkinson’s disease patients

S. Anderson, C. Bermudez, N. Sun-Suslow, L. Segala, H. Moore, C. Singer, J. Jagid, G. Rey, B. Levin (Chicago, IL, USA)

1:15pm-2:45pm: CLOCK rs1801260 polymorphism is associated with suscepibilty of Parkinson’s disease in Chinese population

F. Lou, X. Luo, M. Li, Y. Ren (Shenyang, China)

1:15pm-2:45pm: CLOCK varriant correlates to motor fluctuation and sleep disorders in Chinese patients with Parkinson’s disease

F. Lou, X. Luo, M. Li, Y. Ren (Shenyang, China)

1:15pm-2:45pm: Cognition in the PREDICT-PD Cohort

A. Nagy, E. Hardaker, J. Bestwick, G. Giovannoni, T. Warner, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

1:15pm-2:45pm: Cognitive and demographic predictors of progression to MCI and dementia in Parkinson’s disease

B. Cholerton, C. Johnson, B. Fish, J. Quinn, K. Chung, A. Peterson-Hiller, L. Rosenthal, T. Dawson, M. Albert, S.-C. Hu, T. Montine, J. Leverenz, C. Zabetian, K. Edwards (Stanford, CA, USA)

1:15pm-2:45pm: Cognitive data in the Parkinson’s Progression Markers Initiative: Comparison of normative data approaches

K. Wyman-Chick, M. Barrett, P. Martin, C. Manning, S. Sperling (Charlottesville, VA, USA)

1:15pm-2:45pm: Cognitive function and impulsive-compulsive behaviors in Parkinson’s disease motor subtypes

S.-C. Yao, P.-N. Wang, K.-K. Liao, D.-E. Shan (Taipei, Taiwan)

1:15pm-2:45pm: Cognitive impairment in early onset and familial Parkinson’s disease.

M. Tan, J. Bras, J. Hong, C. Brugaletta, T. Samakomva, K. Hoffmann, S. Lubbe, D. Grosset, N. Wood, A. Schapira, J. Hardy, H. Houlden, H. Morris (London, United Kingdom)

1:15pm-2:45pm: Cognitive strategy use during daily activities in people with Parkinson’s Disease

I. Sturkenboom, E. Steultjens, M. Nott, C. Chapparo (Nijmegen, Netherlands)

1:15pm-2:45pm: Combination of multimodal neuroimaging techniques is useful to diagnose multiple system atrophy

K. Abe, K. Fukushima, k. Ando, Y. Maeda, N. Kotoura, R. Ishikura, H. Yoshikawa (Nishinomiya, Japan)

1:15pm-2:45pm: Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness

A. Cucca, M. Biagioni, J. Golomb, J. Fleisher (New York, NY, USA)

1:15pm-2:45pm: Comparative Age-Relatedness of Dyskinesia, Dystonia and Ataxia Rating Scales in Healthy Children

M. Kuiper, R. Brandsma, L. Vrijenhoek, H. Burger, D. Sival (Groningen, Netherlands)

1:15pm-2:45pm: Comparison of the effect of thalamic DBS/coagulation on tremor and thalamic neuronal activity in spinocerebellar ataxia and essential tremor

T. Hashimoto, A. Muralidharan, K. Yoshida, T. Goto, T. Yako, K. Baker, J. Vitek (Matsumoto, Japan)

1:15pm-2:45pm: Comparison of the non-motor symptom assessment scale between LRRK2 G2019S positive versus matched control Parkinson disease

S. Gunzler, S. Mittal, C. Tatsuoka, A. Wilson-Delfosse, S. Chen, J. Mieyal, I.J. Feng, D. Riley (Cleveland, OH, USA)

1:15pm-2:45pm: Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa

P. Barbosa, T. Warner, A. Djamshidian (London, United Kingdom)

1:15pm-2:45pm: Consideration of the relationship between severity of Parkinson’s disease and cognitive function, depression, quality of life

M. Saruwatari, M. Sagawa, A. Kumon, K. Hasegawa (Sagamihara, Japan)

1:15pm-2:45pm: Cortical excitability during a movement compared with postural control task in healthy subjects

F. Chang, P. Menon, M. VanDen Bos, M. Kiernan, S. Vucic, V. Fung (Sydney, Australia)

1:15pm-2:45pm: Corticobasal syndrome due to brain tumor

P. Tsitsi, G. Xiromerisiou, T. Kalantzakou, T. Bourinaris, G. Deretzi (Stockholm, Sweden)

1:15pm-2:45pm: Corticospinal tract dysfunction precede the cerebellar syndrome in spinocerebellar ataxia 2

R. Rodríguez-Labrada, L. Velázquez-Pérez, R. Torres-Vega, J. Medrano-Montero, Y. Vázquez-Mojena, G. Auburger, U. Ziemann (Holguín, Cuba)

1:15pm-2:45pm: Curcumin I prevents the developmental defective sensorimotor patterns resulted from Lead poisoning in rat

H. BENAMMI, O. EL HIBA, H. GAMRANI (Marrakech, Morocco)

1:15pm-2:45pm: Curcumin I protect against copper induced neurobehavioral features of Parkinson’s disease in rat

A. Abbaoui, O. EL Hiba, H. Gamrani (Marrakech, Morocco)

1:15pm-2:45pm: Data driven analysis for exploring phenotypic differences in patients with Parkinson’s disease with or without genetic mutations.

A. Mirelman, T. Kozlovski, A. Thaler, A. Mitelpunkt, T. Gurevich, M. Kestenbaum, Z. Gan Or, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, M. Marcus-Kalish, Y. Benjamini, N. Giladi (Tel Aviv, Israel)

1:15pm-2:45pm: DaTscan in clinical evaluation of Multiple System Atrophy

P. Khemani, S. Vernino (Dallas, TX, USA)

1:15pm-2:45pm: Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase

J. Corrow, M. Cherkasova, A. Taylor, J. Stoessl, M. McKeown, S. Apple Creswell, J. Barton (Vancouver, BC, Canada)

1:15pm-2:45pm: Decisional capacity for Goals of Care in Parkinson’s Disease with Cognitive Concerns

M. Abu Snineh, R. Camicioli, J. Miyasaki (Jerusalen, Israel)

1:15pm-2:45pm: Defective visual perception in patients with Lewy body disease: assessment of hallucinations with pareidolia test.

Y. Higashi, T. Tabuchi, M. Tabata (Himeji, Japan)

1:15pm-2:45pm: Delayed progressive spastic cerebellar ataxia and cerebellar atrophy after Heat Stroke

D. Desai, S. Desai, C. Sapre (Anand, India)

1:15pm-2:45pm: Delusional Misidentification Syndrome for “Self” in two patients with Parkinson`s Disease.

S. Ray, D. Park, D. Burdick, A. Griffith, J. Shaw, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm: Depression and Cognitive Performance in Patients with Parkinson’s Disease

A.J. Jacob, S. OJ, S. K, G. Kumarpillai (Bangalore, India)

1:15pm-2:45pm: Determinants of balance confidence and concern about falling in people with Parkinson’s disease

L. Almeida, G. Valenca, E. Pinto, J. Oliveira-Filho (Salvador, Brazil)

1:15pm-2:45pm: Development and validation of an alternative version of the Parkinson’s Disease-Cognitive Rating Scale

R. Fernandez-Bobadilla, S. Martinez-Horta, J. Marin-Lahoz, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Development and validation of diagnostic criteria for advanced Parkinson disease: the CDEPA questionnaire

M.-R. Luquin, J. Kulisevsky, P. Martinez-Martin, P. Mir, E. Tolosa, P. Garcia-Delgado (Pamplona, Spain)

1:15pm-2:45pm: Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease

J. Etcheverry, M. Cesarini, G. Rojas, E. Gatto (Buenos Aires, Argentina)

1:15pm-2:45pm: Diagnostic utility of regional [18F]AV-1451 tau-PET measurements in PSP

J. Whitwell, V. Lowe, N. Tosakulwong, S. Weigand, M. Senjem, C. Schwarz, A. Spychalla, R. Petersen, C. Jack, K. Josephs (Rochester, MN, USA)

1:15pm-2:45pm: Diaphragmatic myoclonus successfully treated with Botulinum toxin A

Y. He, B. Li, Y. Pan, X. Zhang, L. Jin (Shanghai, China)

1:15pm-2:45pm: Differential Item Functioning in the Unified Dyskinesia Rating Scale (UDysRS)

S. Luo, G. Stebbins, Y. Liu, C. Goetz (Houston, TX, USA)

1:15pm-2:45pm: Differential peculiarities of cognitive disorders in Parkinson’s disease dementia and Vascular dementia

V. Mykhaylov, I. Zdesenko (Kharkiv, Ukraine)

1:15pm-2:45pm: Difficulties in executing the MDS recommendations in the brazilian population

E. Carreira, E. CARREIRA, A. PRADO, N. BRAZ, F. TAVARES, N. ROCHA, L. DE SOUZA, F. CARDOSO, A. TEIXEIRA (Belo Horizonte, Brazil)

1:15pm-2:45pm: Diffusion Weighted Magnetic Resonance Imaging in Child Cerebral Palsy with Symptomatic Epilepsy

k. aminov (tashkent, Uzbekistan)

1:15pm-2:45pm: Diplopia: An Interesting Complication of Dropped Head Syndrome

W. Deeb, I. Malaty (Gainesville, FL, USA)

1:15pm-2:45pm: Distinguishing Subclinical Postural Instability in Early-stage Parkinson disease and postural instability of normal elderly using Sensory Organization Test and Limit of Stability

S.-K. Lee, J.-H. Park (Bucheon, Republic of Korea)

1:15pm-2:45pm: Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

1:15pm-2:45pm: Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?

H. Moes, M. Drent, T. Laar (Groningen, Netherlands)

1:15pm-2:45pm: Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis

J. Hinkle, K. Perepezko, C. Bakker, T. Dawson, V. Johnson, Z. Mari, C. Marvel, K. Mills, A. Pantelyat, O. Pletnikova, L. Rosenthal, M. Shepard, D. Stevens, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Domain-specific impact of cerebral white matter hyperintensities on Parkinson’s disease cognitive functioning

P. Linortner, S. Chernavsky, T. Hendershott, K. Poston (Palo Alto, CA, USA)

1:15pm-2:45pm: Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.

T. Turner, J. Renfroe, V. Hinson (Charleston, SC, USA)

1:15pm-2:45pm: Dopamine replacement influences on postural motor learning in Parkinson disease

S. Paul, G. Olivier, C. Walter, S. Schaefer, L. Dibble (Salt Lake City, UT, USA)

1:15pm-2:45pm: Dynamics of brain iron content and cortical pencil lining in healthy aging: An MRI study

M. van_der Weijden, P.-J. van Laar, R. Lambrechts, D. Verbeek, M. Tijssen (Groningen, Netherlands)

1:15pm-2:45pm: Early diagnosis in Spinocerebellar Ataxias: Prospects for clinical alterations and ethical dilemmas during preclinical trials.

L. Velázquez-Pérez, R. Rodríguez-Labrada, J. Rodríguez-Diaz, Y. Vazquez-Mojena, J. Medrano-Montero, A. Estupiñán-Rodríguez (Holguín, Cuba)

1:15pm-2:45pm: Early-Onset Parkinson Disease with Hypocalcemia: Adult Presentation of 22q11.2 Deletion Syndrome

F. Moreira, J. Lopes, M. Sousa, L. Pires, C. Januário (Coimbra, Portugal)

1:15pm-2:45pm: Early-Onset Parkinsonism and Short Stature in a Puerto Rican Kindred. Possible DJ1 deletion?

K. Celis, J. Vance, A. Vinuela (Miami, FL, USA)

1:15pm-2:45pm: eEF1A2 promotes cell survival and protects against MPP+-induced apoptotic neuronal death through the PI3K/Akt/mTOR pathway

K. Khwanraj, P. Dharmasaroja, B. Morris (Ratchathewi, Thailand)

1:15pm-2:45pm: Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients

R. Rosales, K.J. Goh, W. Kumthornthip, M. Mazlan, L. Abdul Latif, M.M. DeLos Santos, C. Chotiyarnwong, P. Tanvijit, J. Balcaitiene, P. Maisonobe, K.-H. Kong (Manila, Philippines)

1:15pm-2:45pm: Effect of Personal Characteristics on Semiology of the First Tic Episode in Children with Tourette Syndrome

J. Oražem Mrak, J. Kodrič, D. Osredkar, D. Neubauer (Ljubljana, Slovenia)

1:15pm-2:45pm: Effect of Virtual Reality on Balance Rehabilitation

B. Zeigelboim, H. Teive, G. Dos Santos, M. Severiano (Curitiba, Brazil)

1:15pm-2:45pm: Effectiveness of Deep Brain Stimulation (DBS) in Mice with Spinocerebellar Ataxia (SCA1).

V. Vedam-Mai, K. McFarland, R. Nathu, S. Kurtovic, Q. Zhang, T. Ashizawa, M. Okun (Gainesville, FL, USA)

1:15pm-2:45pm: Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

1:15pm-2:45pm: Effects of dopaminergic medication on executive function in Parkinson’s disease differs according to the clinical stage

H. Murakami, M. Kezuka, R. Kon, M. Kawamura, K. Ono (Tokyo, Japan)

1:15pm-2:45pm: Effects of education level on motor and non-motor symptoms of Brazilian patients with Parkinson’s disease.

E. Lirani-Silva, R. Vitório, P.C. Santos, C. Teixeira-Arroyo, L. Simieli, N. Conceicao, P. Sousa, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm: Effects of TRH therapy on the prism adaptation task in patients with spinocerebellar degeneration.

T. Shimizu, R. Hanajima, R. Tsutsumi, K. Shimizu, N. Tominaga, Y. Ugawa, K. Nishiyama (Sagamihara, Japan)

1:15pm-2:45pm: Effects of zonisamide, an anti-parkinsonian drug, on cognition and BPSD in DLB patients: A post-hoc analysis of DLB Ph2 study

M. Murata, T. Odawara, O. Konishi, M. Nakamura, K. Kosaka (Tokyo, Japan)

1:15pm-2:45pm: Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity

D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

1:15pm-2:45pm: Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults

D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

1:15pm-2:45pm: Electrophysiological markers for emotional and cognitive impairment in Parkinson’s disease

N. Dissanayaka, T. Au, A. Angwin, J. O'Sullivan, G. Byrne, P. Silburn, R. Marsh, G. Mellick, D. Copland (Brisbane, Australia)

1:15pm-2:45pm: Emotion regulation and neuropsychological status in psychogenic subtypes.

B. Scott, A. Strutt, P. Lundberg-Love, A. Schmitt, J. Jankovic, D. Bowers (Gainesville, FL, USA)

1:15pm-2:45pm: Event-related potentials and mild cognitive impairment in Parkinson’s disease.

J. Pagonabarraga, J. Marin-Lahoz, A. Horta, M. Cornella, H. Bejr-Kasem, S. Martinez-Horta, J. Pérez-Pérez, M.Á. Boti, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Evidence of putaminal petechial hemorrhage as the cause of hyperglycemic chorea

J.-J. Lin (Nantou, Taiwan)

1:15pm-2:45pm: Exome sequencing in patients with impulse control disorders in Parkinson’s disease: a pilot study

S. Prud'hon, F. Danjou, S. Bekadar, Y. Marie, A. Rastetter, J. Guégan, F. Cormier-Dequaire, S. Lesage, A. Brice, J.-c. Corvol (Paris, France)

1:15pm-2:45pm: Expanding the spectrum of Faciobrachial Dystonic Seizures

G. Riboldi, L. Borellini, G. Franco, M. Carrabba, P. Bernasconi, F. Andreetta, S. Corti, G. Comi, A. Di Fonzo (New York, NY, USA)

1:15pm-2:45pm: Expression of OX40 and OX40 serum level in patients with Parkinson’s disease

F. Alsahebfosoul, A. SeyedJoodaki, N. Eskandari, V. Shaygannejad, M. Salehi, M. Kazemi, M.T. Kardi, O. Mirmossayeb (Isfahan, Islamic Republic of Iran)

1:15pm-2:45pm: Extended “Timed Up and Go”: A Clinical Indicator of Cognitive State in Parkinson’s Disease?

T. Evans, A. Jefferson, M. Byrnes, S. Walters, S. Ghosh, F. Mastaglia, B. Power, R. Anderton (Perth, Australia)

1:15pm-2:45pm: Eye Movements in Huntington Disease Like 2

D. Anderson, R. Margolis, A. Krause (Johannesburg, South Africa)

1:15pm-2:45pm: Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia

L. Kadastik-Eerme, N. Taba, T. Asser, P. Taba (Tartu, Estonia)

1:15pm-2:45pm: Fatigue in Functional Motor Disorders.

J. Gelauff, E. Kingma, J. Stone, J. Rosmalen, M. Tijssen (Groningen, Netherlands)

1:15pm-2:45pm: FDG PET studies in the differential diagnose of atypical parkinsonism and dementia syndromes.

M.C. Peralta, M. Tourreilles, D. Menna, P. Perez Leguizamon, F. Taragano, M. Bastianello (Buenos Aires, Argentina)

1:15pm-2:45pm: Feasibility of utilizing the NIH Toolbox in Parkinson’s disease subjects with deep brain stimulation

J. Emerson, P. Dhruva, C. McLeod, R. Moses-Kessler, L. Metman, G. Pal (Chicago, IL, USA)

1:15pm-2:45pm: Feasibility, tolerability and acceptance of a psychosocial intervention for people with Parkinsonian dementia: The INVEST trial.

S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

1:15pm-2:45pm: Fentanyl Induced Chorea: A Case Report

M. Gallagher, A. Colcher, A. McGarry (Camden, NJ, USA)

1:15pm-2:45pm: First Reported Case of Parkinsonism in a Patient with Argininosuccinate Lyase Deficiency

K. Woodward, D. Bhatti, E. Rush (Omaha, NE, USA)

1:15pm-2:45pm: Fluency boost from walking in Parkinson’s disease

O. Barthelemy, R. Salazar, S. Neargarder, J. DeGutis, T. Ellis, A. Cronin-Golomb (Boston, MA, USA)

1:15pm-2:45pm: Freezing of gait in Parkinson’s disease: Clinical features and possible predictors

S. Prasad, A. Lenka, N. Kamble, R. Yadav, P. Pal (Bangalore, India)

1:15pm-2:45pm: Fulfilment of Movement Disorder Society clinical diagnostic criteria for Parkinson’s disease in a large cohort study of recent onset cases.

N. Malek, M. Lawton, K. Grosset, N. Bajaj, R. Barker, Y. Ben-Shlomo, D. Burn, T. Foltynie, J. Hardy, H. Morris, N. Williams, N. Wood, D. Grosset (Ipswich, United Kingdom)

1:15pm-2:45pm: Full sequencing and GWAS markers analysis of SNCA in RBD and progression to synucleinopathies.

Z. Gan-Or, J. Ruskey, I. Arnulf, Y. Dauvilliers, B. Hogl, A. Stefani, C. Charley Monaca, P. Dion, A. Desautels, J.-F. Gagnon, N. Dupre, R. Postuma, J. Montplaisir, G. Rouleau (Montreal, QC, Canada)

1:15pm-2:45pm: Gait characteristics of freezing in patients with Parkinson’s disease

S.-M. Cheon, S.-Y. Lee, J.W. Kim (Busna, Republic of Korea)

1:15pm-2:45pm: Gene associated differences in pre-diagnostic symptoms of Parkinson’s Disease: a retrospective study

S. Liu, Z. Zheng, Z. Gu, C. Wang, J. An, H. Ding, M. Zhou, H. Zhang, X. Dan, Y. Li, M. Cao, S. Cen, T. Mi, P. Chan (Beijing, China)

1:15pm-2:45pm: Generalized choreodystonia in a patient with HIV and hepatitis C with the history of opioid drug abuse after treating with interferon- 2alpha (Peginton)

D. Khasanova, Z. Zalyalova (Kazan, Russian Federation)

1:15pm-2:45pm: Genetic analysis of RAB39B mutations in early-onset and familial Parkinson’s Disease in a Taiwanese population.

C.-H. Lin, H.-H. Lin, R.-M. Wu, H.-I. Lin (Taipei, Taiwan)

1:15pm-2:45pm: Genetic and pharmacological rescue of DJ-1 loss-of-function caused by a c.192G>C mutation in PARK7

I. Boussaad, C. Obermaier, Z. Hanss, N. Weisschuh, B. Schmid, S. Hoffmann, L. Burbulla, C. Klein, S. Duga, D. Krainc, T.G. Gasser, B. Wissinger, R. Krüger (Esch-sur-Alzette, Luxembourg)

1:15pm-2:45pm: Genetic variants influencing dyskinesia; potential consequences for treatment in Parkinson’s disease

C. Kusters, K. Paul, I. Guella, J. Bronstein, J. Sinsheimer, M. Farrer, B. Ritz (Los Angeles, CA, USA)

1:15pm-2:45pm: Genetic variations in Amyloid-beta1-42 clearance proteins determine onset of dementia in Parkinson’s disease and dementia with Lewy bodies

K. Brockmann, S. Lerche, A. Apel, A.-K. Hauser, I. Liepelt Scarfone, D. Berg, T. Gasser, C. Schulte, W. Maetzler (Tübingen, Germany)

1:15pm-2:45pm: Genetic, epigenetic and expression profiles in alpha-synucleinopathies

E. Scott, I. Guella, A. Rajput, A. Rajput, L. Parkkinen, M. Kobor, M. Farrer (Vancouver, BC, Canada)

1:15pm-2:45pm: Genetics of impulse control disorders in Parkinson’s disease: a case control study

J.-C. Corvol, F. Cormier-Dequaire, S. Bekadar, S. Prud'hon, M. Anheim, J.-P. Azulay, F. Durif, J.-L. Houeto, A. Destée, K. Tahiri, G. Mangone, L. Lacomblez, P. Krack, P. Krystkowiak, D. Maltête, O. Rascol, C. Tranchant, M. Vidailhet, A. Brice, S. Tezenas duMontcel (Paris, France)

1:15pm-2:45pm: Genome-wide DNA methylation analysis reveals epigenetic perturbations in Parkinson disease.

J. Young, S. Sivasankaran, L. Wang, A. Ali, A. Mehta, D. Davis, K. Belle, D. Dykxhoorn, C. Petito, G. Beecham, E. Martin, D. Mash, W. Scott, J. Vance (Miami, FL, USA)

1:15pm-2:45pm: Genotype-Phenotype correlations and expansion of the molecular spectrum of AP4M1-related Hereditary Spastic Paraplegia

S. Efthymiou, C. Bettencourt, V. Salpietro Damiano, H. Houlden (London, United Kingdom)

1:15pm-2:45pm: Genotype-phenotype correlations in Parkinson disease patients who carry mutations in the GBA gene.

A. Thaler, T. Gurevich, A. Ezra, M. Kestenbaum, N. Giladi, A. Mirelman (Tel Aviv, Israel)

1:15pm-2:45pm: Ghrelin and the IGF-1 axis in cognitive impairment in PD

F. Johnston, M. Siervo, A. Hornsby, J. Davies, D. Burn (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Global inhibitory control in PD is impaired ON dopaminergic medication but not ON STN-DBS

D. Kübler, H. Schroll, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Glucocerebrosidase mutations in neurodegenerative disorders other than Parkinson’s disease

G. Buongarzone, C. Fenoglio, J. Nicoli, E. Monfrini, I. Trezzi, A. Arighi, R. Del Bo, N. Bresolin, E. Scarpini, G. Comi, S. Corti, A. Di Fonzo (Milan, Italy)

1:15pm-2:45pm: Goalkeeper game: a novel test to identify early implicit learning alterations in people with Parkinson’s disease

M.E. Pimentel Piemonte, A. Galves, A. Frazao Helene, M. D'Alencar (Sao Paulo, Brazil)

1:15pm-2:45pm: High systolic blood pressure is associated with cognitive impairment in Parkinson’s disease (PD)

H. Chan, Y. Cheung, T. Fung, A. Leung, W. Fong (Hong Kong, Hong Kong)

1:15pm-2:45pm: Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease

S. Lerche, I. Wurster, B. Roeben, E. Schaeffer, C. Schulte, S. Akbas, A.-K. Hauser, C. Deuschle, T. Gasser, D. Berg, K. Brockmann (Tuebingen, Germany)

1:15pm-2:45pm: Higher risk of cognitive impairment in Parkinson’s disease with comorbid diabetes

P. Schmidt, F. Cubillos, K. Lyons, C. Marras, T. Davis, E. Nelson, M. Okun (Miami, FL, USA)

1:15pm-2:45pm: Holmes’ tremor and olivary hypertrophy: lessons from this neuroanatomical correlation

R. Ellis, S. Biswas, R. Pullicino, J. Panicker, B. Hammersley, J. Farah, S. Alusi (Liverpool, United Kingdom)

1:15pm-2:45pm: How common are the genomic rearrangements among possibly autosomal recessive PD cases in Turkey?

G. Yalcin Cakmakli, A. Yuzbasioglu, G. Onal, B. Peynircioglu, M. Ozguc, S. Dokmeci (Emre), B. Elibol (Ankara, Turkey)

1:15pm-2:45pm: How do ataxias with oculomotor apraxia look and look like? A comparative controlled multimodal study of AT, AOA1 and AOA2 focusing on video-oculography.

L.-L. MARIANI, S. Rivaud-Péchoux, B. Gaymard, M. Anheim (Paris, France)

1:15pm-2:45pm: How do Parkinson’s Disease patients manage Ramadan Fasting?

W. Kamel, P. Damier, J. Al-Hashel (Kuwait, Kuwait)

1:15pm-2:45pm: Hypertrophic Olivary Degeneration

G. Moreno, K. Ng, A. Duffy (Sacramento, CA, USA)

1:15pm-2:45pm: Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease

J. Koprich, P. Howson, T. Johnston, M. Hill, P. Ravenscroft, J. Brotchie (Toronto, ON, Canada)

1:15pm-2:45pm: IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson’s disease patients

G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Impaired cerebellum to motor cortex associative plasticity in patients with spinocerebellar ataxia type 3

M.-K. Lu, J.-C. Chen, C.-M. Chen, C.-H. Tsai (Taichung, Taiwan)

1:15pm-2:45pm: Impaired Color Vision in Patients with DLB or Prodromal DLB.

B. Tousi, P. Flanigan, M. Khosravi (Cleveland, OH, USA)

1:15pm-2:45pm: Implicit memory analysis in patients with Parkinson’s Disease with Deep Brain Stimulation, in ON and OFF stages, using a computerized test battery.

E. Barbosa, H. Charchat-Fichman, J. Santos (Rio de Janeiro, Brazil)

1:15pm-2:45pm: Improved diagnosis of dementia with Lewy bodies by the combination of Tc-99m ECD SPECT with eZIS analysis and quantitative TRODAT-1 SPECT images

C.-Y. Wei, P.-Y. Chiu (Changhua County, Taiwan)

1:15pm-2:45pm: Improving Diagnosis and Treatment of Anxiety in Parkinson’s Disease: IDATA-PD Study

N. Dissanayaka, N. Pachana, J. O'Sullivan, R. Marsh, P. Silburn, E. White, E. Torbey, D. Pye, L. Mitchell, J.H. Yang, T. Au, G. Mellick, D. Copland, A. Toft, G. Byrne (Brisbane, Australia)

1:15pm-2:45pm: Impulse Control Disorders in Parkinson’s Disease: Prevalence and Clinical Features in the Rush University Movement Disorders Clinic

M. Rossi, G. Stebbins, B. Barton (Chicago, IL, USA)

1:15pm-2:45pm: In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome

F. Niccolini, H. Wilson, S. Hirschbichler, G. Pagano, R. Erro, T. Yousaf, A. Whittington, J. Holton, D. Martino, E. Rabiner, R. Gunn, K. Bhatia, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Indian ARSACS (Autosomal Recessive Spastic Ataxia of Charlevoix- Saugenay): Clinical report of the first genetically proven case from India, due to a novel SACS duplication

P. Agarwal (Mumbai, India)

1:15pm-2:45pm: Induced pluripotent stem cells based in-vitro modelling of Spinocerebellar Ataxia type -12 (SCA-12).

D. Kumar, M. Faruq, A. Srivastava, M. Mukerji, O. Mukherjee (Delhi, India)

1:15pm-2:45pm: INFLUENCES OF GENDER, DEPRESSION AND DISEASE SEVERITY ON MoCA SUBSCORES IN PARKSINON’S DISEASE

P. Surathi, M. Mirian, K. Sundvick, S. Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: Information Content of Spoken Language in Parkinson’s Disease Without Dementia

A. Roberts, D. Post, S. Gutierrez (Evanston, IL, USA)

1:15pm-2:45pm: Intention Awareness in Parkinson’s Disease

S. Di Costa, E. Barow, C. Moll, U. Hidding, O. Fründt, C. Gerloff, R. Erro, M. Pötter-Nerger, C. Buhmann, P. Haggard, C. Ganos (LONDON, United Kingdom)

1:15pm-2:45pm: Interest in Genetic Testing in Parkinson’s disease patients with DBS

A. Fraint, G. Pal, C. Timms, E. Tam, R. Bhavsar, L. Verhagen, D. Hall, K. Marder (Chicago, IL, USA)

1:15pm-2:45pm: Interval from onset of Parkinson disease to onset of motor and non-motor complications in Leucine-rich repeat kinase 2 (LRRK2) G2019S positive versus matched PD controls

S. Gunzler, D. Riley, A. Wilson-Delfosse, S. Chen, J. Mieyal, C. Tatsuoka (Cleveland, OH, USA)

1:15pm-2:45pm: Investigating the Lipidomic Signature of Spinocerebellar Ataxia (SCA1) Using A Liquid-Microjunction Surface Sampling Probe

V. Vedam-Mai, E. Gill, M. Marks, R. Yost, T. Garrett (Gainesville, FL, USA)

1:15pm-2:45pm: Is the cerebellum a good target for neuromodulation in movement disorders?

C. França, M. Teixeira, D. de Andrade, R. Galhardoni, V. Barbosa, V. Silva, G. Lepski, E. Barbosa, R. Cury (São Paulo, Brazil)

1:15pm-2:45pm: Is There a Correlation Between Functional Capacity Upper Limbs and Falls Risk and Postural Instability in Parkinson’s Disease?

T. Capato, R. RODRIGUES, E. Barbosa, M.E. Piemonte (SAO PAULO, Brazil)

1:15pm-2:45pm: Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.

B. Schroeder, E. Thomas, T. Williams, S. Mahon, B. Mohamed (Cardiff, United Kingdom)

1:15pm-2:45pm: Item Response Theory Analysis of the MDS-UPDRS Items

G. Stebbins, C. Goetz, Y. Liu, S. Luo (Chicago, IL, USA)

1:15pm-2:45pm: Joint pain as premonitory urge in patient with Ehlers Danlos Syndrome and Tourette’s Syndrome

A. Fraint, G. Pal (Chicago, IL, USA)

1:15pm-2:45pm: Knowledge of Levododopa-induced Dyskinesias among PD patients

R. Doyle Maia, F. Cardoso, P. Caramelli (Vitória, Brazil)

1:15pm-2:45pm: Kufor-Rakeb Syndrome due to a Novel ATP13A2 Mutation in two Chinese brothers

E. Noch, N. Hellmers, C. Henchcliffe, H. Sarva (New York, NY, USA)

1:15pm-2:45pm: Lack of accurate self-appraisal is equally likely in Mild Cognitive Impairment from Parkinson’s disease and Other Neurodegenerative Disorders

J. Leverenz, A. Bonner-Jackson, D. Floden, H. Fernanadez, J. Pillai (Cleveland, OH, USA)

1:15pm-2:45pm: Late-Onset Wilson’s disease, Dementia, Ekbom syndrome and whitte matter hyperintensities

F. Germiniani, P. Marques, F. Zorzetto, L. de Oliveira, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Lateralization of fine motor actions in Tourette syndrome persisting through adulthood

D. Martino, C. Delorme, E. Pelosin, A. Hartmann, Y. Worbe, L. Avanzino (Calgary, AB, Canada)

1:15pm-2:45pm: Leg Stereotypy Disorder: Clinical Characteristics and Prevalence

J. Jankovic, M. Lotia, M. York, A. Strutt (Houston, TX, USA)

1:15pm-2:45pm: Living with Ataxia in Ireland 2016–a nationwide survey of 130 Irish patients with inherited Ataxia

P. Bogdanova-Mihaylova, R. Walsh, S. Murphy (Dublin, Ireland)

1:15pm-2:45pm: Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease

j.-c. corvol, F. Artaud, O. Rascol, F. Durif, P. Derkinderen, F. Bourdain, J.-P. Brandel, f. Pico, L. Lacomblez, C. Bonnet, D. Grabli, S. Klebe, G. Mangone, H. You, v. Mesnage, P.C. Lee, A. Brice, M. Vidailhet, F. Cormier-Dequaire, A. Elbaz (Paris, France)

1:15pm-2:45pm: Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome

A. Sierowf, M. Grossman, D. Russell, I. Litvan, E. Roberson, A. Boxer, M. Devous, M. Navitsky, I. Kennedy, M. Lu, S. Doyle, M. Pontecorvo, M. Mintun (Philadelphia, PA, USA)

1:15pm-2:45pm: Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations

F. Niccolini, N. Mencacci, E. Rabiner, V. Salpietro, G. Pagano, B. Balint, H. Houlden, R. Gunn, N. Wood, K. Bhatia, M. Politis (London, United Kingdom)

1:15pm-2:45pm: MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.

Z. Zhang (Shanghai, China)

1:15pm-2:45pm: Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex

M. Bartlett, A. Flores, T. Ye, H. Dollish, K. Doyle, S. Cowen, S. Sherman, T. Falk (Tucson, AZ, USA)

1:15pm-2:45pm: Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments

T. Virmani (Little Rock, AR, USA)

1:15pm-2:45pm: Meta-analysis of the interaction between HLA-DRB1 and smoking with Parkinson’s disease

Y.-H. Chuang, P.-C. Lee, A. Elbaz, B. Ritz (LA, CA, USA)

1:15pm-2:45pm: Metabolic pattern of acute hemichorea associated with contralateral carotid stenosis

L. Savsek, A. Andlovic, N. Ozimic, L. Jensterle, P. Tomse, M. Grmek, J. Pretnar Oblak, Z. Pirtosek, M. Trost, M. Kojovic (Celje, Slovenia)

1:15pm-2:45pm: Middle cerebellar peduncle width in multiple system atrophy

F. Krismer, S. Bajaj, G. Wenning, C. Scherfler, W. Poewe, M. Schocke, A. Hussl, K. Seppi (Innsbruck, Austria)

1:15pm-2:45pm: Mild cognitive impairment in newly diagnosed Parkinson’s disease: a three year follow up

R. Lawson, A. Yarnall, G. Duncan, D. Breen, T. Khoo, C. Williams-Gray, R. Barker, D. Burn (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Minor hallucinations in Parkinson’s disease: neuropshycological and neurophysiological correlates in a representative sample of non-demented patients.

J. Pagonabarraga, J. Marin-Lahoz, A. Horta, H. Bejr-Kasem, M. Cornella, J. Pérez-Pérez, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Mirror Movements in extrapiramidal diseases

A. Manin, S. Rodríguez-Quiroga, L. Piedrafita Vico, N. Larripa, L. Assante, J. Casen, T. Arakaki, N. Garretto (Buenos Aires, Argentina)

1:15pm-2:45pm: Mitochondrial DNA variants function as potential genetic risk factors for Parkinson disease

X. Zhang, T. Li, Z.-F. Fan, B.-L. Hu, J.-H. Zhu (Wenzhou, China)

1:15pm-2:45pm: Motor and Nonmotor clinical phenotype in LRRK2 Parkinson’s disease patients: a Case-control study

L. Correia Guedes, R. Bouça, N. Gonçalves, T. Soares, D. Abreu, M. Fabbri, M. Coelho, M.M. Rosa, M. Quadri, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

1:15pm-2:45pm: Motor imagery increases imitation of hand movements in Parkinson’s disease

J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Poliakoff (Manchester, United Kingdom)

1:15pm-2:45pm: Motor resonance in Parkinson’s disease: Effects of observed actions on behaviour

E. Poliakoff, J. Bek, S. Vogt, T. Crawford, E. Gowen (Manchester, United Kingdom)

1:15pm-2:45pm: Movement Disorders and Clinical Progression in Spinocerebellar Ataxias

P.-H. Kuo, J. Wang, K. Figueroa, S. Pulst, S. Perlman, G. Wilmot, C. Gomez, J. Schmahmann, H. Paulson, V. Shakkottai, S. Ying, T. Zesiewicz, K. Bushara, M. Geschwind, G. Xia, S. Subramony, T. Ashizawa, S.-H. Kuo (Hualien, Taiwan)

1:15pm-2:45pm: Movement Disorders secondary to Spinal Cord Demyelination: an Evolving Spectrum

H. Abboud, H. Fernandez, X.X. Yu, M. Mealy, M. Levy, J. Cohen (Cleveland, OH, USA)

1:15pm-2:45pm: MRI-based Brain Networks of Perfusion and Structural Abnormalities in Patients with Cerebellar Variant of Multiple System Atrophy

P. Wu, S. Peng, J. Ge, J. Wang, D. Eidelberg, C. Zuo, Y. Ma (Shanghai, China)

1:15pm-2:45pm: Multimodal biomarkers as predictors of cognitive decline in Parkinson’s Disease

T. Tropea, J. Berlyand, J. McBride, J. Doshi, C. Davatzikos, L. Shaw, S. Xie, J. Trojanowski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

1:15pm-2:45pm: Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Myoclonus in the Elderly: Retrospective Analysis of Clinical and Electrophysiological characteristics of patients referred to an electrophysiology laboratory

M. Kiziltan, A. Gunduz, M. Tutuncu, U. Uygunoglu, A. Sifoglu, S. Ertan, H. Apaydin, M. Bozluolcay, S. Saip, G. Kiziltan (Istanbul, Turkey)

1:15pm-2:45pm: Network for parallel gamma synchronizations during upper limb movement

G. Tamas, A. Anwar, G. Deuschl, J. Raethjen, S. Groppa, M. Muthuraman (Budapest, Hungary)

1:15pm-2:45pm: Neurodegenerative biomarker abnormality frequency in idiopathic REM sleep behavior disorder

A. Boeve, S. McCord, P. Timm, D. Sandness, N. Commers, E. Duwell, G. Tabatabai, S. McCarter, M. Junna, M. Lipford, M. Tippmann-Peikert, B. Boeve, M. Silber, E. St. Louis (Rochester, MN, USA)

1:15pm-2:45pm: Neuroferritinopathy pedigree in 2 families from India

J. Kaur, G. Singh, B. Paul (Ludhiana, India)

1:15pm-2:45pm: Neurofilament light chain levels in cerebrospinal fluid do not discriminate between patients with prion disease and mimics

B. Roeben, E. Stransky, K. Brockmann, R. Schüle, W. Maetzler, T. Gasser, G. Machetanz (Tübingen, Germany)

1:15pm-2:45pm: Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review

J. Fernandez Bonfante, G. Pagano, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Neurological examination of motor Functional Neurological Disorders: an evidence-based review towards the development of consensus guidelines from the Committee on Research of the ANPA

S. Aybek, D. Perez, W.C. LaFrance, C. Stephen, R. Shura, S. Glass, S. Ducharme, V. Voon (Bern, Switzerland)

1:15pm-2:45pm: Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease

L. Correia Guedes, S. Reimão, P. Paulino, R. Nunes, R. Bouça, D. Abreu, N. Gonçalves, T. Soares, M. Fabbri, C. Godinho, P. Lobo, D. Neutel, M. Quadri, M. Coelho, M.M. Rosa, J. Campos, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

1:15pm-2:45pm: Neuroprotection of indole-derivative compound NC001-8 in Parkinson disease cell model by regulatory of NRF2 pathway

P.-C. Wei (Tao-Yuan, Taiwan)

1:15pm-2:45pm: Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

1:15pm-2:45pm: Neuropsychological profile of corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia patients

M.M. Carmona-Abellan, M. Riverol, M. Recio, B. Echeveste, L. Imaz, R. Luquin (Pamplona, Spain)

1:15pm-2:45pm: Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study

N. Titova, N. Sotnikova, E. Katunina (Moscow, Russian Federation)

1:15pm-2:45pm: Neurotological Findings in Sporadic Ataxia

B. Zeigelboim, H. Teive, K. Kronbauer, A. Scheidt, J. Faryniuk, T. Oliveira, A. Lacerda (Curitiba, Brazil)

1:15pm-2:45pm: New XK deletion associated with McLeod syndrome

A. DoedeMaindreville, G. Jouret, E. Landais, P. Feucher, S. Bakchine, D. Gaillard, A.S. Lebre (Reims, France)

1:15pm-2:45pm: Non-Progressive Coreoatethosis Secondary to Infantile Necrotizing Encephalopathy Mimicking Leigh Disease.

G. Fabiani, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Nutritional status and changes in body weight in patients with multiple system atrophy

T. Shimohata, T. Sato, M. Nishizawa (Niigata, Japan)

1:15pm-2:45pm: Objective biomarkers of posture balance for early and advanced Parkinson’s disease

I. Miliukhina, E. Gracheva, A. Kudrevatykh, T. Sergeev, M. Didur (Saint-Petersburg, Russian Federation)

1:15pm-2:45pm: Objective measurement of upper extremity bradykinesia using the keyboard-based dexterity test

S.-k. Song, J.-H. Kang (Jejusi, Republic of Korea)

1:15pm-2:45pm: Onabotulinumtoxin A (Botox) displays superior activity to incobotulinumtoxinA (Xeomin) in multiple in vitro and in vivo assays

D. Canty, L. Le, J. Wang, G. Nicholson, A. Brideau-Andersen, L. Steward, B. Jacky, R. Broide, M. Washburn, D. Rupp (Irvine, CA, USA)

1:15pm-2:45pm: Orthostatic myoclonus after brain tumor surgery and radiation

J. Cutsforth-Gregory, J. Hammack, J. Matsumoto (Rochester, MN, USA)

1:15pm-2:45pm: Oscillatory dynamics of impaired novelty detection at early Parkinson’s disease

R. Solis-Vivanco, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico City, Mexico)

1:15pm-2:45pm: Othello syndrome amongst patients with Parkinson’s disease in a rural movement disorders clinic in western India

S. Desai, D. Desai (Anand, India)

1:15pm-2:45pm: Parkin (PARK 2) Mutations in Patients with Early-Onset Parkinson’s Disease

A. Ivashynka, S. Likhachev (Minsk, Belarus)

1:15pm-2:45pm: Parkinson’s disease in untreated Gaucher patients is associated with reduced glucosylsphingosine (Lyso-Gb1) serum levels

D. Arkadir, T. Dinur, A. Rolfs, A. Zimran (Jerusalem, Israel)

1:15pm-2:45pm: Parkinson’s disease subtypes correlate with clinical severity: a Brazilian population study

C. Batista, M. Medeiros, C. Rieder, A. Schuh (Porto Alegre, Brazil)

1:15pm-2:45pm: Parkinson’s disease GWAS risk loci and symptom progression

K. Paul, J. Schulz, J. Bronstein, C. Lill, B. Ritz (los angeles, CA, USA)

1:15pm-2:45pm: Parkinsonian Features in a Cohort of Gaucher’s Disease (GD) Patients and Relatives.

I. Trezzi, E. Monfrini, G. Buongarzone, E. Cassinerio, I. Motta, F. Nascimbeni, F. Carubbi, N. Bresolin, G. Comi, M. Cappellini, A. Di Fonzo (Milan, Italy)

1:15pm-2:45pm: Patient-derived GBA1-PARK2 double-mutant cellular models to study the effect of GBA1 as a modifier of familial Parkinson’s disease

Z. Hanss, I. Boussaad, P. Barbuti, S. Goldwurm, R. Krüger (Belvaux, Luxembourg)

1:15pm-2:45pm: Patient-reported hallucinations and the probability of progression to dementia in Parkinson’s disease

K.-L. Horne, D. Myall, M. MacAskill, L. Livingston, S. Grenfell, T. Melzer, T. Pitcher, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

1:15pm-2:45pm: Pattern of MRI findings in ephedronic encephalopathy

M. Okujava, F. Todua, M. Janelidze, I. Khatiashvili (Tbilisi, Georgia)

1:15pm-2:45pm: PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins

A. Perez-Soriano, J. Arena, V. Sossi, K. Dinelle, Q. Miao, J. McKenzie, N. Neilson, A. Puschmann, P. Schaffer, H. Shinotoh, J. Smith-Forrester, E. Shahinfard, N. Vafai, D. Wile, Z. Wszolek, M. Higuchi, A.J. Stoessl (Vancouver, BC, Canada)

1:15pm-2:45pm: Perceptions of Fluctuation Treatment in Parkinson’s Disease Impact Suicidality

J. Hinkle, K. Perepezko, Z. Mari, L. Marsh, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Physical and cognitive stimulation through environmental enrichment prevents early molecular pathology in a Parkinson´s disease model

Z. Wassouf, T. Hentrich, S. Samer, O. Riess, N. Casadei, J. Schulze-Hentrich (Tübingen, Germany)

1:15pm-2:45pm: Piper betle L. Attenuates 6-OHDA Induced Apoptosis in SH-SY5Y Cells and Neuronal Injury in Caenorhabditis elegans Parkinson’s Model

G. Shanmugam, A. Mohankumar, P. Sundararaj (Coimbatore, India)

1:15pm-2:45pm: Piperine potentiate the neuroprotective effect of quercetin against MPTP induced neurotoxicity in rats

S. Singh, P. Kumar (Moga, India)

1:15pm-2:45pm: Potential preclinical gait and balance markers for developing Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

J. O'Keefe, E. Robertson, A. McAsey, M. Swanson, C. Huml, E. Berry-Kravis, D. Hall (Chicago, IL, USA)

1:15pm-2:45pm: Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Predict cognitive decline with non-clinical markers in Parkinson’s disease

T. Yousaf, G. Pagano, F. NIccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Prediction of cognitive progression in Parkinson’s disease using three cognitive screening measures

C. Nazor, C. Zabetian, C. Johnson, B. Fish, J. Quinn, K. Chung, A. Peterson-Hiller, S.-C. Hu, T. Montine, J. Leverenz, K. Edwards, B. Cholerton (Seattle, WA, USA)

1:15pm-2:45pm: Predictive Ability of Clinical Timed Tests for Postural Instability and Gait Difficulty in Parkinson’s Disease

M. Bryant, J.-G. Hou, F. Jamal, G. Jackson, C. Workman, E. Protas (Houston, TX, USA)

1:15pm-2:45pm: Predictor of progressive mild cognitive impairment in patients with Parkinson’s disease.

Y. Tajiri, K. Wada-Isoe, M. Hamada, M. Sawada, K. Nakashima (Yonago, Japan)

1:15pm-2:45pm: Predictors of onset of psychosis in Parkinson’s disease: “Who gets it early?”

P. Pal, A. Lenka, L. George, S. Arumugham, S. Hegde, N. Kamble, R. Yadav (Bangalore, India)

1:15pm-2:45pm: Preliminary results of 18F-DTBZ PET study in the patients with vascular parkinsonism

W.-Y. Lin, Y.-H. Weng, K.-J. Lin, C.-S. Lu (Taoyuan, Taiwan)

1:15pm-2:45pm: Presence of abnormalities on structural MRI associate with faster disease progression in multiple system atrophy

K. Seppi, F. Krismer, G. Wenning, S. Papapetropoulos, V. Abler, W. Poewe (Innsbruck, Austria)

1:15pm-2:45pm: Pro-saccades predict decline in attention over 18months in newly diagnosed Parkinson’s disease

S. Stuart, L. Alcock, J. Nell, R. Lawson, R. Morris, A. Yarnall, D. Burn, L. Rochester (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Progression to Parkinson’s disease in carriers of LRRK2 G2019S mutation: a 4-year prospective study with serial dopamine transporter imaging

J. Infante, M. Sierra, I. Martínez-Rodríguez, P. Sánchjez-Juan, I. González-Aramburu, M. Jimenez-Alonso, A. Sánchez-Rodriguez, I. Banzo (Santander, Spain)

1:15pm-2:45pm: Progressive ataxia and palatal tremor: 2 autopsy cases of a novel tauopathy

A. Gao, A. Faust-Socher, M. Del Bigio, A. Lang, D. Munoz (Toronto, ON, Canada)

1:15pm-2:45pm: Prospective longitudinal CSF measurements and cognitive decline in GBA-associated Parkinsonism: not Abeta or Tau but Lewy body pathology?

S. Lerche, C. Schulte, K. Srulijes, A. Pilotto, T. Rattay, A.-K. Hauser, E. Stransky, C. Deuschle, I. Csoti, H. Zetterberg, I. Liepelt-Scarfone, T. Gasser, W. Maetzler, D. Berg, K. Brockmann (Tübingen, Germany)

1:15pm-2:45pm: Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

1:15pm-2:45pm: Psychiatric Manifestations of Neuroacanthocytosis Syndromes

Z. Brahem, i. bedoui, a. riahi, h. derbali, m. mansour, j. zaouali, r. mrissa (Tunis, Tunisia)

1:15pm-2:45pm: Psychogenic abdominal myoclonus in Pregnancy: Case Report

D. García, P.O. Vargaz, Z. Lopez (Toluca de Lerdo, Mexico)

1:15pm-2:45pm: Pure ATXN10 repeat expansion causes Parkinson’s disease

F. Jimenez Gil, K. McFarland, K. Lee, Y.-C. Tsai, C. Byrne, R. Gopi, N. Huang, J. Langston, T. Clark, T. Ashizawa, B. Schuele (Guadalajara, Jalisco, Mexico)

1:15pm-2:45pm: Putaminal Diffusion Imaging for the Differential Diagnosis of the Parkinsonian Variant of Multiple System Atrophy from Parkinson’s Disease: Impact of Segmentation Accuracy

R. De Marzi, S. Bajaj, F. Krismer, B. Larcher, S. Ringler, G. Wenning, M. Schocke, W. Poewe, K. Seppi (Innsbruck, Austria)

1:15pm-2:45pm: Quantifying reinforcement learning deficits in early stage Parkinson’s patients using a strategic decision-making task

A. Parr, B. Coe, S. Murdison, G. Pari, D. Munoz (Kingston, ON, Canada)

1:15pm-2:45pm: Quantitative evaluation of gait ataxia by triaxial accelerometers is more sensitive than SARA within 1.5 years.

S. Shirai, I. Yabe, M. Matsushima, Y. Ito, M. Yoneyama, H. Sasaki (Sapporo, Japan)

1:15pm-2:45pm: Rapidly progressive dementia and parkinsonism caused by a cortical dural AV fistula: a case report

T. Weissfeld, D. Kremens, J. McCall (Philadelphia, PA, USA)

1:15pm-2:45pm: Rare variant analysis of the PPMI dataset to uncover the complex genetic architecture of Parkinson’s disease

d. BOBBILI, P. MAY, R. KRUEGER (Esch-sur-Alzette, Luxembourg)

1:15pm-2:45pm: RBD predicts the cognitive impairment in Parkinson’s disease

E. Stefanova, T. Stojkovic, I. Stankovic, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Reappraisal of cortical myoclonus: a retrospective study of clinical neurophysiology

A. Latorre, L. Rocchi, A. Berardelli, K. Bhatia, C. Cordivari (London, United Kingdom)

1:15pm-2:45pm: Reappraisal of Progressive Myoclonus Ataxia

S. vd Veen, R. Zutt, T. De Koning, M. Tijssen (Groningen, Netherlands)

1:15pm-2:45pm: Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson’s disease

H. Sawada, S. Orimo, A. Inaba, M. Takahashi (Tokyo, Japan)

1:15pm-2:45pm: Relationship between Insulin-like Growth Factor-1 and characteristics of physical activity in patients with Parkinson’s disease

K. Nagaki, M. Ikenaga, S. Fujioka, Y. Tsuboi (fukuoka, Japan)

1:15pm-2:45pm: Relationship between sensory augmentation and exercise routine in the improvement in balance and gait in a patient with lithium-induced ataxia

M. Maldonado (Santiago, Chile)

1:15pm-2:45pm: Risk Factors for Dementia in Parkinson’s disease

M.I. Khalil, M.R. Rahman, S. Munira (Dhaka, Bangladesh)

1:15pm-2:45pm: Role of Apocyanin in modulating glial cell functions and associated inflammatory response in Lipopolysaccharide induced Parkinson’s disease model.

N. Sharma, B. Nehru (Chandigarh, India)

1:15pm-2:45pm: Rotenone induces astrocyte-mediated non-cell autonomous dopaminergic neurotoxicity

I. Miyazaki, S. Murakami, R. Kikuoka, N. Isooka, Y. Kitamura, M. Asanuma (Okayama, Japan)

1:15pm-2:45pm: Screening of GBA and LRRK2 G2019S Mutations in Egyptian Parkinson’s Disease Patients

L. R'Bibo, S. Hamed, H. Houlden, N. Wood (London, United Kingdom)

1:15pm-2:45pm: Segregation of subjective and objective clinical measures in Parkinson’s disease

K. Markopoulou, R. Frigerio, A. Premkumar, B. Schoneburg, M. Dudek, S. Walters, C. Wang, D. Maraganore (Evanston, IL, USA)

1:15pm-2:45pm: Self-awareness of cognitive functions in Parkinson’s disease patients with and without mild cognitive impairment.

M. Hoock, F. Maier, R. Kaur, C. Eggers, L. Timmermann (Cologne, Germany)

1:15pm-2:45pm: Semi-automated MRI algorithm using susceptibility weighted imaging for differentiating multiple system atrophy with parkinsonism from Parkinson Disease

W.-W. Lee, H.-J. Kim, C.-H. Sohn, H. Park, B. Jeon (Seoul, Republic of Korea)

1:15pm-2:45pm: Sensory trick phenomenon in cervical dystonia: a functional MRI study

E. Sarasso, F. Agosta, S. Amadio, C. Butera, F. Bianchi, P. Valsasina, R. Guerriero, G. Comi, R. Gatti, U. Del Carro, M. Filippi (Milan, Italy)

1:15pm-2:45pm: Serum uric acid levels and freezing of gait in Parkinson’s disease

R. Ou, B. Cao, Q. Wei, Y. Hou, Y. Xu, W. Song, B. Zhao (Chengdu, China)

1:15pm-2:45pm: Serum vitamin B12 levels in patients with Parkinson’s disease and its association with peripheral neuropathy and cognition

R. Kandadai, N. Mathukumali, S.S. Meka, S. Tandra, A. Kohat, M. Kanikannan, R. Borgohain (Hyd, India)

1:15pm-2:45pm: Severity Assessment, Functional Capacity and Balance in Patients with Spinocerebellar Ataxias (SCAs): comparison between types 3 and 10.

F. Germiniani, K. Konno, M. Zonta, A. Guimarães, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Short term effects of bilateral STN DBS on psychiatric profile in Parkinson’s disease

R. Alugolu, M.B. Kesani, B. Ganji, V. Mudumba, R. Mrudula, R. Borgohain, P. Gaddamanugu (Hyderabad, India)

1:15pm-2:45pm: Sleep architecture in Parkinson´s disease and Parkinson’s disease associated dementia

L. Sousa, I. Laranjinha, J. Lopes, J. Ramalheira, A.M. da Silva, A.B. Lima, M. Magalhães (Porto, Portugal)

1:15pm-2:45pm: SNCA multiplication consortium: Clinicogenetic analysis of SNCA multiplication probands and families.

A. Book, M. Farrer, T. Candido, I. Guella, D. Evans, E. Gustavsson (Vancouver, BC, Canada)

1:15pm-2:45pm: Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease

C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, B. Berryhill, M. Hacker, D. Charlesdavid.charles@Vanderbilt.Edu, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

1:15pm-2:45pm: Specific Metabolic Brain Networks Associated with Parkinsonian and Cerebellar Variants of Multiple System Atrophy

P. Wu, S. Peng, J. Wang, J. Wu, C. Jiang, J. Ge, D. Eidelberg, Y. Ma, C. Zuo (Shanghai, China)

1:15pm-2:45pm: SPG7 related spastic ataxia differs according to the presence of the A510V variant

G. Coarelli, M.-L. Monin, C. Ewenczyk, B. Fontaine, J.-P. Azulay, P. Calvas, E. Ollagnon-Roman, G. Sole, G. Banneau, A. Brice, G. Stevanin, C. Duyckaerts, A. Durr (Paris, France)

1:15pm-2:45pm: SPG7-related ataxia in the Irish National Ataxia Clinic cohort: case series

P. Bogdanova-Mihaylova, S. Murphy, R. Walsh (Dublin, Ireland)

1:15pm-2:45pm: Spinocerebellar Ataxia type 11 in a Hispanic Kindred

D. Machado, J.A. deMarcaida (Vernon, CT, USA)

1:15pm-2:45pm: Spinocerebellar ataxia type-17: An Indian Scenario

S. Shakya, P. Negi, A. Garg, M. Prasad, M. Faruq, A. Srivastava (New Delhi, India)

1:15pm-2:45pm: Spiral Analysis is a Promising Biomarker in LRRK2 G2019S carriers

R. Ortega, M. Pullman, A. Glickman, I. Perera, M. San Luciano, A. Mirelman, C. Pont-Sunyer, N. Giladi, E. Tolosa, Q. Yu, S. Bressman, S. Pullman, R. Saunders-Pullman (New York, NY, USA)

1:15pm-2:45pm: Sports or no sports – is that the question in PD?

M. Strothjohann, P. Kostopoulos, F. Weber (Bad Camberg, Germany)

1:15pm-2:45pm: Stabile cognitive profile one year after subthalamic nucleus deep brain stimulation in patients with advanced Parkinson’s disease

T. Remšak, A. Bujisić, S. Šešok, S. Brezovar, A. Pražnikar, M. Kramberger, D. Georgiev, D. Flisar, K. Boetzel, J. Mehrkens, M. Benedičič, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

1:15pm-2:45pm: Steroid-responsive encephalopathy with associated thyroiditis (SREAT) presenting with pure cerebellar ataxia

P. Termsarasab, Y. Pitakpatapee, S. Frucht, P. Srivanitchapoom (Bangkok, Thailand)

1:15pm-2:45pm: Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats

K. Schwabe, J. Krauss, M. Alam (Hannover, Germany)

1:15pm-2:45pm: Striatal dopamine transporter abnormalities in pure autonomic failure and speculation about the relationship with Lewy bodies

M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)

1:15pm-2:45pm: Structural brain changes in patients with Multi System Atrophy: A VBM and DTI based study.

J. Saini, P. Pal, L. George, S. Dash (Bangalore, India)

1:15pm-2:45pm: Study of neuroprotective effects of Ginsenside Rg3 , the prototypal epigenetic Sirtuin-1 activator, in targeting microglia activation and neurotrophic factor (NF) neural plasticity in MPTP model of Parkinson’s disease (PD)

H. Raheb, J. Hou, S. Chiu (London, ON, Canada)

1:15pm-2:45pm: Subcortical involvement in body and mental action processing: an electrophysiological registration study

M. De Letter, P. Santens, D. Van Roost, G. Strobbe, P. Van Mierlo, A. Aerts, A. Bruggeman, K. De Keyser (Ghent, Belgium)

1:15pm-2:45pm: Subcortical involvement in phonological input processing: an electrophysiological registration study

A. Bruggeman, K. De Keyser, A. Aerts, P. Van Mierlo, G. Strobbe, D. Van Roost, P. Santens, M. De Letter (Ghent, Belgium)

1:15pm-2:45pm: Subjective cognitive complaints in Parkinson’s disease patients: what should we value ?

R. Barbosa, M. Mendonça, T. Lampreia, R. Miguel, A. Caetano, P. Bugalho (Lisbon, Portugal)

1:15pm-2:45pm: Subjective cognitive decline reflects recent cognitive change in non-demented patients with Parkinson’s disease

J.Y. Hong, Y. Lee, M. Sunwoo, Y. Sohn, P.H. Lee (Wonju, Republic of Korea)

1:15pm-2:45pm: Suicidality in Parkinson’s Disease: A Case Control Study

M. Akbostanci, E. Bayram, D. Sayar, T. Ayidaga (Ankara, Turkey)

1:15pm-2:45pm: Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease

C. Kulick, K. Montgomery, M. Nirenberg (New York, NY, USA)

1:15pm-2:45pm: TANDEM REPEATS BEYOND THE CLINICAL DIAGNOSIS IN ADCAs

A. Srivastava, M. Faruq, S. Shakya, I. Singh, V. Swarup (New Delhi, India)

1:15pm-2:45pm: Targeting the intracellular localization of Ataxin-3 as novel treatment strategy for Spinocerebellar Ataxia Type 3

T. Schmidt, Z. Wang, A. Sowa, J. Schmidt, M. Anders, M.I. Martins, A. de Castro, D. Weishäupl, J. Weber, H. Tricoire, P. Maciel, O. Riess (Tuebingen, Germany)

1:15pm-2:45pm: Tau predicts cognitive impairment in a prospective longitudinal CSF study in Parkinson’s Disease

S. Lerche, I. Wurster, O. Hanson, B. Roeben, C. Schulte, T. Gasser, H. Zetterberg, D. Berg, W. Maetzler, K. Brockmann (Tuebingen, Germany)

1:15pm-2:45pm: The 3-step clinical prediction tool for falls in Parkinson’s disease: can it be used as a self-assessment measure?

L. Mewburn, N. Allen, R. Adams, C. Canning (Lidcombe, Sydney, Australia)

1:15pm-2:45pm: The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results

G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

1:15pm-2:45pm: The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity

G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

1:15pm-2:45pm: The association between motor laterality and cognitive impairment in Parkinson’s disease

J.S. Kim, J.W. Cho, J. Youn (Seoul, Republic of Korea)

1:15pm-2:45pm: The autonomic nervous system in Friedreich´s Ataxia: preliminary findings

E. Indelicato, A. Fanciulli, J. Wanschitz, W. Nachbauer, W. Poewe, G. Wenning, S. Boesch (Innsbruck, Austria)

1:15pm-2:45pm: The Cats & Dogs Test: a web-based platform to detect early visual processing deficits in Parkinson’s disease

R. Weil, B. Bahrami, D. Schwarzkopf, I. Pavisic, K. Pappa, R. Schade, H. Morris (London, United Kingdom)

1:15pm-2:45pm: The clinical and neuroimaging analysis in hemifacial spasm with associated cranial neuropathy: retrospective case series study

Y.-Y. Chang, Y.-F. Chen, Y.-F. Chen, M.-Y. Lan, J.-S. Liu (Kaohsiung, Taiwan)

1:15pm-2:45pm: The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients

I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, K. Brockmann, T. Gasser, S. Becker, J. Streffer, D. Berg (Tübingen, Germany)

1:15pm-2:45pm: The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm: The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)

1:15pm-2:45pm: The diagnostic dilemma of olivopontocerebellar atrophy and spinocerebellar ataxia, a comparative analysis of clinical cases.

S. Gazieva, O. Turgunkhujaev (Tashkent, Uzbekistan)

1:15pm-2:45pm: The Effect of Anxiety on Cognition in Parkinson’s Disease

S. Anderson, G. Stebbins, B. Bernard, A. Negron, J. Goldman (Chicago, IL, USA)

1:15pm-2:45pm: The Effects of Contingency-based Musical Gait Feedback on Cognition in Individuals with Parkinson’s disease: An Interim Analysis

J. Burt, E. Ravid, S. Bradford, N. Fisher, Y. Zeng, B. Hu, R. Camicioli (Edmonton, AB, Canada)

1:15pm-2:45pm: The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

R. Borgemeester, T. van Laar (Groningen, Netherlands)

1:15pm-2:45pm: The French version of the Munich Dysphagia Test-Parkinson’s disease (MDT-PD): Translation and validation in a multilingual population of the Luxembourg Parkinson’s Study (HELP-PD).

G. Hipp, M. Vaillant, M. Gantenbein, M. Kerschenmeyer, P. Kolber, C. Stallinger, K. Roomp, L. Longhino, A. Schweicher, R. Krüger, J. Simons (Belvaux, Luxembourg)

1:15pm-2:45pm: The hardest symptoms that bother patients with Parkinson’s disease

V. Vuletic (Rijeka, Croatia)

1:15pm-2:45pm: The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm: The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, V. Nafade, D. Gagnon, M.-J. Wallman, L. Sid-Otmane, M. Parent, A. Parent, C. Rouillard, H. Adjia, P. Huot (Montreal, QC, Canada)

1:15pm-2:45pm: The identification of molecular-genetic background of familial atypical parkinsonism in “Hornacko”, a specific region of the south-eastern Moravia, Czech Republic.

K. Mensikova, R. Vodicka, K. Kolarikova, T. Bartonikova, P. Kanovsky (Olomouc, Czech Republic)

1:15pm-2:45pm: The Impact of Cognitive Changes on Everyday Life for People with Parkinson’s: The Patient’s Perspective

J. Wertheimer, A. Gottuso, A. Duboille, M. Tuchman, C. Walton (Los Angeles, CA, USA)

1:15pm-2:45pm: The role of habenula and amygdala dysfunction in Parkinson’s disease patients with punding

V. Markovic, F. Agosta, E. Canu, A. Inuggi, I. Petrovic, I. Stankovic, F. Imperiale, T. Stojkovic, V. Kostic, M. Filippi (Belgrade, Serbia)

1:15pm-2:45pm: The spectrum of composite autonomic severity score in SCA1, SCA2 and SCA3 patients

D. Tamuli, A. Godiyal, A. Jaryal, A. Srivastava, K. Deepak (New Delhi, India)

1:15pm-2:45pm: The Study of Deep Brain Stimulation of Globus Pallidus Internus for Refractory Tourette Syndrome

M. Zhao, Y. Guan, J. Zhou (Beijing, China)

1:15pm-2:45pm: The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease

y. liu (shanghai city, China)

1:15pm-2:45pm: The value of classical cerebrospinal fluid protein ratios and peripheral inflammation in Parkinson’s disease cognitive impairment

M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gómez, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, M. Rodríguez-Oroz (San Sebastián, Spain)

1:15pm-2:45pm: Tic Severity and Treatment in Children: The Effect of Comorbid Attention Deficit Hyperactivity Disorder and Obsessive Compulsive Behaviours

T. Pringsheim (Calgary, AB, Canada)

1:15pm-2:45pm: Tics Exacerbations in Adults with Tic Disorders: A Case series

S. Schaefer, C. Chow, E. Louis, D. Robakis (New Haven, CT, USA)

1:15pm-2:45pm: Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study

L. Turner-Stokes, S. Ashford, J. Jacinto, K. Fheodoroff, G. Suarez, P. Maisonobe (London, United Kingdom)

1:15pm-2:45pm: TMEM230 mutation analysis in Parkinson’s disease in a Chinese population

Z. Liu (Changsha, China)

1:15pm-2:45pm: Tongue strength in Parkinson’s disease.

H. Kalf, J. van Asperen, F. Tuenter, L. van Vucht, J. Vanderwegen, G. van Nuffelen (Nijmegen, Netherlands)

1:15pm-2:45pm: Tourettism associated with the Xq25 Microduplication Syndrome

C. Spears, I. Malaty (Gainesville, FL, USA)

1:15pm-2:45pm: Translating the Parkinson´s Disease Sleep Scale (PDSS-2) into 31 Languages Using a Standardized Methodology

K.R. Chaudhuri, C. Trenkwalder, C. Anfray, M.-P. Emery, C. Acquadro (London, United Kingdom)

1:15pm-2:45pm: Translating the Rapid Eye Movement (REM) Sleep Behavior Disorder Screening Questionnaire (RBDSQ) into 21 Languages Using a Standardized Methodology

M.-P. Emery, C. Anfray, K. Stiasny-Kolster, C. Acquadro (Lyon, France)

1:15pm-2:45pm: Treatment associated improvement in motor scores is not reflected in improvement in hand dexterity in Parkinson’s disease patients

S. Filipović, A. Kačar (Beograd, Serbia)

1:15pm-2:45pm: Treatment of Parkinson’s disease psychosis–a systematic review of RCTs

K. Cook, D. Nellesen, K. Adamski, A. Shim (Menlo Park, CA, USA)

1:15pm-2:45pm: Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice

L.G. Chan, A. Kong, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.

A. Schumacher-Schuh, F. Drumond, J. Leal, M. Dotto, S. Machado, C. Rieder (Porto Alegre, Brazil)

1:15pm-2:45pm: Understanding the role of LRRK2 in Indian population

A. Kishore, M. Sturm, A. Sreelatha, S. Robert, S. Krishnan, M. Banerjee, O. Riess, P. Bauer, R. Kruger, T. Gasser, M. Sharma (Trivandrum, India)

1:15pm-2:45pm: Unusual MRI findings of the syndrome of acute bilateral basal ganglia lesions in diabetic uremia with hyperglycemia associated dyskinesia

P.-Y. Chen, A. Gutfreund, K. Brockmann, I. Wurster, G. Eschweiler, F. Metzger, W. Maetzler, D. Berg (Taipei, Taiwan)

1:15pm-2:45pm: Use of latent class analysis and growth mixture modeling to examine longitudinal neurocognitive trajectories in non-demented Parkinson’s disease

L. Brennan, K. Devlin, D. Mechanic-Hamilton, J. Rick, S. Xie, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J. Duda, J. Morley, R. Akhtar, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson’s disease

N. Visanji, A. Lacoste, S. Ezell, S. Spangler, E. Argentinis, J. Brotchie, A. Lang, T. Johnston (Toronto, ON, Canada)

1:15pm-2:45pm: Using eye tracking to identify pupil and saccade biomarkers of neurodegenerative disease

D. Munoz, B. Coe, J. Huang, M. Smorenburg, D. Brien, S. Black, M. Borrie, D. Dowlatshahi, E. Finger, D. Grimes, M. Freedman, A. Lang, C. Marras, M. Masellis, R. Swartz, C. Tartaglia, L. Zinman, t. ONDRI Investigators (Kingston, ON, Canada)

1:15pm-2:45pm: Utility of ataxia gene panel testing in diagnosing inherited ataxia: evaluation of an Irish cohort

P. Bogdanova-Mihaylova, R. Walsh, S. Murphy (Dublin 24,, Ireland)

1:15pm-2:45pm: Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease

S. Holden, L. Medina, B. Hoyt, S. Sillau, J. Goldman, D. Weintraub, B. Kluger (Aurora, CO, USA)

1:15pm-2:45pm: Validation of Computerised Measures of Executive Functioning for use in Parkinson’s Disease Assessments.

T. Dominey, C. Carroll, R. Noad, C. Newman, S. Hall (Plymouth, United Kingdom)

1:15pm-2:45pm: Variation in Longevity Gene KLOTHO Associates with Measures of Resilience Against Parkinson’s Disease

N. Luthra, J. Ostrem, D. Dubal (San Francisco, CA, USA)

1:15pm-2:45pm: Video-oculography assessment in neurodegenerative ataxias and Neimann Pick Type C

H. Hanagasi, Z. Karaarslan, B. Bilgiç, Z. Tüfekçioğlu, A. Demirtaş Tatlıdede, H. Gürvit, M. Emre (İstanbul, Turkey)

1:15pm-2:45pm: VIT-D and Tics Movement Disorder

N. GEMAWAT (MUMBAI, India)

1:15pm-2:45pm: Voice Cepstral Analysis in Adductor-Type Spasmodic Dysphonia

L. Marsili, A. Suppa, G. Costantini, G. Saggio, D. Casali, G. Delgado, G. Ruoppolo, A. Berardelli (Rome, Italy)

1:15pm-2:45pm: Volumetric analysis of limbic structures in patients with functional movement disorders

C. Maurer, K. LaFaver, G. Limachia, G. Capitan, S. Horovitz, M. Hallett (Bethesda, MD, USA)

1:15pm-2:45pm: Voxel-based Analysis of Cholinesterase Inhibitor Response in Lewy Body Disorders: A Prospective Observational Study

J. Compagnone, H. Mustaerts, J. Li, M. Freedman, K. Galit, J. Lee, J. Kennedy, R. Chen, D. Tang-Wai, A. Lang, N. Herrmann, S. Black, M. Masellis (Toronto, ON, Canada)

1:15pm-2:45pm: Wearable gait sensors to measure degenerative cerebellar ataxia

R. Sakakibara, K. Terayama, O. Akihiro, H. Haruta, T. Akiba, F. Tateno, M. Kishi, Y. Tsuyusaki, Y. Aiba, T. Ogata (Sakura, Japan)

1:15pm-2:45pm: What do patients with Parkinson’s disease see in their hallucinations? Classification of hallucinations which are seen in Parkinson’s Disease; Single Center Experience

A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

1:15pm-2:45pm: What strategies do Parkinson’s disease patients use for getting out of bed in the early morning? Preliminary results from home video analysis of 22 patients.

J. Sringean, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:15pm-2:45pm: Which self-report motor experiences of daily living best predict objective motor function in patients with Parkinson’s disease?

S. Anderson, J. Goldman, S. Luo, A. Negron, C. Goetz, G. Stebbins (Chicago, IL, USA)

1:15pm-2:45pm: White matter lesions and peripheral vessel reactivity in dementia with Lewy bodies

A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russian Federation)

1:15pm-2:45pm: White matter microstructural damage as predictor of cognitive decline in Parkinson’s disease

T. Stojkovic, E. Stefanova, F. Agosta, S. Galantucci, I. Stankovic, V. Markovic, E. Canu, M. Copetti, M. Filippi, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Young Onset Parkinson’s Disease (YOPD): A different disease entity?

H. Chan, Y. Cheung, D. Chau, V. Lo, C. Woo, S. Tse, T. Fung, A. Leung, W. Fong (Hong Kong, Hong Kong)

1:15pm-2:45pm: [18F]-AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP

S. Coakeley, S.S. Cho, Y. Koshimori, P. Rusjan, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm: 18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease

A. Hansen, M. Damholdt, K. Knudsen, T. Fedorova, K. Østergaard, D. Brooks, P. Borghammer (Aarhus C, Denmark)

1:15pm-2:45pm: 18F-labeled FP-CIT PET Findings in a series of cirrhotic patients with parkinsonism

H.-J. Yang, S.H. Park, Y. Kim (Ulsan, Republic of Korea)

1:15pm-2:45pm: 3D image as a complimentary assist in patients with Parkinson’s disease

D. Khodjieva, N. Mansurova, N. Khaydarov (Bukhara, Uzbekistan)

1:15pm-2:45pm: 5-year results from the NSTAPS trial: comparing bilateral deep brain stimulation of the globus pallidus pars interna versus the subthalamic nucleus for advanced Parkinson’s disease.

J. Boel, V. Odekerken, P. vanden Munckhof, G. Geurtsen, M. Figee, J. Dijk, R. de Haan, B. Schmand, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:15pm-2:45pm: 99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson’s disease.

A. Ghabeli Juibary, V.R. Dabbagh Kakhki, P. Sasannejad, R. Sadeghi, K. Sadri, M. Sabour, H. Alizadeh (Mashhad, Islamic Republic of Iran)

1:15pm-2:45pm: A combined cognitive and motor exercise program for people with Parkinson’s disease and Freezing of gait; a pilot study.

L. King, K. Smulders, M. Mancini, J. Lapidus, P. Carlson-Kuhta, B. Fling, J. Nutt, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: A Comparison of Temporal Discrimination Thresholds in Musicians with and without Dystonia

O. Killian, K. Simonyan, E. McGovern, B. Quinlivan, S. Narasimham, I. Beiser, J. Butler, R. Beck, S. O'Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

1:15pm-2:45pm: A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome

J. Horie, H. Fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Matsubara, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

1:15pm-2:45pm: A kinematic analysis of finger tapping in dystonia

R. Newby, S. Muhamed, S. Smith, J. Alty, S. Jamieson, P. Kempster (Melbourne, Australia)

1:15pm-2:45pm: A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients

K.R. Chaudhuri, A. Antonini, W. Poewe, D. Standaert, P. Odin, J. Zamudio, L. Bergmann (London, United Kingdom)

1:15pm-2:45pm: A neuroimaging-based model for disease progression in Parkinson’s disease

N. Shenkov, I. Klyuzhin, A. Rahmim, V. Sossi (Vancouver, BC, Canada)

1:15pm-2:45pm: A novel paradigm of variable frequency deep brain stimulation to improve freezing of gait in Parkinson’s disease

F. Jia, A. Wagle Shukla, w. Hu, L. Almeida, M. Okun, L. Li (Beijing, China)

1:15pm-2:45pm: A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations

S. Ramaswamy, W. Wen, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

1:15pm-2:45pm: A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of Daxibotulinumtoxina for Injection (RT002) in Isolated Cervical Dystonia

C. Comella, J. Jankovic, D. Truong, A. Brashear, A. Patel, M. Evatt, C. Chung, R. Rubio (Chicago, IL, USA)

1:15pm-2:45pm: A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update

K. Biglan, J. Lowell, D. Oakes, K. Hodgeman, R. Rockhill, B. Greco, R. Holloway, T. Simuni (Rochester, NY, USA)

1:15pm-2:45pm: A Pilot Multiparametric MEG Study of coherence in generalized and cervical dystonia

A. Mahajan, S. Bowyer, A. Zillgitt, P. LeWitt, P. Kaminski, C. Sidiropoulos (Detroit, MI, USA)

1:15pm-2:45pm: A Preliminary Study: Validity and Reliability of Parkinson Fatigue Scale (PFS) in Turkish Patients with Parkinson’s Disease (PD)

E. Ozturk, E. Ozturk, B. Gonenli Kocer, I. Gundogdu, A. Cakci, E. Umay (Ankara, Turkey)

1:15pm-2:45pm: A Preliminary Study: Validity and Reliability of Turkish Version of Fatigue Severity Scale (FSS) in Patients with Parkinson’s Disease (PD)

E. Ozturk, B. Gonenli Kocer, I. Gundogdu, A. Cakci, E. Umay (Ankara, Turkey)

1:15pm-2:45pm: A prospective comparison of apomorphine, STN deep brain stimulation and levodopa-carbidopa intestinal gel therapy for motor fluctuations in PD

H.-L. Chiang, F. Chang, D. Tsui, Y. Tai, A. Ha, N. Mahant, J. Griffith, D. Galea, S. Kim, B. Cruse, H. Morales-Briceño (New Taipei City, Taiwan)

1:15pm-2:45pm: A prospective randomized cross-over study of telemedicine system in Parkinson’s disease

S. Sekimoto, G. Oyama, T. Hatano, F. Sasaki, R. Nakamura, T. Jo, Y. Shimo, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm: A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson’s Disease.

A. Faust- Socher, M. Criaud, A. Mihaescu, A. Lang, S. Cho, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm: A randomised control trial to investigate if people with Parkinson’s disease can exercise at high intensity, and does this improve their cardiorespiratory function? A feasibility study

M. Harvey, R. Walker, W. Gray, K. Weston, L. Oates (North Shields, United Kingdom)

1:15pm-2:45pm: A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome

D. Gilbert, T. Murphy, J. Jankovic, C. Budman, K. Black, R. Kurlan, K. Coffman, J. McCracken, J. Juncos, J. Grant, R. Chipkin (Cincinnati, OH, USA)

1:15pm-2:45pm: A single aerobic exercise session of treadmill increases BDNF levels in Parkinson’s disease patients

P. Scalzo, L. Dos Santos, J. Pereira, R. Santos, N. Rocha, A. Texeira, P. Christo (Belo Horizonte, Brazil)

1:15pm-2:45pm: Aberrant resting state functional brain networks in patients with Parkinson’s disease and visual hallucinations

A. Lenka, R. Panda, L. George, S. Hegde, S. Arumugham, J. Saini, R. Bharath, P. Pal (Bangalore, India)

1:15pm-2:45pm: Abnormal DaTscan in a case of Anoxic brain injury

S. Byreddy, U. Zahid, H. Lei (Tucson, AZ, USA)

1:15pm-2:45pm: Abnormal patterns of action selection in the dominant motor cortex in writer’s cramp

A. Kishore, S. Meunier, P. James, S. Krishnan, T. Popa (Trivandrum, India)

1:15pm-2:45pm: Abnormal spontaneous activity and functional connectivity in patients with Parkinson’s disease with anxiety

M. Criaud, M. Zurowski, N. Lobaugh, S. Chavez, Y. Koshimori, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm: Acquisition, Validation and Preprocessing of Wrist-Worn Sensor Data in Patients with Parkinson’s Disease and Healthy Controls

D. Pichler, M. Lang, D. Kulić, F. Pfister, G. König, T. Um, A. Ahmadi, S. Endo, F. Achilles, K. Abedinpour, K. Bötzel, A. Ceballos-Baumann, S. Hirche, U. Fietzek (Munich, Germany)

1:15pm-2:45pm: Action Observation Training Effects on Brain Structural and Functional Changes in Parkinson’s Disease Patients

E. Sarasso, F. Agosta, M. Di Meo, M. Giacobbe, M.A. Volonté, G. Comi, A. Tettamanti, R. Gatti, M. Filippi (Milan, Italy)

1:15pm-2:45pm: Active Arms: a randomized controlled trial of an interactive videogame for people with Parkinson’s disease

N. Allen, J. Song, S. Paul, S. Smith, J. O'Duffy, M. Schmidt, R. Love, C. Sherrington, C. Canning (Lidcombe, Australia)

1:15pm-2:45pm: Aerobic Exercise Combined with rTMS for Parkinson’s Disease: A Randomized Trial

H. Migdadi, M. Biagioni, S. Agarwal, A. Cucca, P. Kumar, A. Quartarone, R. Rossi, M. Ghilardi, A. Di Rocco (New York, NY, USA)

1:15pm-2:45pm: Alterations in Dynamic Brain Connectivity Patterns in Parkinson’s Disease

X. Dan, A. Liu, J. Wang, M. McKeown, T. Wu, P. Chan (Beijing, China)

1:15pm-2:45pm: Altered attentional brain network in Parkinson’s disease with mild cognitive impairment

J.H. Yang, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

1:15pm-2:45pm: Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation

Y. Hou, C. Luo, J. Yang, R. Ou, W. Song, Y. Chen, Q. Gong, H. Shang (Chengdu, China)

1:15pm-2:45pm: Altered PDE10A Expression Detectable Early in Untreated Parkinson’s Disease Patients

G. Pagano, F. Niccolini, H. Wilson, T. Yousaf, N. Khan, D. Martino, R. Gunn, E. Rabiner, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Altered Resting-State Functional Interhemispheric Connectivity in Parkinson’s Disease

X. Dan, S. Lin, A. Liu, J. Wang, T. Wu, P. Chan, M. McKeown (Beijing, China)

1:15pm-2:45pm: Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson’s Disease

C.-M. Chen, K.-H. Chang, Y.-R. Wu, M.-L. Cheng (Taoyuan, Taiwan)

1:15pm-2:45pm: Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease

M. Koivu, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

1:15pm-2:45pm: Antiparkinson and antioxidant effect of N-Methanesulfonylpyrazolinyl substituted Heterosteroids in LPS induced Neuroinflammation Model of Rats

R. Singh (Chandigarh, India)

1:15pm-2:45pm: Anxiety influences the neural correlates associated with freezing of gait in Parkinson’s disease

K. Ehgoetz Martens, M. Georgiades, M. Gilat, J. Hall, J. Shine, C. Walton, S. Lewis (Camperdown, Australia)

1:15pm-2:45pm: Aquatic Dual Task Exercise: Effects on Body Balance of Individuals with Parkinson’s Disease

A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm: Aquatic Physical Exercises: Balance in People with Parkinson’s Disease

M. Ferreira, B. Yamaguchi, A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm: Are the exergaming effective for improving functional exercise capacity, and quality of life in Patients with Parkinson’s Disease?

C. Gemin, L. da Silva, M. Ribas Correa, H. Ghizone Teive, S. Valderramas (curitiba, Brazil)

1:15pm-2:45pm: Assessing cholinergic innervation in Parkinson’s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol

S. vander Zee, I. Alves, A. Willemsen, P. Elsinga, T. van Laar (Groningen, Netherlands)

1:15pm-2:45pm: Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI

A. Martin-Bastida, Y. Xing, S. Pietracupa, A. Roussakis, N. Lao-Kaim, W. Li, X. Li, P. Mahlknecht, S. Schwarz, T. Foltynie, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Assessing the involvement of ARSG and RAB12 variants in Musician’s Focal Dystonia from the US.

C. Stephen, M. Charness, K. Mangkalaphiban, T. Francoeur, A. Hamzehei-Sichani, S. Frucht, K. Simonyan, T. Multhaupt-Buell, N. Sharma, L. Ozelius (Boston, MA, USA)

1:15pm-2:45pm: Assessment of substantia nigra degeneration with magnetic resonance and transcranial ultrasonography

C. Prieto, V. Suárez, C. Ordás, B. Venegas, R. Cazorla, A. Vinagre (Valdemoro, Spain)

1:15pm-2:45pm: Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study

C. Kenney, A. Glass, W. Olanow (Ardsley, NY, USA)

1:15pm-2:45pm: Association of vitamin D deficiency in Parkinson disease

A. MUJTABA, N. ALSOMALI, A. ALSHAMRANI, S. MARAR, T. Alayan, J. BAJWA (RIYADH, Saudi Arabia)

1:15pm-2:45pm: Associations between Functional Networks and Temporal Discrimination Thresholds in Cervical Dystonia patients and their unaffected relatives

S. Narasimham, V. Sundararajan, E. McGovern, B. Quinlivan, I. Beiser, R. Beck, S. Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

1:15pm-2:45pm: Associations of DAT SPECT and TCS with prodromal features of Parkinson’s disease: results in PREDICT-PD participants

A. Noyce, J. Dickson, J. Bestwick, I. Isaias, M. Politis, G. Giovannoni, T. Warner, A. Lees, A. Schrag (London, United Kingdom)

1:15pm-2:45pm: Automated dosing schemes for administration of microtablets of levodopa for Parkinson’s disease, using wearable sensors

I. Thomas, F. Bergquist, D. Johansson, D. Nyholm, M. Memedi, J. Westin (Falun, Sweden)

1:15pm-2:45pm: Availability of anti-Parkinsonian drugs in Thailand

K. Sakdisornchai, R. Bhidayasiri, O. Jitkritsadakul, p. panyakaew, J. Sringean (Bangkok, Thailand)

1:15pm-2:45pm: Basal Ganglia Circuits for Motor and Behavioral, Emotional Performances

F. Fujiyama (Kyotanabe, Japan)

1:15pm-2:45pm: Basal Ganglia Infarction and Striatal Toe- A Case Report

S. Usar Incirli, F. Selcuk Muhtaroglu, C. Akbostanci (Nicosia, Cyprus)

1:15pm-2:45pm: Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD

W. Olanow, A. Ellenbogen, R. Djaldetti, T. Rachmilewitz Minei, Y. Cohen, S. Oren, K. Kieburtz (New York, NY, USA)

1:15pm-2:45pm: Baseline predictors for clinical progression after 48 month follow-up in early Parkinson’s disease from the DeNoPa cohort

B. Mollenhauer, J. Zimmermann, F. Sixel-Döring, N. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, C. Trenkwalder (Kassel, Germany)

1:15pm-2:45pm: Beta oscillatory changes during practice and retention of motor skills in healthy subjects and patients with PD

A. Nelson (NY, USA)

1:15pm-2:45pm: Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease

E. Robin, A. Verger, F. Fluchere, T. Witjas, J.P. Azulay, E. Guedj, A. Eusebio (Marseille, France)

1:15pm-2:45pm: Brain structural and functional changes associated with frequent falls in Parkinson’s disease

H. Otomune, M. Mihara, H. Fujimoto, Y. Kajiyama, K. Konaka, Y. Mitani, G. Revankar, H. Mochizuki (Suita, Japan)

1:15pm-2:45pm: Brain volume changes in relation to intracortical inhibition and clinical benefit of pallidal stimulation in dystonia: a combined VBM and TMS study.

R. Jech, A. Fečíková, V. Čejka, V. Čapek, D. Šťastná, F. Růžička, D. Urgošík, E. Růžička (Prague, Czech Republic)

1:15pm-2:45pm: Brainstem connection of Writer’s cramp: Electrophysiological correlates

S. Choudhury, P. Chatterjee, R. Singh, S. Shubham, S. Trivedi, M. Baker, S. Baker, H. Kumar (Kolkata, India)

1:15pm-2:45pm: Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)

R. Postuma, J. Anang, A. Pelletier, M. Moscovich, D. Grimes, A. Borys, S. Furtado, R. Munhoz, S. Cresswell, A. Moro, D. Hobson, L. Joseph, A. Lang (Montreal, QC, Canada)

1:15pm-2:45pm: Cardiac 123I-MIBG Scintigraphy, olfactory testing and transcranial sonography for differentiating between Parkinson’s disease and atypical parkinsonian syndromes during the early stage

h. fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

1:15pm-2:45pm: Cardiac-related pulsatility in white matter is associated with cognitive and motor performance in patients with Parkinson’s disease

Z. Shirzadi, H. Sharmarke, A. Robertson, A. Metcalfe, S. Duff-Canning, C. Marras, A. Lang, M. Masellis, B. MacIntosh (Toronto, ON, Canada)

1:15pm-2:45pm: Central pain processing in “drug-naïve” pain-free patients with Parkinson’s disease

R. De Micco, A. Russo, F. Esposito, A. Giordano, M. Fratello, G. Caiazzo, M. Cirillo, G. Tedeschi, A. Tessitore (Naples, Italy)

1:15pm-2:45pm: Characterization of Pisa syndrome in Parkinson’s disease.

T. Clark, J. Nutt, F. Horak, M. Mancini, M. Jurado, T. Hullar (Portland, OR, USA)

1:15pm-2:45pm: Characterizing task-based acoustic variations of vowels in Parkinson’s disease: Preliminary data

C. Kuo (Harrisonburg, VA, USA)

1:15pm-2:45pm: Cinnamomum verum on Learning and Memory in Wistar Albino Rats

N. AHMED, D. AGRAWAL, A. CHUGHTAI (ALIGARH, India)

1:15pm-2:45pm: Clinical analysis of patients with servical dystonia who Botulinum toxin injection is performed: 10 years experience of Ege University Neurology Department of Movement Disorders Clinic

A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

1:15pm-2:45pm: Clinical and demographics of cervical dystonia related to the direction of the neck movement

K. Asanuma (Kyoto, Japan)

1:15pm-2:45pm: Clinical and electrophysiological features of seven patients with moving toes syndrome: Is it a type of spinal segmental myoclonus?

G. Kiziltan, H. Kurucu, C. Yalcinkaya, A. Gunduz, M. E. Kiziltan (Istanbul, Turkey)

1:15pm-2:45pm: Clinical and Imaging and phenoconversion in the PARS prodromal cohort

K. Marek, A. Siderowf, S. Eberly, D. Oakes, M. Stern, D. Russell, J. Seibyl, D. Jennings (New Haven, CT, USA)

1:15pm-2:45pm: Clinical characteristics of cognitive impairment in patients with Parkinson’s disease and its related pattern in 18F-FDG PET imaging

F.-t. Liu, J.-j. Ge, L. Wu, Y.-j. Yang, J. Zhao, S.-s. Luo, Y.-m. Sun, J.-j. Wu, Z.-t. Ding, C.-t. Zuo, J. Wang (Shanghai, China)

1:15pm-2:45pm: Clinical characteristics of scan without evidence of dopaminergic deficits (SWEDDs) in Japan.

M. Takahashi, Y. Tashiro, N. Ito, T. Sato, T. Sekiguchi, A. Inaba, S. Orimo (Tokyo, Japan)

1:15pm-2:45pm: Clinical Criteria for Subtyping Parkinson’s Disease: Differences in imaging and CSF biomarkers and longitudinal progression

S.-M. Fereshtehnejad, Y. Zeighami, A. Dagher, R. Postuma (Montreal, QC, Canada)

1:15pm-2:45pm: Clinical effects are persistent at the end of one abobotulinumtoxinA injection cycle in cervical dystonia – results from a meta-analysis of 1091 subjects

R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

1:15pm-2:45pm: Clinical profile of patients with blepharospasm

S. Kaleagasi, O. Dogu (Mersin, Turkey)

1:15pm-2:45pm: Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study

K. Dashtipour, Z. Mari, J. Jankovic, C. Adler, M. Schwartz, M. Brin (Loma Linda, CA, USA)

1:15pm-2:45pm: Clinical Utility of Optimized Parameters for a Quantitative Analysis of 123I-ioflupane SPECT (DaTscan) Images

G. Zubal, S. Tinaz, C. Chow, H. Blumenfeld, E. Louis (New Haven, CT, USA)

1:15pm-2:45pm: Clinical utility of visualization of Nigrosome-1 in patients with Parkinson’s disease

A. Sunny, R. Naduthota, R. Botta, S. Varadharajan, J. Saini, R. Yadav, P. Pal (Bangalore, India)

1:15pm-2:45pm: Cognitive changes and cortical thinning evolution of parkinson’s disease patients: 4-year-follow up.

A. Campabadal, C. Uribe, B. Segura, H. Baggio, A. Abos, A. Garcia-Diaz, M.-J. Marti, Y. Compta, F. Valldeoriola, C. Junque (Barcelona, Spain)

1:15pm-2:45pm: Cognitive Function is Preserved 10 Years Following DBS in People with Dystonia

E. Hogg, J. Eskenazi, E. During, J. Wertheimer, R. Alterman, M. Tagliati (Los Angeles, CA, USA)

1:15pm-2:45pm: Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm

A. Wagle Shukla, J. Legacy, W. Deeb, W. Hu (Gainesville, FL, USA)

1:15pm-2:45pm: Comparison of hand functions between people with Parkinson’s disease and healthy subjects

M. Mak, I. Wong (Hong Kong, Hong Kong)

1:15pm-2:45pm: Connectivity patterns in frontal cognitive regions in Parkinson’s disease

A. Hanganu, A. Nagano-Saito, A. Tam, N. Auclair-Ouellet, S. Jobert, B. Mejia-Constain, D. Schoemaker, C. Degroot, A.-L. Lafontaine, H. Chertkow, P. Bellec, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Correlation analysis between dopamine release in striatal sub-regions and motor impairment in Parkinson’s disease subjects

I. Klyuzhin, M. Sacheli, N. Vafai, E. Shahinfard, B. Lakhani, J. Neva, J. Fu, J. McKenzie, N. Neilson, K. Dinelle, L. Boyd, A. Stoessl, V. Sossi (Vancouver, BC, Canada)

1:15pm-2:45pm: Correlation Between Time Course, Level of Impact of Illness, Functionality, and Postural Measures of Patients with Cervical Dystonia.

F. Germiniani, S. Mattozo, R. Werle, A. Guimarães, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Correlation of Electrode Position and Clinical Outcomes in Globus Pallidus Stimulation for Dystonia

H. Park (Seoul, Republic of Korea)

1:15pm-2:45pm: Cortical phase-amplitude coupling across Parkinson’s disease phenotypes measured with magnetoencephalograph

J. Bajwa, E. Peña, L. Rosedahl, T. Mohammed, F. Almohammed, T. AlOtaibi, L. Soualmi, V. Poghosyan, S. Cooper, V. Jousmäki, M. Johnson (Riyadh, Saudi Arabia)

1:15pm-2:45pm: Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada.

M.-E. Gendron, M.-E. Gendron, R. Kazerooni (Burlington, ON, Canada)

1:15pm-2:45pm: CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study

R. Alcalay, A. Amara, P. Taylor, H. Andrews, J. Goldman, T. Xi, P. Tuite, C. Henchcliffe, P. Hogarth, S. Frank, M.-H. Saint Hilaire, A. Naito, M. Frasier, V. Arnedo, A. Reimer, M. Sutherland, C. Swanson-Fischer, K. Gwinn, U. Kang (NYC, NY, USA)

1:15pm-2:45pm: DBS Plus: Investigating cell therapy and deep brain stimulation as an approach to alter disease progression and treat motor and non-motor symptoms of Parkinson’s disease

C. van Horne, J. Quintero, J. Gurwell, A. Anderson-Mooney, A. Welleford, J. Lamm, J. Slevin, G. Gerhardt (Lexngton, KY, USA)

1:15pm-2:45pm: Death in patients with Parkinson’s disease – an observational study

R. Mappilakkandy, A. Pieris, D. Miodrag, A. Chunduri (Northampton, United Kingdom)

1:15pm-2:45pm: Decision-making process for opicapone’s bedtime regimen

A. Falcão, A. Santos, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (Coimbra, Portugal)

1:15pm-2:45pm: Decreased Fronto-Parietal connection is associated with face pareidolia in Parkinson’s disease.

Y. Kajiyama, M. Mihara, Y. Mitani, H. Otomune, H. Fujimoto, G. Revankar, K. Konaka, H. Mochizuki (Osaka, Japan)

1:15pm-2:45pm: Deep brain stimulation in Parkinson’s disease: Outcome after more than nine years

B. Thomsen, S. Jensen, A. Clausen, B. Jespersen, M. Karlsborg, A. Løkkegaard (Copenhagen, Denmark)

1:15pm-2:45pm: Deep Brain Stimulation of Subthalamic Nucleus Selectively Modulates Striato-Thalamo-Cortical Circuit in Parkinson’s Disease: a Systematic Review and ALE Meta-analysis

H. Chen (Beijing, China)

1:15pm-2:45pm: Deep Learning in Objective Classification of Spontaneous Movement of Patients with Parkinson’s Disease Using Large-Scale Free-Living Sensor Data

F. Pfister, D. Kulić, T. Um, D. Pichler, A. Ahmadi, M. Lang, G. König, F. Achilles, S. Endo, K. Abedinpour, K. Ziegler, K. Bötzel, S. Hirche, A. Ceballos-Baumann, U. Fietzek (Munich, Germany)

1:15pm-2:45pm: Determinants of health-related quality of life in children and young adults with dystonia

H. Eggink, M. Coenen, A. Elema, W. Veenstra, K. Peall, D. Sival, M. Tijssen (Groningen, Netherlands)

1:15pm-2:45pm: Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement

N. Shaw, V. Evans, J. Rideout, C. Carroll (Plymouth, United Kingdom)

1:15pm-2:45pm: Development of a Clinical Outcomes Assessment (COA) in Pantothenate-Kinase Associated Neurodegeneration (PKAN): Item Generation and Clinimetric Properties

R. Marshall, A. Collins, M. Escolar, H.A. Jinnah, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, W. Lenderking (Cambridge, MA, USA)

1:15pm-2:45pm: Development of a New Kinematic Model for Head and Neck Movement Assessment in Cervical Dystonia

A. Castagna, D. Anastasi, A. Crippa, L. Lanzotti, A. Montesano, A. Marzegan (Milano, Italy)

1:15pm-2:45pm: Development of utility to evaluate a symptomatic diary of motor fluctuations of Parkinson’s disease (PD) using a smartphone application.

H. Ohtsubo, H. Iwaki, H. Yabe, M. Nagai, M. Nomoto (Matsuyama Ehime, Japan)

1:15pm-2:45pm: Differences between Hemifacial spasm with or without neurovascular conflict. Therapeutic implications with botulinum toxin type A.

J.S. Bestoso, L. Ciancaglini, C. Stefani, C. Azcona, M.L. Contartese, A. Pappolla, J.I. Rojas, D. Bauso (Buenos Aires, Argentina)

1:15pm-2:45pm: Differences in cerebral perfusion between Major depression disorder and depression with Parkinson’s disease : Brain HMPAO SPECT study using SPM analysis

Y.-D. Kim, Y.-D. Kim (Incheon, Republic of Korea)

1:15pm-2:45pm: Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson’s disease

I. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J. Goldman (San Francisco, CA, USA)

1:15pm-2:45pm: Disability-Adjusted Life Years (DALY) in X-linked Dystonia Parkinsonism

P. Acuna, C. Go (Charlestown, MA, USA)

1:15pm-2:45pm: Disease modeling for Perry syndrome using patient induced pluripotent stem cells

T. Mishima, T. Ishikawa, K. Imamura, T. Kondo, Y. Koshiba, R. Takahashi, J. Takahashi, A. Watanabe, N. Fujii, Y. Tsuboi, H. Inoue (Fukuoka, Japan)

1:15pm-2:45pm: Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

1:15pm-2:45pm: Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression

N. Kanzato (Haebaru-cho, Japan)

1:15pm-2:45pm: Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms

E. Mc Govern, O. Killian, S. Narasimham, B. Quinlivan, I. Beiser, L. Williams, R. Beck, J. Butler, S. O'Riordan, R. Reilly, M. Hutchinson (Dublin, Ireland)

1:15pm-2:45pm: Distinct pattern of striatal dopaminergic depletion in patients with parkin mutation

K.-Y. Kwon (Seoul, Republic of Korea)

1:15pm-2:45pm: Does smoking impact dopamine neuronal loss in de novo Parkinson’s disease?

Y. Lee, H.s. Yoo, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

1:15pm-2:45pm: Does the side of onset affect motor and non-motor symptoms in Parkinson’s disease?

J. Silva, A. D'Abreu (Campinas, Brazil)

1:15pm-2:45pm: Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson’s disease

M. Gilat, P. Bell, K. Ehgoetz Martens, M. Georgiades, J. Hall, C. Walton, S. Lewis, J. Shine (Sydney, Australia)

1:15pm-2:45pm: Dopamine Normalizes Putamen to Insula Activation Shift During Choice Reaction Time Task in PD

J. Kim, K. Zhang, S. YorkWilliams, M. Ua Cruadhlaoich, V. Menon, K. Poston (Palo Alto, CA, USA)

1:15pm-2:45pm: Dopamine transporter imaging predicts motor response to dopaminergic therapy for patients with advanced Parkinson’s disease: Possible role in patient selection for subthalamic deep brain stimulation.

A. Nakajima, Y. Shimo, S. Sekimoto, K. Kamagata, J. Takayuki, G. Oyama, A. Umemura, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm: Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, A. Lees (Vienna, Austria)

1:15pm-2:45pm: Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study

S. Sharma, T. Simuni, B. Greco, K. Biglan, C. Tarolli, K. Hodgeman, D. Oakes, D. Penz (Rochester, NY, USA)

1:15pm-2:45pm: Dystonia due to bilateral caudate hemorrhage associated with a COL4A1 mutation

T. Hatano, K. Daida, Y. Hoshino, Y. Li, H. Saitsu, N.c. Matsumoto, N. Hatter (Tokyo, Japan)

1:15pm-2:45pm: Dystonia Gravidarum Improved After Joint Position Error Training

T. Pham, A. Elder, A. Wu (Los Angeles, CA, USA)

1:15pm-2:45pm: Dystonia treatment in an international cohort: a longitudinal analysis

S. Pirio Richardson, A. Wegele, A. Deligtisch, F. Qeadan (Albuquerque, NM, USA)

1:15pm-2:45pm: Dystonia-like phenotype in a DYT1 rat model after peripheral trauma

S. Knorr, K. Grundmann-Hauser, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

1:15pm-2:45pm: Early caudate involvement in Parkinson’s disease may predict future cognitive decline

R. Durcan, D. Brooks, D. Burn, N. Pavese (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Early cognitive impairment phenotype and functional connectivity in non-demented Parkinson’s disease patients

K. Kawabata, H. Watanabe, K. Hara, E. Bagarinao, N. Yoneyama, A. Ogura, K. Imai, M. Masuda, T. Yokoi, R. Ohdake, T. Tsuboi, M. Ito, N. Atsuta, M. Katsuno, G. Sobue (Nagoya, Japan)

1:15pm-2:45pm: Early morning OFF problems are common in PD patients attending a routine clinical appointment

F. Stocchi, C. Coletti, S. Bonassi, L. Vacca (Rome, Italy)

1:15pm-2:45pm: EEG Markers for Emotional Inhibition in Parkinson’s Disease

N. Dissanayaka, D. Hennessy, T. Au, A. Angwin, J.H. Yang, J. O'Sullivan, D. Copland (Brisbane, Australia)

1:15pm-2:45pm: EEG Shows Subclinical Motor Preparation Deficits in Parkinson’s Disease Patients with Freezing of Gait During Locomotion

C. Fearon, J. Butler, S. Waechter, I. Killane, L. Newman, T. Munteanu, D. Birsanu, B. Magennis, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:15pm-2:45pm: Effect of deep brain stimulation on visuospatial impairment in Parkinson’s disease

Y. Okahara, Y. Higuchi, K. Aoyagi, M. Abe, T. Yamamoto, Y. Yamanaka, S. Hirano, Y. Iwadate (Chiba, Japan)

1:15pm-2:45pm: Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results

S. Kymes, C. François, G. Peng, G. Rowse, S. Isaacson (Deerfield, IL, USA)

1:15pm-2:45pm: Effect of food on Opicapone pharmacokinetics and pharmacodynamics

A. Santos, A. Falcão, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (S. Mamede Coronado, Portugal)

1:15pm-2:45pm: Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

1:15pm-2:45pm: Effect Of Non-Invasive Vagus Nerve Stimulation In Freezing And Oxidative Stress In Parkinson’s Disease Patients

B. MONDAL, S. CHOUDHURY, G. PAUL, M. MONDAL, M. BAKER, K. CHATTERJEE, P. CHATTERJEE, R. BANERJEE, R. SINGH, H. KUMAR (KOLKATA, India)

1:15pm-2:45pm: Effect of object size and obstacle avoidance on of Reach-to-Grasp Actions in Individuals with Parkinson’s disease

S. Khacharoen, J. Tretriluxana, P. Srivanitchapoom, A. Pisarnpong, T. Chandharohit (Nakhon Pathom, Thailand)

1:15pm-2:45pm: Effect of Valproic Acid on Dystonia in a patient with Traumatic Brain Injury: a case report.

N. Fatima (Lahore, Pakistan)

1:15pm-2:45pm: Effects of a Aquatic Dual Task Activity Program on the Quality of Life and Activities of Daily Living in Individuals with Parkinson’s Disease

A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm: Effects of a Parkinson-Specific, Interdisciplinary Approach, To Inpatient Rehabilitation

C. Benedict, D. Fredericks, C. Manganiello, H. Herrstrom, D. Schmitt, K. Lyons (Topeka, KS, USA)

1:15pm-2:45pm: Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia

M. Lew, D. Snyder (Los Angeles, CA, USA)

1:15pm-2:45pm: Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial

M. Jog, J. Lee, M. Althaus, A. Scheschonka, H. Dersch, E.T. Study Team, D. Simpson (London, ON, Canada)

1:15pm-2:45pm: Efficacy and Safety of Therapeutic Interventions to Treat Motor Symptoms in Late Stage Parkinson’s Disease: A Systematic Review

M. Coelho, K. Destri, M. Fabbri, A. Schrag, J. Ferreira, b.C. Consortium (Lisbon, Portugal)

1:15pm-2:45pm: Efficacy of miglustat in Korean patients with Niemann-Pick disease type C

J.W. Kim, S.-Y. Lee, R. Kim (Busan, Republic of Korea)

1:15pm-2:45pm: Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis

M. Asgharnejad, H. Pesch, E. Dohin (Raleigh, NC, USA)

1:15pm-2:45pm: Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase

R. Hauser, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, H. Fernandez (Tampa, FL, USA)

1:15pm-2:45pm: Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease

P. Lingor, A. Leha, B. Michalke, M. Börger, M. Bähr, I. Zerr, F. Maass (Göttingen, Germany)

1:15pm-2:45pm: Elevated GM3 Plasma Concentration in Idiopathic Parkinson’s Disease: a Lipidomics Analysis

R. Alcalay, R. Chan, C. Liong, A. Perotte, B. Zhou, E. Shorr, K. Marder, U. Kang, C. Waters, O. Levy, Y. Xu, H. Shim, I. Pe'er, G. Di Paolo (New York, NY, USA)

1:15pm-2:45pm: EMG-US guided incobotulinum toxinA treatment of a cohort of musicians affected by upper limb focal dystonia

A. Castagna, M. Ramella, G. Giacobbi, P. Cecconi, R. Converti (Milano, Italy)

1:15pm-2:45pm: End of Life Care in Parkinson’s Disease

S. Mole, S. Jackson (Exeter, United Kingdom)

1:15pm-2:45pm: Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

1:15pm-2:45pm: Epilepsy and Cranial nerve affection in a Patient with Wilson’s disease and Intracranial developmental venous anomaly; A Case Report

W. Ezzat, A. Mohamed (cairo, Egypt)

1:15pm-2:45pm: Evaluating the Experience of Diagnosis in Parkinson’s Disease

A. Robinson, E. Pearson, F. Murphy, J. Davis, C. Carroll (Plymouth, United Kingdom)

1:15pm-2:45pm: Evaluation of Brainstem Auditory Evoked Response and Nerve Conduction in Parkinson’s Disease

D. AGRAWAL, N. AHMED, A. CHUGHTAI (ALIGARH-202002, India)

1:15pm-2:45pm: Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis

E. Dohin, F. Woltering, M. Asgharnejad (Brussels, Belgium)

1:15pm-2:45pm: Evaluation of SV2A expression with [18F]MNI-944 PET imaging in healthy controls (HC) and Parkinson disease (PD)

D. Russell, D. Alagille, V. Carroll, M. Thompson, J. Madonia, O. Barret, C. Constantinescu, J. Seibyl, K. Marek, G. Tamagnan (New Haven, CT, USA)

1:15pm-2:45pm: Evolution in Dopamine Transporter (DaT) Scan Utilization Patterns and its Effect on Treatment Decisions: Results of the Next 200 Scans

X.X. Yu (Cleveland, OH, USA)

1:15pm-2:45pm: Exercise alters response of reward anticipation in the ventral striatum of subjects with Parkinson’s disease

M. Sacheli, D. Murray, N. Vafai, E. Shahinfard, M. Cherkasova, K. Dinelle, N. Neilson, J. McKenzie, S. Appel-Cresswell, M. McKeown, V. Sossi, A. Stoessl (Vancouver, BC, Canada)

1:15pm-2:45pm: Exergaming in Patients with Parkinson’s Disease

C. Gemin, L. da Silva, M. Ribas Corrêa, H. Ghizone Teive, S. Valderramas (Curitiba, Brazil)

1:15pm-2:45pm: Experience Of Pallidal Deep Brain Stimulation (DBS) In Dystonia At A Tertiary Care Centre In India.

D. Srinivas, P. Pal, R. Yadav (Bangalore, India)

1:15pm-2:45pm: Exploring the neurophysiology of cervical dystonia using TMS-EEG

S. Singh, H. Cho, N. Thirugnanasambandam, H. Shitara, O. Panyakaew, M. Hallett (Bethesda, MD, USA)

1:15pm-2:45pm: Extrapyramidal signs in neurosarcoidosis versus multiple sclerosis: is TNF alpha the link?

T. Drori, J. Chapman, M. Lidar, P. Langevitz, Y. Shoenfeld, O. Cohen (Ramat-Gan, Israel)

1:15pm-2:45pm: F-18-DOPA-PET predicts impulsive behavior under dopaminergic therapy in Parkinson patients

J. Hammes, M. Tittgemeyer, C. Eggers, A. Drzezga, T. van Eimeren (Cologne, Germany)

1:15pm-2:45pm: Factors associated with perceived walking difficulties in people with Parkinson’s disease

M. Kader, S. Ullén, S. Iwarsson, P. Odin, M. Nilsson (Lund, Sweden)

1:15pm-2:45pm: Falls characteristics of male and female patients with Parkinson’s disease (PD)

G. Alg, A. Chatterjee, F. Zahir (Reading, United Kingdom)

1:15pm-2:45pm: Falls in Parkinson’s disease are related to delayed recovery time after unexpected external perturbations

V. Beretta, F. Barbieri, D. Orcioli-Silva, P. Santos, M. Pereira, R. Vitório, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm: Feasibility of using a smartphone application for the objective evaluation of Parkinson disease

R. Schneider, J. Adams, M. Elson, C. Tarolli, S. Sharma, A. Glidden, T. Felong, A. Zhan, R. Korn, S. Goldenthal, D. Harris, M. Xiong, M. Little, K. Biglan, R. Dorsey (Rochester, NY, USA)

1:15pm-2:45pm: Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study

T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

1:15pm-2:45pm: Focal dystonia as an early symptom of CACNA1A mutation: case report and literature review.

Y. Gu, K. Kumar, C. Sue (Sydney, Australia)

1:15pm-2:45pm: Focused ultrasoud ventro-oral thalamotomy for musician’s dystonia

S. Horisawa, T. Yamaguchi, K. Abe, T. Taira (shinjyuku, Japan)

1:15pm-2:45pm: Focused ultrasound subthalamotomy for Parkinson’s disease: A pilot study

R. Martinez-Fernandez, R. Rodriguez-Rojas, M. del Álamo, F. Hernandez, J.A. Pineda-Pardo, M. di Leone, F. Alonso, I. Obeso, C. Gasca-Salas, E. de Luis, L. Vela, J.A. Obeso (Mostoles, Spain)

1:15pm-2:45pm: Four year outcomes of a prospective, multi-center trial evaluating Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Seijo, E. San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

1:15pm-2:45pm: Functional Connectivity Differences Across Parkinson Disease Subtypes

M. Campbell, C. Gratton, J. Koller, W. Shannon, C. Lessov-Schlaggar, S. Petersen, J. Perlmutter (St. Louis, MO, USA)

1:15pm-2:45pm: Functional MAOB gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson’s disease

M. Löhle, G. Mangone, M. Wolz, B. Beuthien-Baumann, L. Oehme, J. Hoff, J. Kotzerke, H. Reichmann, J.-C. Corvol, A. Storch (Rostock, Germany)

1:15pm-2:45pm: Functional role of the cerebellum in Parkinson’s disease : a PET-Study

A. Riou, F. Le Jeune, J.-F. Houvenaghel, S. Drapier, M. Vérin, G. Robert (RENNES, France)

1:15pm-2:45pm: Gait and Balance Impairment After Methanol Intoxication

K. Peterová, H. Brožová, J. Klempíř, I. Lišková, S. Zakharov, O. Bezdíček, M. Vaněčková, Z. Seidl, E. Růžička (Prague, Czech Republic)

1:15pm-2:45pm: Gait asymmetry and asymmetry index in a sample of patients with PD and control group in Cali – Colombia.

B. Munoz, A. Enriquez-Marulanda, J. Orozco (Cali, Colombia)

1:15pm-2:45pm: Gait Asymmetry and Parkinson’s Disease

C. Ashton, L. Solis-Cohen, L. Wagenaar, R. Laracuente, E. Sorberg, V. Vanderhorst, L. Shih (Boston, MA, USA)

1:15pm-2:45pm: Gait asymmetry in people with Parkinson’s disease is linked to reduced integrity of callosal sensorimotor regions

F. Horak, C. Curtze, B. Fling (Portland, OR, USA)

1:15pm-2:45pm: Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium

D. Stephenson, J. Cedarbaum, J. Eberling, M. Facheris, D. Grosset, M. Gordon, D. Hill, S. Imam, V. Kern, G. Klein, D. Matthews, P. Muglia, A. Roach, K. Romero, D. Russell, J. Seibyl, L. Slieker, E. Somer, C. Sur, Z. Xie, K. Marek (Tucson, AZ, USA)

1:15pm-2:45pm: Globus Pallidus and Pedunculopontine Nucleus Oscillations during Executed and Imagined Gait in Patient with Parkinson’s Disease and Freezing of Gait Symptoms.

E. Opri, R. Molina, J. Shute, K. Foote, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:15pm-2:45pm: Gpi DBS for Dystonia in Pediatric Patients

S. Aydın, H. Canaz (Istanbul, Turkey)

1:15pm-2:45pm: Grey matter abnormalities associated with early cognitive decline in Parkinson’s disease

A. Moonen, R. Lopes, A. Leentjens, A. Duits, K. Dujardin (Maastricht, Netherlands)

1:15pm-2:45pm: Head turning onset and velocity in response to a peripheral visual stimulus in cervical dystonia patients, their unaffected relatives with and without abnormal temporal discrimination and healthy controls.

I. Beiser, B. Quinlivan, E. McGovern, L. Williams, S. Narasimham, O. Killian, R. Beck, S. O'Riordan, J. Butler, R. Reilly, M. Hutchinson (Dublin 4, Ireland)

1:15pm-2:45pm: High intensity interval training improves psychomotor function in individuals with Parkinson’s disease

J. Marusiak, B. Fisher, A. Jaskólska, K. Słotwinski, S. Budrewicz, M. Koszewicz, K. Kisiel-Sajewicz, A. Jaskólski (Wroclaw, Poland)

1:15pm-2:45pm: High-Pass Filtered Phase MR Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson’s Disease

A. Martin-Bastida, N. Lao-Kaim, Y. Xing, C. Loane, A. Roussakis, S. Schwarz, N. Valle-Guzman, P. Mahlknecht, X. Li, G. Paul-Visse, H. Widner, M. Politis, T. Foltynie, R. Barker, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Hippocampal iron deposition in Parkinson disease and Parkinson disease with dementia/Lewy body dementia: quantitative susceptibility mapping assessments

M. Miyata, S. Kakeda, J. Moriya, H. Narimatsu, T. Sato, H. Adachi, Y. Wang, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm: History and Management of Status Dystonicus

E. Nerrant, V. GONZALEZ, C. MILESI, T. Roujeau, E. Chan Seng, F. Cyprien, G. Cambonie, P. Coubes, L. CIF (Montpellier, France)

1:15pm-2:45pm: Home-based step training using videogame technology in people with Parkinson’s disease: a randomized controlled trial

J. SONG, S. Paul, M.J. Caetano, S. Smith, L. Dibble, R. Love, D. Schoene, J. Menant, C. Sherrington, S. Lord, C. Canning, N. Allen (Ultimo, NSW, Australia)

1:15pm-2:45pm: How to switch from Entacapone to Opicapone based on BIPARK-I study experience

J. Ferreira, A. Lees, A. Santos, B. Hernandez, F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:15pm-2:45pm: How will new technology change deep brain stimulation programming?

G. Duffley, A. Schiewe, B. Lutz, J. Krüger, M. Okun (Salt Lake City, UT, USA)

1:15pm-2:45pm: Hypertension and Parkinson’s disease

B. Giordano, G. Pagano, J. Hood, N. Ferrara, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Hypometabolism in Orbitofrontal and Perirhinal Cortex is Associated with Impulse Control Disorder in Parkinson´s Disease

I. Navalpotro-Gomez, A. Botas-Peñín, F. Molinet-Dronda, C. Gasca-Salas, M. Carmona-Abellán, H. Jiménez-Urbieta, M. Delgado-Alvarado, A. Quiroga-Varela, B. Gago, M.C. Rodríguez-Oroz (San Sebastian, Spain)

1:15pm-2:45pm: Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC): a Mexican case report.

A. Kleinert-Altamirano, J. Patricio-Villagran, M. Fiesco-Roa, M. Gutierrez-Arriola (Tuxtla Gutierrez, Mexico)

1:15pm-2:45pm: Identification of the optimal carbidopa concentration in subcutaneously administered ND0612

L. Adar, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

1:15pm-2:45pm: Immunomodulatory therapy in stiff-person syndrome (SPS): a controlled Rituximab-randomised study

M. Amarandei (Bucharest, Romania)

1:15pm-2:45pm: Impact of injection interval on patient satisfaction in the routine treatment of cervical dystonia with abobotulinumtoxinA

R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

1:15pm-2:45pm: Impacts of White Matter Hyperintensities on Limit of Stability in Drug-naïve, de novo Patients with Idiopathic Parkinson’s Disease

J.-H. Park, S.-K. Lee, T.-K. Lee (Bucheon-si, Republic of Korea)

1:15pm-2:45pm: Impaired Pain Processing in Functional Dystonia

F. Morgante, A. Matinella, E. Andrenelli, C. Allegra, C. Terranova, P. Girlanda, M. Tinazzi (Messina, Italy)

1:15pm-2:45pm: Impaired sensorimotor and visual networks in drug naive Parkinson’s disease based on graph theoretical analysis

H. Chen (Beijing, China)

1:15pm-2:45pm: Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life

D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow (Birmingham, AL, USA)

1:15pm-2:45pm: Improvement in hand tremor following carpal tunnel release surgery

A. Hollingsworth, S. Wijemanne (San Antonio, TX, USA)

1:15pm-2:45pm: Improvement Observed in Children with combined GPi and VL Thalamus Deep Brain Stimulation for the Treatment of Secondary Dystonia

D. German, T. Sanger (Los Angeles, CA, USA)

1:15pm-2:45pm: Improvement of memory guided saccade amplitude by the STN DBS and target eccentricity

A. YUGETA, Y. TERAO, Y. UGAWA (Tokyo, Japan)

1:15pm-2:45pm: Improvement on gait in Parkinson’s disease patients using Honda stride management assist device

N. Kawashima, M. Matsuhashi, T. Hamano, K. Nagami, T. Furukado, M. Iijima, M. Isogai, M. Komachi, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

1:15pm-2:45pm: Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation

K. Schroeder, M. Fenney, D. Gray, T. Rolph, S. Sohur, V. Todaro (New York, NY, USA)

1:15pm-2:45pm: Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials

S. Ray, A. Madan, D. Burdick, A. Griffith, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm: In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.

P. Fazio, P. Svenningsson, Z. Cselenyi, C. Halldin, L. Farde, A. Varrone (Stockholm, Sweden)

1:15pm-2:45pm: In-patient Parkinson courses and caregiver burden

K. Martikainen, S. Kinos, R. Marttila (Turku, Finland)

1:15pm-2:45pm: Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service

D. Fletcher, E. Thomas, B. Mohamed (Cardiff, United Kingdom)

1:15pm-2:45pm: Increased hippocampal activation in Parkinson’s disease related amnestic mild cognitive impairment

K. Perepezko, A. Gold, A. Bakker, G. Pontone, C. Speck, L. Rosenthal (Baltimore, MD, USA)

1:15pm-2:45pm: Injection guidance use in the management of cervical dystonia with botulinum toxin

D. Charles, T.M. Chung, C. Colosimo, V. Misra, P. Maisonobe, S. Om (Nashville, TN, USA)

1:15pm-2:45pm: Innovative recruitment strategies accelerate enrollment of genetic mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI)

V. Arnedo, S. Lasch, T. Foroud, L. Heathers, J. Martorelli, C. Halter, N. Ryerson, J. Verbrugge, L. Cook, K. Marek (New York, NY, USA)

1:15pm-2:45pm: Inpatient care for stiff person syndrome in the United States: A nationwide readmission study

J. Crispo, D. Thibault, Y. Fortin, A. Willis (Sudbury, ON, Canada)

1:15pm-2:45pm: Intensive Short-Term Dance Intervention in Parkinson’s Disease

D. Rabinovich, J. DeSouza, T. Arakaki, S. Rodriguez Quiroga, V. Litvak, J. Firmani, N. Garreto (Toronto, ON, Canada)

1:15pm-2:45pm: Interactions between amyloid-β and microglial activation in Parkinson’s disease

C. Ghadery, Y. Koshimori, J. Kim, S. Coakeley, M. Harris, L. Christopher, P. Rusjan, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm: Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)

R. Hauser, R. Pahwa, C. Tanner, W. Oertel, S. Isaacson, M.J. Stempien, L. Felt, R. Johnson (Tampa, FL, USA)

1:15pm-2:45pm: Intermuscular and cortico-muscular coherence of patients with writer’s cramp

H. Kumar, S. Choudhury, P. Chatterjee, R. Singh, S. Trivedi, S. Shubham, M. Baker, S. Baker (Kolkata, India)

1:15pm-2:45pm: Intracranial calcifications and dystonia associated with a novel deletion encompassing SLC20A2 and THAP1

L. Tochen, H. Singer, K. Baranano (Washington, DC, USA)

1:15pm-2:45pm: INTREPID Trial: A Prospective, Double blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple-Source, Constant-Current Rechargeable System in Parkinson’s Disease

J. Vitek, R. Jain, P. Starr (Minneapolis, MN, USA)

1:15pm-2:45pm: Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease

A. Negida, Z. Hassan, H. Ahmed, O. Hassan, A. Elsherbiny, S. Azzam, O. Osama, Y. Ibrahim (Zagazig, El-Sharkia, Egypt)

1:15pm-2:45pm: Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study

K. Suzuki, M. Miyamoto, T. Miyamoto, T. Uchiyama, Y. Watanabe, T. Kadowaki, K. Hirata (Mibu, Japan)

1:15pm-2:45pm: Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

1:15pm-2:45pm: Levodopa effect and motor function in late stage Parkinson’s disease

K. Rosqvist, P. Odin, M. Horne, P. Hagell, S. Iwarsson, M. Nilsson (Lund, Sweden)

1:15pm-2:45pm: Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.

N. Malek, M. Lawton, K. Grosset, N. Bajaj, R. Barker, Y. Ben-Shlomo, D. Burn, T. Foltynie, J. Hardy, H. Morris, N. Williams, N. Wood, D. Grosset (Ipswich, United Kingdom)

1:15pm-2:45pm: Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study

N. Kovacs, A. Juhász, Z. Aschermann, P. Ács, J. Janszky, M. Kovács, A. Makkos, M. Harmat, D. Tényi, K. Katádi, S. Komoly, A. Takáts, A. Tóth, H. Nagy, P. Klivényi, G. Dibó, L. Dézsi, D. Zádori, Á. Annus, L. Vécsei, L. Varannai (Pécs, Hungary)

1:15pm-2:45pm: Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease

A. Greuel, M. Tahmasian, F. Schwartz, S. Aschenberg, F. Maier, L. Timmermann, A. Drzezga, M. Tittgemeyer, C. Eggers (Cologne, Germany)

1:15pm-2:45pm: Long-Term Dopamine Transporter Imaging and Clinical Effects of the Mixed-Lineage Kinase Inhibitor CEP-1347 in the PRECEPT Parkinson Trial

I. Shoulson, S.E. Eberly, D. Oakes, A. Lang, M. Schwarzschild, C. Tanner, J. Seibyl, K. Marek (Washington, DC, USA)

1:15pm-2:45pm: Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

H. Todo (Sanda, Japan)

1:15pm-2:45pm: Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease

W. Li, N. Lao-Kaim, A.-A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Longitudinal Cortical Thickness Changes in GBA-Positive Relative to GBA-negative Parkinson’s Disease Patients with Hemiparkinsonism

I. Stankovic, N. Kresojevic, F. Agosta, V. Markovic, E. Sarasso, P. Valsasina, I. Petrovic, M. Filippi, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Longitudinal white matter microstructural change in Parkinson’s disease

C. Gallagher, V. Pozorski, J. Oh, F. Theisen, N. Adluru, A. Alexander (Madison, WI, USA)

1:15pm-2:45pm: Management of fragility fractures in Parkinson’s Disease (PD)

G. Alg, A. Chatterjee (Reading, United Kingdom)

1:15pm-2:45pm: Manual and Verbal guidance during the balance training based in virtual reality is essential for therapeutic results in people with Parkinson’s disease: a randomized clinical trial

M.E. Pimentel Piemonte, A. Falconi, M. D"Alencar, E. Okamoto (Sao Paulo, Brazil)

1:15pm-2:45pm: Marc Chagall’s L’homme à La Tète Renversée (Man with His Head Thrown Back) – An Artistic Depiction of Severe Retrocollis in Neurodegeneration with Brain Iron Accumulation

L. Oliveira, M. Caeira, F. Germiniani, H. Teive, T. Roza, C.H. Camargo (Curitiba, Brazil)

1:15pm-2:45pm: Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease

K. Kashihara, M. Kitayama, T. Hamaguchi (Okayama, Japan)

1:15pm-2:45pm: Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series

D.H. Kim, D.H. Kim, J.J. Choi, B.J. Park (Daejeon, Republic of Korea)

1:15pm-2:45pm: Medically refractory paroxysmal kinesigenic dyskinesia in a 7 year old with a novel PRRT2 mutation

K. Chillag, E. Chillag (Wyoming, MI, USA)

1:15pm-2:45pm: Metabolic changes following transcranial magnetic resonance-guided focused ultrasound subthalamotomy

R. Rodriguez-Rojas, R. Martinez-Fernandez, J. Pineda-Pardo, C. Sanchez-Catasus, M. del Alamo, J. Obeso (Mostoles, Spain)

1:15pm-2:45pm: Mirror dysonia in writer`s aramp: a study with advanced multi-channel micro-electrode recording EMG system

V. Rama Raju, R. Borgohain, R. Kandadai (Hderabad, IN, India)

1:15pm-2:45pm: MitoQ and Reduced Glutathione Protects Against Dopamine Induced Brain Mitochondrial Electron Transport Chain Inhibition During Extended In Vitro Incubation: Involvement of Free Radicals and Quinone Products

A. MAITI (Bengaluru, India)

1:15pm-2:45pm: Modulation of executive motor network after neurofeedback training in Parkinson’s disease

N. Smulders, D. Mehler, L. Subramanian, D. Linden, J. Whittaker (Cardiff, United Kingdom)

1:15pm-2:45pm: Morphometric changes in Parkinson’s disease manifesting freezing of gait

S. Pietracupa, A. Suppa, N. Upadhyay, A. Zampogna, F. Di Biasio, G. Grillea, N. Modugno, G. Fabbrini, A. Berardelli, P. Pantano (Pozzilli, Italy)

1:15pm-2:45pm: Motor and Body Composition Variables by Parkinson’s Disease Staging

L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

1:15pm-2:45pm: Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study

M. Stacy, V. Biton, J. Aldred, A. Ellenbogen, R. Rubens, N. Modi, A. Mittur, S. Khanna, S. Gupta (Durham, NC, USA)

1:15pm-2:45pm: Motor Heterogeneity in Parkinson’s Disease: A Bayesian Perspective

A. Johnson, A. Loftus, N. Gasson, B. Lawrence, M. Thomas, R. Bucks (Perth, Australia)

1:15pm-2:45pm: Motor stress elicits dystonia-like movements in a pharmacological mouse model for Rapid-Onset Dystonia-Parkinsonism (DYT12)

L. Rauschenberger, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

1:15pm-2:45pm: Movement disorder specialists’ determination of eligibility for device aided treatment in advanced Parkinson’s disease: Results from the OBSERVE-PD study

A. Fasano, K. Seppi, V.SC. Fung, J.C. Parra, L. Bergmann, A. Yegin, K. Sail, Y. Jalundhwala, K. Onuk (Toronto, ON, Canada)

1:15pm-2:45pm: Movement Disorders in Demyelinating Diseases: a retrospective review from a tertiary academic center.

G. Suarez-Cedeno, M. Raja (Houston, TX, USA)

1:15pm-2:45pm: Moxibustion for Parkinson’s disease: a systematic review of randomized controlled trials

T.-H. Kim, S. Kwon, W.-S. Jung, S.-K. Moon, C.-N. Ko, S.-Y. Cho, C.-Y. Jun, S.-H. Lee, K.-H. Cho (Seoul, Republic of Korea)

1:15pm-2:45pm: Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

1:15pm-2:45pm: Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI

K. Schindlbeck, A. Vo, Y. Ma, S. Peng, K. Poston, H. Hurtig, N. Dahodwala, D. Eidelberg (Manhasset, NY, USA)

1:15pm-2:45pm: Multidisciplinary intensive outpatient rehabilitation program for patients with advanced Parkinson’s disease: feasibility and primary proof of concept

T. Gurevich, T. GAIL, n. choen, o. KADURRI, L. SHTRAIFLER, I. BADICHI, N. RIPS CASSERI (tel aviv, Israel)

1:15pm-2:45pm: Multiple Neural Networks dysfunction in Primary Blepharospasm: An Independent Components Analysis Study

X. Huang, Z.-h. Liang, M.-r. Zhu (Dalian, China)

1:15pm-2:45pm: ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD

N. Giladi, Y. Caraco, T. Gurevich, R. Djaldetti, L. Adar, T. Rachmilewitz Minei, S. Oren (Tel Aviv, Israel)

1:15pm-2:45pm: ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

1:15pm-2:45pm: Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study

H. Bejr-kasem, J. Pagonabarraga, S. Martinez-Horta, F. Sampedro, J. Marin-Lahoz, J. Perez-Perez, A. Horta-Barba, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Neural correlates of movement sequence kinematics in substantia nigra dopaminergic cells

M. Mendonça, J. Alves Silva, L. Hernandez, J. Obeso, R. Costa (Lisboa, Portugal)

1:15pm-2:45pm: Neural Correlates Underlying Reward Processing and Decision-Making in Impulse Control Disorder in Parkinson´s Disease

I. Navalpotro-Gomez, P. Paz-Alonso, P. Boddy, M. Delgado-Alvarado, H. Jimenez-Urbieta, A. Quiroga-Varela, B. Gago, M. Carreiras, M.C. Rodriguez-Oroz (San Sebastian, Spain)

1:15pm-2:45pm: Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease

N. Lakkappa, P. Thaggikuppe Krishnamurthy, P.D. Mirazkar, N. Lakkappa, P. Krishnamurthy, P.M.D., M.M. Srinivas Bharath, B. Hammock, S.H. Hwang (Udhagamandalam, India)

1:15pm-2:45pm: New method to evaluate new motor skill learning

A.P. Quixadá, V. Sotero, J.-F. Daneault, G. Diaz, Â. Torres, J.P. Vieira, M. Fonseca, P. Bonato, N. Peña, J.G. Miranda (Salvador, Brazil)

1:15pm-2:45pm: Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

1:15pm-2:45pm: Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats

R. Deshmukh, S. Singh (Moga, India)

1:15pm-2:45pm: Non motor symptoms in patients with Writer’s cramp

R. Singh, P. Chatterjee, S. Choudhury, S. Anand, S. Shubham, S. Trivedi, H. Kumar (Kolkata, India)

1:15pm-2:45pm: Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease

F. Niccolini, H. Wilson, B. Giordano, K. Diamantopoulos, G. Pagano, K. Ray Chaudhuri, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients

M. Qamar, A. Sauerbier, A. Rizos, K. Chaudhuri (London, United Kingdom)

1:15pm-2:45pm: Noninvasive cerebellar stimulation for adults with cervical dystonia

A. McCambridge (Sydney, Australia)

1:15pm-2:45pm: NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders

E. Dellapina, V. Chaigneau, F. Durif, J.-C. Corvol, O. Rascol, F. NS-PARK/FCRIN network (Toulouse, France)

1:15pm-2:45pm: NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy

B. Balint, G. Charlesworth, M. Stamelou, L. Carr, N. Wood, K. Bhatia (London, United Kingdom)

1:15pm-2:45pm: Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients

D. Woitalla, M. Asgharnejad, L. Joeres, J.-C. Schuller, K.R. Chaudhuri (Bochum, Germany)

1:15pm-2:45pm: Ocular Motor Disorders Among Filipino “LUBAG” or X-Linked Dystonia Parkinsonism (XDP) Patients

M. Macas, E.C. Rossi, S. Abantas-Diamla, A. Punzalan-Sotelo, E. Palisoc, C. Go (Manila, Philippines)

1:15pm-2:45pm: Oculogyric Crisis Due to Treatment With flunarizine

M. Kurtz, D. Ballesteros, J. Crespo, J. Perez Garcia, J. Lopez, I. Lagger, F. Knorre (CF, Argentina)

1:15pm-2:45pm: Olfactory Impairment in Parkinson’s Disease and White Matter Abnormalities in Central Olfactory Areas

S. Sobhani, M. Aarabi (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: ON-time evolution following one-year open-label opicapone: BIPARK-I study

J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, I. Oliveira, B. Hernandez, F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:15pm-2:45pm: Open label study of cannabidiol in Parkinson disease

M. Leehey, Y. LIU, C. EPSTEIN, F. HART, J. BAINBRIDGE, M. COOK, S. SILLAU, Z. BAUD, H. NEWMAN (AURORA, CO, USA)

1:15pm-2:45pm: Optimization and evaluation of whole body MRI sequences for patients with deep brain stimulators

C. Drews, S. Wolff, L. Lunden, O. Jansen (Kiel, Germany)

1:15pm-2:45pm: Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)

S. Factor, M. Silver, J. Hanfelt, E. Sperine, L. Scorr, A. Freeman, H. Jinnah (Atlanta, GA, USA)

1:15pm-2:45pm: Oscillatory Activity in the Nucleus Basalis of Meynert

M. Nazmuddin, D. Oterdoom, J. van Zijl, A. Kampman, J. van Dijk, G. Drost, T. van Laar, M. Beudel (Groningen, Netherlands)

1:15pm-2:45pm: Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, A. Kühn, L. Timmermann, M. Pötter-Nerger, P. Eldridge, J. Volkmann, J. Fitzgerald, A. Schnitzler, H. Mehdorn, J. Vesper (Kiel, Germany)

1:15pm-2:45pm: Palmaris Brevis Spasm:A rare cause of paediatric movement disorder

T. Yeo, A. Yacoob (Singapore, Singapore)

1:15pm-2:45pm: Parkinson’s disease with visual hallucination: optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

M. Miyata, S. Kakeda, T. Yoneda, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm: Parkinsonics – A Prospective, Randomized, Blinded, Cross-Over Trial of Group Singing for Motor and Non-Motor Symptoms in Idiopathic Parkinson Disease (PD)

A. Butala, A. Swaminathan, S. Dunlop, Y. Salnikova, B. Ficek, B. Portnoff, M. Harper, B. Vernon, Z. Mari, A. Pantelyat (Baltimore, MD, USA)

1:15pm-2:45pm: Patient Engagement in Parkinson’s Research: A Comparison of Attitudes and Impact in the UK and the US

V. Todaro, C. Nolan, K. Schroeder, I. Abbey-Vital, M. Feeney (New York, NY, USA)

1:15pm-2:45pm: Patient perspectives of using the ND0612 mini-pump

S. Nash, M. Gera, E. Shor, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

1:15pm-2:45pm: Patients affected by functional motor symptoms are not liars: an experimental deception study with the Guilty Knowledge Task

B. Demartini, R. Ferrucci, D. Goeta, F. Ruggiero, A. Priori, O. Gambini (Milano, Italy)

1:15pm-2:45pm: Pattern and Predictors Of Tremor In Patients With Primary Dystonia

R. Rajan, S. Zafer, S. Krishnan, A. Kishore (Trivandrum, India, India)

1:15pm-2:45pm: Patterns of Striatal DAT Binding Loss in a Progressing Parkinson Disease (PD) Cohort: Four year PPMI Follow-up

J. Seibyl, K. Marek (New Haven, CT, USA)

1:15pm-2:45pm: Persistent L-Dopa Responsive Hemiparkinsonism After Cryptococcoal Meningoencephalitis in an Immunocompetent Man

G. Fabiani, R. Filho, F. Germiniani, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)

L. Adar, T. Rachmilewitz Minei, Y. Cohen, S. Oren (Rehovot, Israel)

1:15pm-2:45pm: Physical activity habits in early Parkinson’s disease and healthy controls

A. Amara, N. Seedorff, L. Chahine, K. Kieburtz, C. Caspell-Garcia, T. Simuni (Birmingham, AL, USA)

1:15pm-2:45pm: Physical Activity in Early Parkinson Disease

S. Mantri, M. Fullard, J. Duda, J. Morley (Philadelphia, PA, USA)

1:15pm-2:45pm: Physical Mobility Predictors and the Bone Health in Parkinson’s Disease

L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

1:15pm-2:45pm: Pilot evaluation of pseudoelastic orthoses for supporting motor control in children with secondary dystonia and dyskinesia

L. Garavaglia, E. Pagliano, M.T. Arnoldi, R. Zanin, M.A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

1:15pm-2:45pm: Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión

F. Carrillo, S. Jesus, L. Vargas, M. Bernal, M.T. Caceres, A.D. Adarmes, M. Carballo, P. Mir (Seville, Spain)

1:15pm-2:45pm: Post-hoc analyses of the recommended starting dose for Rytary based on “off” time

N. Modi, S. Khanna, S. Gupta (Hayward, CA, USA)

1:15pm-2:45pm: Post-movement beta rebound inhibits future movement

E. Rhodes, A. Kharko, W. Gaetz, S. Hall (Plymouth, United Kingdom)

1:15pm-2:45pm: Postural control is maintained after a 8-months period of exercise in people with Parkinson’s disease

L. Gobbi, N. Rinaldi, P. Pelicioni, E. Lirani-Silva, L. Moraes, M. Pereira (Rio Claro, Brazil)

1:15pm-2:45pm: Postural Instability is a Predictor for Driving Cessation Among Parkinson’s Disease Drivers: A Study of a Computer-Based 3D Driving Simulator.

O. Jitkritsadakul, S. Krootjohn, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:15pm-2:45pm: Pregnancy and Parkinson’s disease: A review and update

M. Seier, A. Hiller (Portland, OR, USA)

1:15pm-2:45pm: Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.

S. Ray, D. Burdick, A. Griffith, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm: Prevalence of Babinski-2 sign in Hemifacial Spasm Patients

O. Dogu, H. Kalegasi (Mersin, Turkey)

1:15pm-2:45pm: Prevelance,clinical pathology and Treatment of Dystonia in Pakistani Population

S. Naureen, A. Arshad, N. Ahmad (RAWALPINDI, Pakistan)

1:15pm-2:45pm: Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease

K. Chung, B. Lobb (Portland, OR, USA)

1:15pm-2:45pm: Prognosis and end-of-life status after emergency admissions in patients with Parkinson disease: a Japanese single center retrospective study

K. Ikeda, K. Takahashi, K. Kawasaki, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Araki, T. Yamamoto (Iruma-gun, Saitama-ken, Japan)

1:15pm-2:45pm: Programming of deep brain stimulators in Parkinson’s disease with early motor complications (EARLYSTIM-study)

K. Knudsen, J.-L. Houeto, P. Krack, J. Rau, C. Schade-Brittinger, A. Schnitzler, W.M.M. Schuepbach, L. Timmermann, L. Tonder, G. Deuschl (Kiel, Germany)

1:15pm-2:45pm: PROMESA: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach – evaluation of serious adverse events

M. Schuberth, J. Levin, S. Maaß, G. Respondek, K. Bötzel, G. Höglinger (Muenchen, Germany)

1:15pm-2:45pm: Proprioceptive Focal Stimulation (Equistasi®) may improve gait in severe Parkinson’s disease patients. Gait Analysis double-blind, double-dummy randomized study

A. Peppe, S. Paravati, g. Chini, P. Paone (Roma, Italy)

1:15pm-2:45pm: Prospective Analysis of Morphological Markers of Development of Impulsive Compulsive Behaviors in De Novo Parkinson’s Disease

L. Ricciardi, C. Lambert, R. De Micco, F. Morgante, M. Edwards (London, United Kingdom)

1:15pm-2:45pm: Quantitative demonstration of the efficacy of rotigotine transdermal patch in the treatment of nocturnal hypokinesia: A randomized, placebo-controlled trial using an axial inertial sensor

R. Bhidayasiri, J. Sringean, S. Chaiwong, C. Anan, K. Boonpang, K. Sakdisornchai, O. Jitkritsadakul, P. Jagota (Bangkok, Thailand)

1:15pm-2:45pm: RAB12 variants and their role in dystonia

K. Lohmann, E. Hebert, F. Borngräber, A. Schmidt, A. Rakovic, A. Weissbach, J. Hampf, E.-J. Vollstedt, S. Schaake, H. Manzoor, H.-C. Jabusch, M. Kasten, V. Kostic, T. Gasser, K. Zeuner, P. Bauer, E. Altenmüller, C. Klein (Luebeck, Germany)

1:15pm-2:45pm: Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

T.G. Study Group (Bristol, United Kingdom)

1:15pm-2:45pm: Rationale and Design of a Phase 2 Study to Evaluate the Efficacy of Intepirdine (RVT-101) in Improving Gait and Balance in Patients with Dementia

S. Ramaswamy, N. Bohnen, M. Muller, I. Lombardo, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

1:15pm-2:45pm: Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of DBS for Parkinson’s disease

G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, M. Pötter-Nerger, L. Timmermann, J. Volkmann, A. Kühn, P. Eldridge, J. Fitzgerald, H. Mehdorn, J. Vesper (Kiel, Germany)

1:15pm-2:45pm: Regional differences may influence the drivers of change in Toronto Western Spasmodic Rating Scale (TWSTRS) scores following botulinum toxin treatment: Analysis of an international observational study

V. Misra, D. Charles, T.M. Chung, C. Colosimo, S. Om, P. Maisonobe (London, United Kingdom)

1:15pm-2:45pm: Rehabilitation program with or without a whey protein-based nutritional support enriched with essential aminoacids and vitamin D in patients with Parkinson’s disease or parkinsonism: study design of a randomized, controlled trial.

m. barichella, E. Cereda, G. Pinelli, l. Iorio, V. Ferri, g. Frazzitta, E. Cassani, G. Riboldazzi, G. Pezzoli (Milano, Italy)

1:15pm-2:45pm: Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease

M. Iijima, H. Yoshizawa, Y. Uchiyama, K. Abe, K. Kitagawa (Tokyo, Japan)

1:15pm-2:45pm: Research on Relationship between Sensory Tricks of Cervical Dystonia and Function of Cerebral Cortex

T. Li, Z. Liang, C. Song, L. Zhou, L. Jing (Dalian, China)

1:15pm-2:45pm: Resting state functional connectivity in PD patients with and without Freezing of gait

K. Bharti, A. Suppa, N. Upadhyay, S. Pietracupa, G. Leodori, A. Zampogna, C. Gianni, N. Petsas, A. Berardelli, P. Pantano (Rome, Italy)

1:15pm-2:45pm: Resting state modulations of EEG low frequency bands in Parkinson’s disease.

A. Pal, N. Mehta, R. Sharma (New Delhi, India)

1:15pm-2:45pm: Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

1:15pm-2:45pm: Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa

C. Zadikoff, J. Boyd, S. Dubow, L. Bergmann, W. Robieson, H. Ijacu, J. Benesh (Chicago, IL, USA)

1:15pm-2:45pm: Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study

S. Isaacson, R. Hauser, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinksi, B. Dzyngel, A. Agro, H. Fernandez (Boca Raton, FL, USA)

1:15pm-2:45pm: Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study

T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

1:15pm-2:45pm: Self Perception of Dysphagia in Parkinson Disease

A. Silbergleit, C. Sidiropoulos, R. Konnai, L. Schultz, A. Kitowski, P. LeWitt (West Bloomfield, MI, USA)

1:15pm-2:45pm: Self-assessed psychological symptoms, fatigue and depersonalization in dystonia

R. Newby, J. Alty, S. Jamieson, S. Smith, P. Kempster (Melbourne, Australia)

1:15pm-2:45pm: Sensory trick in a dystonic patient: insights from Magnetoencephalogram

A. Mahajan, A. Zillgitt, S. Bowyer, C. Sidiropoulos (Detroit, MI, USA)

1:15pm-2:45pm: Sentence comprehension in Slovak speaking patients with Parkinson´s disease – preliminary results

A. Kušnírová, J. Marková, Z. Košutzká, M. Egryová, M. Pápayová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:15pm-2:45pm: Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study

A. Maillet, E. Météreau, E. Favre, E. Lhommée, H. Klinger, D. Le Bars, A. Castrioto, V. Sgambato-Faure, L. Tremblay, E. Broussolle, P. Krack, S. Thobois (Lyon, France)

1:15pm-2:45pm: Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study

A.-A. Roussakis, N. Lao-Kaim, A. Martin-Bastida, N. Valle-Guzman, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Signal intensity of cerebral gyri in corticobasal degeneration on phase difference enhanced MR images: Comparison with progressive supranuclear palsy and Parkinson’s disease

M. Miyata, S. Kakeda, T. Yoneda, S. Ide, K. Watanabe, J. Moriya, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm: Sleep disturbance may alter white matter and resting state functional connectivities in Parkinson’s disease

S.J. Chung, Y.-H. Choi, H. Kwon, Y.-H. Park, H.J. Yun, H.S. Yoo, Y.H. Sohn, J.-M. Lee, P.H. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).

C. Olanow, K. Kieburtz, N. Livnah (New York, NY, USA)

1:15pm-2:45pm: Social importance of care and rehabilitation in restoring of psycho-emotional and movement deficits in Parkinsonism.

M. Sanoeva, M. Gulova, M. Avezova, N. Mansurova (Bukhara, Uzbekistan)

1:15pm-2:45pm: Somatosensory Mismatch Negativity is abnormal in Cervical Dystonia.

J.-C. CHEN, M. Edwards, J. Rothwell, A. Macerollo (Taichung city, Taiwan)

1:15pm-2:45pm: Some clincal features of movement disorders after cerebral anoxia.

B. Tserensodnom (Ulaanbaatar, Mongolia)

1:15pm-2:45pm: SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

A.-A. Roussakis, D. Towey, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson’s disease

S. Polychronis, F. Niccolini, G. Pagano, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Spinal cord stimulation as therapeutic option in gait disorder in Parkinson disease.

H. Cécile, D'H. Vincent, B.M. MALEK, p.-k. nathalie, t. Jean-Batiste, Z. MARC, B. Jean-Philippe (PARIS, France)

1:15pm-2:45pm: Stiff-limb syndrome with cerebellar features and atypical EMG findings responds to IVIG

S. Rametta, G. Robinson, N. Hellmers, N. Jacoby, H. Sarva (Brooklyn, NY, USA)

1:15pm-2:45pm: Striatal Cholinergic Neurons in Cervical Dystonia

K. Mente, N. Edwards, D. Pratt, D. Iacono, D. Urbano, A. Ray-Chaudhury, M. Hallett (Bethesda, MD, USA)

1:15pm-2:45pm: Striato-cortical connections in Parkinson’s and Alzheimer’s diseases: relation to cognition

I. Rektorova, L. Anderkova, M. Barton (Brno, Czech Republic)

1:15pm-2:45pm: Structural and Functional Correlates of Anxiety in Parkinson’s disease.

F. Růžička, T. Ballarini, O. Bezdíček, J. Roth, T. Sieger, J. Vymazal, E. Růžička, K. Mueller, R. Jech (Prague, Czech Republic)

1:15pm-2:45pm: Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.

C. Lambert, O. Williams, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)

1:15pm-2:45pm: Study Design for a Multi-Modal Approach to Understanding Parkinson’s Disease: The Personalized Parkinson Project

W. Marks, Jr., L. Evers, M. Faber, M. Verbeek, N. de Vries, B. Bloem (South San Francisco, CA, USA)

1:15pm-2:45pm: Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)

C.W. Olanow, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro (New York, NY, USA)

1:15pm-2:45pm: Study in Parkinson’s Disease of Exercise (SPARX): A Randomized, Controlled Futility Trial

D. Corcos, C. Moore, W. Kohrt, D. Hall, A. Delitto, C. Comella, D. Josbeno, C. Christiansen, B. Berman, B. Kluger, E. Melanson, S. Jain, J. Robichaud, C. Poon, M. Schenkman (Chicago, IL, USA)

1:15pm-2:45pm: Subcortical local shape volume analysis of progressive mild cognitive impairment in Parkinson`s disease

S.J. Chung, J.-H. Shin, K.h. Cho, Y. Lee, H.S. Yoo, S.J. Chung, Y.H. Sohn, J.-K. Seong, P.H. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease

M. Fabbri, S. Reimão, M. Carbalho, R. Nunes, D. Abreu, L. Guedes, R. Bouça, P. Lobo, C. Godinho, M. Coelho, N. Gonçalves, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

1:15pm-2:45pm: Substantial psychiatric symptoms, sleep disturbances and reduced quality of life in well-treated adult patients with GTP-cyclohydrolase deficient dopa-responsive dystonia

A. Kuiper, E. Timmers, M. Smit, T. De Koning, M. Tijssen (Groningen, Netherlands)

1:15pm-2:45pm: Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis

M. Hacker, M. Turchan, A. Currie, L. Heusinkveld, S. Millan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

1:15pm-2:45pm: Swallowing difficulties and Parkinson’s disease

S. Polychronis, G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Syndenham’s chorea in Senegalese children: A case series

F.S. NGOUNGOURE HALIMA, M. NDIAYE, A.D. SOW, B. SECK, M.M. NDIAYE (Dakar, Senegal)

1:15pm-2:45pm: Tandem Standing

E. Okuyucu, E. Dogru Huzmeli, S. Colakoglu Yesildag, I. Huzmeli (Hatay, Turkey)

1:15pm-2:45pm: The brain plasticity for controlling reach-to-grasp functions of Parkinson’s disease

J. Tretriluxana, S. Tretriluxana, J. Thanakamchokchai, A. Nanbancha, A. Pisarnpong (Nakhon Pathom, Thailand)

1:15pm-2:45pm: The combination of clinical scales and walking measures to predict falls in Parkinson’s disease: Does the length of the prospective follow-up period matter?

R. Vitório, R. Moraes, A. Baptista, E. Lirani-Silva, L. Simieli, D. Orcioli-Silva, F. Barbieri, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm: The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.

S. Tada, H. Ohtsubo, Y. Yamanishi, N. Miyaue, R. Ando, H. Yabe, N. Nishikawa, M. Nagai, M. Miyagawa, M. Nomoto (Ehime, Japan)

1:15pm-2:45pm: The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine

K. Romero, D. Conrado, B. Corrigan, K. Tsai, M. Ahamadi, S. Macha, V. Sinha, I. Watson, M. Bani, P. Muglia, V. Kern, C. Williams-Gray, D. Grosset, M. Hu, D. Burn, R. Lawson, K. Marek, A. Roach, D. Stephenson, T. Nicholas (Tucson, AZ, USA)

1:15pm-2:45pm: The effect of dance and Nordic Walking on balance, gait and motor function in Parkinson’s disease

J. Stożek, M. Rudzińska, I. Staszczak-Gawełda, A. Stenwak, K. Świątek, S. Podsiadło, U. Pustułka-Piwnik, A. Szczudlik (Krakow, Poland)

1:15pm-2:45pm: The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)

M. Barbe, L. Tonder, F. Sixel-Döring, B. Debû, L. Timmermann, A. Schnitzler, C. Schade-Brittinger, J. Rau, P. Krack, J.-L. Houeto, M. Schüpbach, G. Deuschl (Cologne, Germany)

1:15pm-2:45pm: The effect of expectation on Parkinson’s Disease: an EEG study

E. Carlino, A. Piedimonte, G. Guerra, A. Romagnolo, E. Frisaldi, S. Vighetti, L. Lopiano (Turin, Italy)

1:15pm-2:45pm: The effects of wearing usual indoor and outdoor footwear on balance and gait performance in people with Parkinson’s disease using clinical tests and instrumented movement analysis.

D. Kunkel, M. Burnett, L. Mamode, R. Pickering, C. Bowen, D. Bader, J. Robison, M. Donovan-Hall, M. Cole, A. Ashburn (Southampton, United Kingdom)

1:15pm-2:45pm: The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, M. Nomoto (Ehime, Japan)

1:15pm-2:45pm: The Importance of Ultrasonographic Evaluation in the Diagnosis of Dysphagia in Parkinson Disease

E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, B. Gonenli, A. Cakci (Ankara, Turkey)

1:15pm-2:45pm: The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study

S. Liu_Shu-Ying@hotmail.com, D. Wile, J. Fu, J. Valerio, E. Shahinfard, S. McCormick, R. Mabrouk, N. Vafai, J. McKenzie, N. Neilson, A. Perez-Soriano, J. Arena, M. Cherkasova, J. Zhang, C. Zabetian, J. Aasly, Z. Wszolek, M. McKeown, V. Sossi, A. Stoessl (Beijing, China)

1:15pm-2:45pm: The involvement of primary olfactory cortex in olfactory deficits in early-stage Parkinson’s disease

J. Wang, T. Subramanian, Q. Yang (Hershey, PA, USA)

1:15pm-2:45pm: The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016

K. Wyant, E. Yasuda, V. Kotagal (Ann Arbor, MI, USA)

1:15pm-2:45pm: The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)

1:15pm-2:45pm: The occurrence of dopamine-responsive and dopamine-resistant resting tremor in Parkinson’s disease

H. Zach, M. Dirkx, D. Roth, j. Pasman, B. Bloem, R. Helmich (Nijmegen, Netherlands)

1:15pm-2:45pm: The prevalence of cerebral microbleeds in patients with Parkinson’s disease and multiple system atrophy

J.-M. Kim (Seongnam, Republic of Korea)

1:15pm-2:45pm: The Pull Test in healthy subjects and Parkinson´s disease: quantitative pull-force measure, postugraphic and electromyographic analysis

J.R. Perez-Sanchez, B. DeLaCasa-Fages, A. Contreras, J.M. Velázquez, A. Muñoz-González, F. Grandas (Madrid, Spain)

1:15pm-2:45pm: The Putamen to Caudate Nucleus Ratio: A Simple Surrogate Marker for Dopaminergic Volume in Putamen

J.J. Lee, Y.H. Sohn (Goyang-si, Republic of Korea)

1:15pm-2:45pm: The Relative Preservation of the Dopaminergic Neuroal Loss of Patients with Parkinson’s Disease Having Dopamine-Unresponsive Resting Tremor

S. You, H.W. Kim (Daegu, Republic of Korea)

1:15pm-2:45pm: The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report

A. Tran, M. Amin, R. Burns (Phoenix, AZ, USA)

1:15pm-2:45pm: The role of phosphodiesterase 4 in sleep disturbances in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, M. Mehta, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)

1:15pm-2:45pm: The spectrum of Pantothenate kinase-associated neurodegeneration.A view from seven cases Cohort.

E. Guartazaca Guerrero, J. Llibre Guerra, A. Soto Lavastida, A. Rodriguez Salgado, G. Bringas, J. Diaz Marante (Cuenca, Ecuador)

1:15pm-2:45pm: The Use of Atypical Antipsychotics in Depression and Anxiety may Unmask Parkinson’s Disease: A Retrospective Chart Review

K. Amodeo, R. Schneider, I. Richard (Rochester, NY, USA)

1:15pm-2:45pm: The Volatility of Local Field Potential Oscillations in Dystonia and Parkinson’s disease

D. Pina Fuentes, J. van Zijl, J.-W. Elting, G. Drost, M. van Egmond, M. Oterdoom, M. Tijssen, M. van Dijk, M. Beudel (Groningen, Netherlands)

1:15pm-2:45pm: Towards a reappraisal of Status Dystonicus : a cohort study

X. VASQUES, E. Nerrant, V. GONZALEZ, C. MILESI, N. MENJOT, G. CAMBONIE, J. PEREZ, A. Bonafe, P. Coubes, L. CIF (Montpellier, France)

1:15pm-2:45pm: Towards Responsive Deep Brain Stimulation for Medically Refractory Freezing of Gait in Parkinson’s Disease

R. Molina, J. Shute, E. Opri, K. Sowalsky, J. Roper, D. Martinez-Ramirez, K. Foote, C. Hass, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:15pm-2:45pm: Tozadenant phase 3 study (TOZ-PD) in Parkinson’s disease patients with motor fluctuations: baseline characteristics

K. Kieburtz, W. Olanow, J. Krishnaswami, C. Resburg, F. Kerwood, C. Kenney (Rochester, NY, USA)

1:15pm-2:45pm: Transcranial direct current stimulation enhances consolidation of learning in Parkinson’s disease

S. Broeder, E. Nackaerts, E. Heremans, K. Cuypers, R. Meesen, G. Verheyden, A. Nieuwboer (Leuven, Belgium)

1:15pm-2:45pm: Treatment of back pain in patient with extensor truncal dystonia with lumbar radiofrequency ablation (RFA)

S. Giles, N. Shneyder, J. Cupido, C. Brock, E. Gaitour (Jacksonville, FL, USA)

1:15pm-2:45pm: Treatment of Functional Neurological Disorders: Towards Expert Consensus Led Guidelines for the American Neuropsychiatric Association Committee for Research

O. Ghaffar, M. Modirrousta, C. LaFrance, N. Williams, R. Shura, S. Ducharme, V. Voon (Whitby, ON, Canada)

1:15pm-2:45pm: Tremor’s Glove – An Innovative Electrical Muscle Stimulation Therapy to Treat Intractable Tremor in Parkinson’s Disease Patients: A Randomized Sham-Controlled Trial

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:15pm-2:45pm: Trisomy 8 Mosaicism and dystonia: a THAP1 overdose?

A. Fois, M. Tchan, V. Fung (Westmead, Australia)

1:15pm-2:45pm: Two sides of a Rare Coin- First report of Rapid onset dystonia-parkinsonism (RDP) and Alternating Hemiplegia of Childhood (AHC) with paroxysmal dystonia from India.

P. Agarwal, S. Ravat (Mumbai, India)

1:15pm-2:45pm: U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson’s disease

A. Metcalfe, S. Udow, H. Sharmarke, Z. Shirzadi, D. Long, S. Duff-Canning, C. Marras, A. Lang, B. MacIntosh, M. Masellis (Toronto, ON, Canada)

1:15pm-2:45pm: Understanding neural activation in semantic fluency in Parkinson’s disease with mild cognitive impairment

J.H. Julia, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

1:15pm-2:45pm: Using an Objective Measure of Movement to Quantify Night Time Sleep

P. Farzanehfar, P. Churchward, M. Horne (Parkville, Australia)

1:15pm-2:45pm: Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism

M. Salgado, D. Panebianco, J. Muller, A. Ortega, S. (Brooklyn, NY, USA)

1:15pm-2:45pm: Utility of susceptibility weighted imaging in the objective diagnosis of idiopathic Parkinson’s Disease: Is DaTscan necessary?

R. Ellis, M. Radon, M. Bonello, M. Steiger (Liverpool, United Kingdom)

1:15pm-2:45pm: Validation of the MDS Research Criteria for Prodromal Parkinson’s Disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort

S.-M. Fereshtehnejad, J. Montplaisir, A. Pelletier, J.-F. Gagnon, D. Berg, R. Postuma (Montreal, QC, Canada)

1:15pm-2:45pm: Vascular hemiballismus due to a lentiform nucleus infarct

D. Gams Massi, J. Nyassinde, K. Toure, N.S. Diagne, M. Ndiaye, A.G. Diop, M.M. Ndiaye (Dakar, Senegal)

1:15pm-2:45pm: Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis

C. Tarolli, K. Andrzejewski, M. Bull, S. Goldenthal, M. O'Brien, T. Simuni, G. Zimmerman, K. Biglan, E.R. Dorsey (Rochester, NY, USA)

1:15pm-2:45pm: Vitamin D and Clinical Phenotypes of Parkinson’s Disease

F. Jamal, G. Jackson, S. Moore, A. Sarwar (Houston, TX, USA)

1:15pm-2:45pm: Voice Therapy Normalizes Feedforward and Feedback Networks of the Speech Motor System

S. Narayana, C. Franklin, E. Peterson, D. Robin, P. Fox, L. Ramig (Memphis, TN, USA)

1:15pm-2:45pm: Volume analysis and localization of midbrain hyperechogenecities via TCS and MRI

A. Plate, S.-A. Ahmadi, K. Boetzel (Munich, Germany)

1:15pm-2:45pm: Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease

H. Cotur Levent, E. Bayram, M. Akbostanci (Ankara, Turkey)

1:15pm-2:45pm: Which factors predict patient satisfaction with botulinum toxin treatment for cervical dystonia?

C. Colosimo, V. Misra, D. Charles, T.M. Chung, S. Om, P. Maisonobe (Terni, Italy)

1:15pm-2:45pm: White Matter Microstructural Features of Motor Subtypes in De Novo, Drug Naïve Parkinson’s Disease Patient

M.-C. Wen, H. Heng, Z. Lu, Z. Xu, L.L. Chan, E.K. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Writing training enhances neural connectivity in Parkinson’s patients with micrographia

E. Nackaerts, J. Michely, E. Heremans, S. Swinnen, B. Smits-Engelsmans, W. Vandenberghe, C. Grefkes, A. Nieuwboer (Leuven, Belgium)

1:15pm-2:45pm: WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)

« View all sessions from the .